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Abstract 
Mouse embryonic stem (ES) cells are continuous undifferentiated cell lines 
derived directly from the inner cell mass of blastocysts. These cells have two 
defining characteristics: self-renewal and pluripotency. Self-renewal is the capacity 
to produce at least one identical daughter cell at each cell division, while 
pluripotency is the potential to differentiate into cellular derivatives of all three 
primary germ layers. 
Nanog is a divergent homeodomain protein with the capacity to direct 
constitutive self-renewal in absence of otherwise obligatory cytokine stimulation. 
Nanog is expressed in the early mouse embryo and is essential for the specification 
of pluripotent cells. However the mechanism by which Nanog governs pluripotency 
is incompletely understood. In this thesis experiments are presented that further the 
functional characterisation of Nanog. 
In the mouse embryo, Nanog is normally down regulated in cells prior to de-
lamination and ingression through the primitive streak. To address the consequence 
of Nanog over-expression in vivo, a revertible Nanog over-expressing cell line has 
been generated which can be tracked in the embryo. Results show that the modest 2-
3 fold increase in Nanog expression does not cause any overt phenotype at this stage 
and Nanog over-expressing cells can be detected in the mesoderm of mouse embryos. 
Nanog is shown to exist in multimers in ES cells. The domain mediating 
multimerisation is identified as a tryptophan repeat motif and the functional 
consequence of deletion of this domain is investigated. 
To identify Nanog partner proteins, a biotinylation tagging system in ES cells 
has been designed, constructed, and implemented. This led to the identification of 
putative Nanog partner proteins via mass-spectrometry. Three Nanog partner 
proteins, Esrrb, HDAC2, and Wdr5 have been confirmed by co-immunoprecipitation. 
In addition, the SLQQ motif within the Nanog homeodomain is shown to be the site 
of interaction between Nanog and Sal14. This SLQQ motif is found at a similar 
location in only one other homeodomain protein, Oct4. Consistent with these 
observations Sal14 is also shown to bind Oct4. 
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Chapter 1. 
Introduction 
1.1 	Pluripotent cell lines. 
1.1.1 	Discovery of embryonic stem cells. 
Embryonic stem cells are characterised by the cardinal attributes of self-renewal and 
pluripotency. Self-renewal describes the capacity, at each cell division, to produce at 
least one identical daughter cell. Pluripotency is the ability to generate tissues of all 
three primary germ layers, as shown by teratoma formation (Evans and Kaufman, 
1981; Martin, 1981), and in aggregation culture (Doetschman et al., 1985). That ES 
cells are truly pluripotent is most remarkably demonstrated following re-introduction 
into a host embryo to create a chimaera, and subsequent transmission of the ES cell 
genome through the mouse germline to form an entire mouse (Bradley etal., 1984). 
Mouse ES cells are derived from pre-implantation embryos (Martin, 1981; Evans and 
Kaufman, 1981) with the embryonic source of ES cells being the epiblast (Brook and 
Gardner, 1997). The experiments leading to the derivation of ES cells were informed 
by studies in teratoma biology. Teratomas are disorganised solid tumours containing 
many different tissues representative of the three primary germ layers, and can be 
benign or malignant with the latter referred to as teratocarcinomas. In 1954, Leroy 
Stevens described the identification of an inbred mouse line that had a high 
frequency (1%) of testicular teratoma and these tumours were of "pleiomorphic 
character," that is to say, contained many different tissue types (Stevens and Little, 
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1954). At low frequency, these tumours could be transplanted, indicating the 
presence of undifferentiated cells. These cells are now known as EC (embryonal 
carcinoma) cells and represent the stem cell population sustaining the 
teratocarcinoma (reviewed by Andrews, 2002). Subsequent studies showed that 
transplanting genital ridges or pre-gastrulation embryos to ectopic sites could 
generate teratocarcinomas (Stevens, 1968; Stevens, 1964; Solter et al., 1970). In the 
latter case the embryological origin of teratocarcinoma was shown to'be the epiblast 
(Diwan and Stevens, 1976). Important in functionally defining a stem cell is the 
concept of clonality, that is to say that a single stem cell is able to produce each of 
the potency restricted cell types in the lineage it supports. Indeed, EC cells were 
shown to possess this property, with a single EC cell being able to generate complex 
teratomas (Kleinsmith and Pierce, 1964). Embryonal carcinoma cells can be cultured 
indefinitely whilst retaining this "histogenetic potentiality", and this caused 
excitement as these cells were hailed as a tool suitable for the study of differentiation 
pathways in vitro (Finch and Ephrussi, 1967). Furthermore, in 1974, it was 
demonstrated that EC cells, when reintroduced into the mouse embryo, are able to 
contribute to the developing foetus (Brinster, 1974). However, the ability of EC cells 
to efficiently differentiate in vitro and in vivo was ultimately found to be low. EC 
cells are often aneuploid, and as such are unable to generate functional gametes 
during meiosis, a trait that precludes passage through the germ-line. A great step 
forward was made in 1981 when embryonic stem (ES) cell lines were derived 
directly from the inner cell mass of mouse embryos without having passed through a 
teratocarcinoma (Martin, 1981; Evans and Kaufman, 1981). ES cells grow 
indefinitely in culture whilst been able to differentiate both in vitro and into complex 
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teratomas, that is, possess the key attributes of self-renewal and pluripotency. Unlike 
EC cells, embryonic stem cells are stably diploid (Evans and Kaufman, 1981) and are 
able to transmit their genome through the germline to generate an entire mouse 
(Bradley etal., 1984). 
1.1.2 Other pluripotent cell types. 
Mouse ES cells are not the only pluripotent cell type that that can be propagated in 
vitro. Explanted primordial germ cells (PGCs) can give rise to embryonic germ (EG) 
cell lines that can be cultured indefinitely in vitro (Resnick et al., 1992; Matsui et al., 
1992). EG cells are able to contribute to mouse embryogenesis and pass through the 
germline (Labosky et al., 1994; Stewart et al., 1994). However, EG cells cannot be 
considered as ES cell equivalents, as EG cells undergo global erasure of imprints at 
the latter stages of PGC development, which leads to diminished developmental 
potential (Tada et al., 1998). More recently, there have been reports of the generation 
of pluripotent stem cells lines deriveddirectly from neonatal testes, albeit with a very 
low frequency (Kanatsu-Shinohara et al., 2004). Hybrids formed by fusing somatic 
cells with EC cells retain pluripotentiality (Miller and Ruddle, 1977). Subsequent 
experiments have shown that pluripotency can be induced by fusing somatic cells 
with undifferentiated mouse ES cells (Tada et al., 2001) and human ES cells (Cowan 
et al., 2005), and that this ability can be increased by a key regulator of ES cells 
(Silva et al., 2006). More excitingly, direct ectopic expression of four ES cell 
specific transcription factors is sufficient to induce pluripotency, or re-program, adult 
somatic cells (Takahashi and Yamanaka, 2006). 
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1.1.3 	Why are ES cells interesting to study? 
1.1.3.1 	ES cells: a tool to study developmental biology. 
ES cells provide a useful tool to study mouse development. Firstly, ES cells represent 
an in vitro cell-line sharing many characteristics with the pluripotent cells of the 
early embryo. Whether ES cells represent a direct counterpart of an embryonic cell 
type or a cell culture artefact remains unclear (Smith, 2001; Buehr and Smith, 2003). 
Secondly, they can be used as an in vitro model for a variety of differentiation 
pathways (reviewed by Smith, 2001), and to produce a homogenous source of tissue 
specific stem cells (Conti et al., 2005). Furthermore, mouse ES cells are amenable to 
genetic manipulation allowing functional analysis of gene mis-expression both in ES 
cells and in the mouse. More specifically, loss of gene function experiments can be 
studied using the technique of homologous recombination through gene targeting in 
ES cells (Thomas and Capecchi, 1987). Thus ES cells can act as, a cellular vector to 
transmit the altered 'genome through the mouse germline (Thompson et al., 1989) 
allowing gene function to be analysed both during development and in adult mice. 
An additional gene ablation strategy namely RNAi (RNA interference) has been 
shown to be efficient in ES cells (Kunath et al., 2003). Coupled with the fact that ES 
cells can be expanded in culture indefinitely, this makes ES cells suitable for 
performing loss-of-function phenotypic screens, for example in the identification of 
key regulators of ES cell self-renewal (Ivanova et al., 2006). Gene function can also 
be investigated in ES cells by over-expressing genes either via standard stable 
additive transgenesis or via high efficiency extra-chromosomal expression of 
episomal DNA (Gassmann et al., 1995). The latter has proved useful in a number of 
experimental setups including the identification of single transcription factors that 
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can drive a particular differentiation program (Fujikura et al., 2002), molecular 
dissection of the functional domains of key proteins in ES cells (Niwa et al., 2002), 
and a gain of function screen for key ES cell regulators (Chambers et al., 2003). 
1.1.3.2 	ES cells and their promise in regenerative medicine. 
Mouse ES cells have been shown to differentiate into myriad tissues in in vitro 
aggregation cultures (Doetscbman et al., 1985; Martin, 1981), in teratomas (Martin, 
1981; Evans and Kaufman, 1981), and in vivo (Bradley et al., 1984; Beddington and 
Robertson, 1989). Embryonic stem cells have also now been derived from human 
blastocysts (Thomson et al., 1998). The resultant cell lines generate complex 
teratomas when transplanted to ectopic sites in the mouse (Thomson et al., 1998) and 
are able to differentiate into somatic cell types in culture (Reubinoff et al., 2000). 
Mouse ES cell studies show that terminally differentiated cell types can be generated 
in vitro, which are functional Upon reintroduction into mice (reviewed by Smith, 
2001; reviewed by Prelle et al., 2002). One striking example is that ES cell derived 
cultures of oligodendrocytes are able to re-myelinate axons in myelin deficient mice 
(Liu et al., 2000). Clearly such a regenerative approach to medicine would be 
advantageous in the treatment of human degenerative diseases such as multiple 
sclerosis (a de-myelination disease). However, to achieve these goals more efficient 
protocols of derivation, propagation and differentiation of human ES cells are 
required, along with technical advances to either derive patient specific ES cell lines 
from somatic cell nuclear transfer embryos, or to entirely bypass the requirement for 
an embryo phase. In addition to usage in regenerative medicine, ES cells harbouring 
a disease causing mutation will be useful in the in vitro study of these diseases. 
5 
These considerations are however beyond the scope of this thesis. Key to the 
efficient and routine handling of human ES cells will be the identification of the 
molecular mechanisms underpinning self-renewal, which permit the propagation of 
uniformly undifferentiated cells whilst retaining the ability to efficiently and 
specifically differentiate on cue. Mouse ES cells can be readily propagated, and it is 
possible, indeed probable, that lessons learnt from studies into mouse ES cell self-
renewal circuitry may be transferable to the human system. 
1.2 	Early mouse embryogenesis 
The development of an adult mouse from a fertilised egg involves many rounds of 
cell-division and cell movements that are governed by dynamic, tightly controlled 
gene expression patterns, and perception and response to environmental cues. The 
development- of the early mouse embryo has been well reviewed (Beddington and 
Robertson, 1999; Tam and Behringer, 1997) and the salient points with relevance to 
this thesis are outlined here, and depicted in Figure 1.1. Fertilisation followed by 
multiple cleavage rounds results in a ball shaped embryo known as a morula (E3.0) 
containing outer polar cells and inner apolar cells. At E3.5 the major morphological 
event of blastulation occurs whereby the distinct tissues of the 1CM and the 
trophectoderm (TE) form. These subpopulations are non-interchangeable, with TE 
generating all the placental tissues and the 1CM generating the embryo proper along 
with the supporting extra-embryonic endoderm and mesoderm (Gardner, 1983). One 
day later (E4.5), the primitive endoderm forms on the blastocoelic surface of the 
1CM, which will later generate the parietal and visceral endoderm. The remaining 
undifferentiated 1CM tissue is now referred to as the epiblast and generates the entire 
31 
ES cells can be derived 
from E3.5 embryos. 
Preirçlantation 






.ndoderm •J I 
Figure 1.1- Schematic representation of early mouse development. Modified 
from Beddington and Robertson (1999). 
After fertilisation, the embryo undergoes a number of cleavage divisions to 
generate a morula (ball shaped embryo) at E3.0. At E3.5 the major event of 
blastulation occurs. At E4.5 the primitive endoderm forms on the surface of the 
fluid filled blastocoelic cavity, with the remaining 1CM tissue now being referred 
to as the epiblast. ES cells can be derived from the 1CM of blastocysts. Over the 
next two days the embryo implants and the epiblast undergoes epithelialisation. 
At E6.5 the embryo begins gastrulation- a complex set of cellular movements 
during which cells of the epiblast generate mesoderm. These cellular movements 
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embryo proper and extra-embryonic mesoderm. Over, the next two days the embryo 
implants into the uterine wall, the epiblast becomes epithelialised and adopts a cup 
shape and gastrulation begins at E6.5. Gastrulation describes a complex set of 
cellular movements whereby epiblast cells undergo an epithelial to mesenchymal 
transition to form mesoderm, with these movements starting at the proximal end of 
the epiblast and extending to the distal tip. This process demarcates the embryonic 
anterior-posterior axis with the proximal tip of the primitive streak marking the 
posterior end of the embryo. 
1.3 	Factors governing ES cell self-renewal. 
1.3.1 	Extrinsic factors governing ES cell self-renewal. 
To both developmental biologist and clinician, it is important to define the minimal 
chemical conditions required for efficient ES cell propagation, in order to understand 
the true nature of the pluripotent cells of the early embryo and to be able to produce 
xeno-free human ES cell culture conditions for clinical use, respectively. 
1.3.1.1 	From feeder cells to the LIF/Stat3 pathway. 
Initial derivation of mouse ES cells relied on co-culture with a feeder layer of STO 
fibroblasts to support propagation (Evans and Kaufman, 1981; Martin, 1981). This 
reliance on fibroblast support cells suggested feeders provided a signal to ES cells 
which favoured maintenance of the undifferentiated 'state during culture (Smith and 
Hooper, 1983). Indeed, medium conditioned by Buffalo rat liver cells was shown to 
inhibit mouse ES cell differentiation (Smith and Hooper, 1987). The effective 
component of the so called 'differentiation inhibiting activity' was identified as 
leukaemia inhibitory factor (LIF) via fractionation of conditioned media (Smith et al., 
1988; Williams et al., 1988). Furthermore, lif' feeder cells have a reduced capacity 
to support ES cell self-renewal (Stewart et al., 1992). LIF is a member of the 1L6 
(Interleukin 6) family of cytokines and indeed provision of 1L6 together with soluble 
1L6 receptor can substitute for LIF both in ES cell cultures (Yoshida et al., 1994) and 
during ES cell derivation (Nichols et al., 1994). LIF acts by first binding to the low 
affinity LIF receptor, LIFR. This binary complex then interacts with gpl3O to form a 
high affinity LIF receptor (Zhang et al., 1997). The formation of this complex 
induces phosphorylation of Janus kinases which then phosphorylate specific tyrosine 
residues on the cytoplasmic tail of gpl30 (Narazaki et al., 1994; Stahl et al., 1994). 
The phosphorylated gpl30 acts as docking site for SH2 (Src homology 2) domain 
containing proteins which are themselves then phosphorylated by JAKs (Lutticken et 
al., 1994; Stahl et al., 1994). The upshot of this intricate membrane associated 
assembly is the initiation of signalling cascades including phosphorylation and 
activation of Stats (Signal transducer and activator of transcription) (Lutticken et al., 
1994; Stahl et al., 1995) and activation of the Ras-MAPK (mitogen activated protein 
kinase) pathway (Boulton et al., 1994; Yin and Yang, 1994; Sheng et al., 1997). 
When phosphorylated Stats translocate to the nucleus, they exert their function as 
activators of transcription (Ihle, 1996). In mouse ES cells, the key positive event 
downstream of the LIF receptor is activation of Stat3 which is required for efficient 
self-renewal (Niwa et al., 1998). In addition, using a conditionally activatable form 
of Stat3, Stat3 was shown to be sufficient for mouse ES cell self-renewal (Matsuda et 
al., 1999) although this not strictly true, due to the continued requirement for foetal 
calf serum in the culture. LIF also stimulates the Ras-MAPK signalling cascade, 
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although this is not required for, and indeed antagonises ES cell self-renewal 
(Burdon et al., 1999; reviewed by Burdon et al., 2002). It has also been suggested 
that LIF dependent ERK suppression occurs in mouse ES cells and is transduced 
through the P13K (phosphoinositide-3 kinase) signalling pathway (Paling et al., 
2004). Although 1ij lzfr, gpl30 are co-expressed in the early mouse embryo in a 
reciprocal pattern suggestive of paracrine signalling (Nichols et al., 1996), targeted 
disruption of either lf, lifr, or gp130, does not impair normal blastocyst development 
(Yoshida et al., 1996; Stewart et al., 1992; Ware et al., 1995). The gpl30 signalling 
pathway is only required for blastocyst development during diapause, with this 
adaptive physiological mechanism likely providing the basis for ES cell 
responsiveness to gpl30 signalling (Nichols et al., 2001). LIF independent paracrine 
signalling is able to support self-renewal in mouse ES cells to a certain degree (Dani 
et al., 1998) and it is possible that the same mechanism maintains an undifferentiated 
1CM population in non-delayed blastocysts. Interestingly, human ES cells, although 
expressing the required components of the LIF/Stat3 pathway, do not require its 
activation for efficient self-renewal (Humphrey et al.; 2004; Daheron et al., 2004). 
This may be due to either additional effective signalling pathways or intrinsic factors 
being present at higher effective concentrations. 
1.3.1.2 	From FCS to BMP. 
Defining the contribution of FCS to ES cell culture would permit self-renewal in a 
completely chemically defined media. Recently, BMP2/4 was identified as the 
critical component of FCS which, together with LIF allows efficient self-renewal 
without the neural differentiation that normally ensues during culture with LIF alone 
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(Ying et al., 2003). BMP signals are transduced by the Smad proteins (reviewed by 
Massague and Wotton, 2000), and their effective targets for mouse ES cell self-
renewal are the Id (Inhibitor of differentiation) proteins. Indeed, forced expression of 
Id proteins can circumvent the requirement for continued BMP stimulation (Ying et 
al., 2003). The gene targets of Id proteins in ES cells are unclear although it is 
thought they may prevent premature neural differentiation via repression of pro-
neural factors such as Mash 1 (Ying et al., 2003). In apparent contradiction, an 
alternative explanation for the mechanism of maintaining self-renewal via BMP 
signalling in ES cells has been offered which is via inhibition of the ERK and p38 
MAPK pathways (Qi et al., 2004). Forced expression of Smadl/4 led to non-neural 
differentiation even in the presence of LIF, which suggests the balance of the 
LIF/Stat3 and BMP/Smad signals is critical for efficient self-renewal (Ying et al., 
2003). Stat3 and active Smadi can physically interact in neuroepithelial cells and can 
co-operate in transcriptional regulation (Nakashima et al., 1999). This physical 
association is also detected in mouse ES cells (Ying et al., 2003), although whether it 
is functionally significant remains unclear. 
1.3.1.3 	Wnt signalling and ES cell self-renewal 
Wnt signalling has previously been shown to be important for self-renewal of 
haematopoeitc stem cells (Reya et al., 2003), and recently has also been implicated - 
in ES cell self-renewal (Sato et al., 2004). This study used a pharmacological 
inhibitor of GSK3 (glycogen synthase kinase 3), which effectively activates the 
canonical wnt pathway to 'maintain' pluripotency. However, GSK3 is known to be 
involved in other pathways and therefore the observed phenotype may not be directly 
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attributable to wnt signalling. Furthermore, these experiments are carried out in high 
density culture on feeder cells and are not passaged throughout the duration of the 
experiment. Further experiments in feeder-free, chemically defined media, that 
involve clonal expansion and serial passaging, will be required to unequivocally add 
wnts to the ES cell self-renewal signalling repertoire. 
1.3.2 	Intrinsic factors governing ES cell self-renewal. 
Recently, four proteins have been proposed to play central roles in directing 
transcriptional networks that define both mouse and human ES cell self-renewal and 
pluripotency (Boyer et al., 2005; Loh et al., 2006; Wu et al., 2006). These are the 
divergent homeodomain protein Nanog, the POU (PitlOctlUnc) domain Oct4, the 
HMG (high mobility group) containing protein Sox2, and the spalt family protein 
Sa114. These proteins will be discussed here along with other proteins important for 
ES cell renewal that are studied in this thesis. Particular attention will be given to 
Nanog- the major focus in this thesis. 
1.3.2.1 	Oct4 
Oct4 is homeodomain protein of the POU class of transcription factors, which can 
regulate a wide range of target genes (Saijoh et al., 1996; Matoba et al., 2006). A 
subset of Oct4 target genes in ES cells such as fgf4 are co-regulated by Sox2 (Yuan 
et al., 1996). Together, Oct4 and Sox2 with Nanog have been localised to many 
common gene targets in mouse and human ES cells (Loh et al., 2006; Boyer et al., 
2005). Oct4 is expressed in the oocyte and expression is then limited to the 
blastomeres, pluripotent cells of the early embryo and germ cells (Rosner et al., 
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1990; Scholer et al., 1990b; Yeom et al., 1996; Pesce etal., 1998). In addition, some 
nascent mesodermal cells express Oct4 mRNA transiently after ingression through 
the primitive streak (Yeom et al., 1996). Oct4 is a key regulator of the pluripotent 
cell type as evidenced by the trophoblastic differentiation of Oct4 blastocysts 
(Nichols et al., 1998) and upon conditional repression in mouse ES cells (Niwa et al., 
2000). Recently, experiments have shown that the mechanism of Oct4 mediated 
suppression of trophectoderm differentiation relies on physical and genetic 
interaction with a second transcription factor, Cdx2 (Niwa et al., 2005). Oct4 and 
Cdx2 exist in a state of reciprocal inhibition whereby Cdx2 is prevented from driving 
trophectoderm differentiation by both Oct4 suppression of Cdx2 expression along 
with blockade of Cdx2 activity in an Oct4-Cdx2 repressive complex, whilst Cdx2 
inhibits Oct4 auto-regulation (Niwa et al., 2005; Smith, 2005). It has been noted that 
constitutive Oct4 expression cannot negate the requirement for gpl3O signalling. On 
the contrary, elevated Oct4 expression initiates a developmental process that mirrors 
that generated by LIF withdrawal in which cells expressing markers of primitive 
endoderm and mesoderm are generated (Niwa et al., 2000). This may reflect the in 
vivo situation whereby a transient burst of Oct4 expression is observed in the nascent 
primitive endoderm (Palmieri et al., 1994). Based on these data the existence of 
another factor which may be active in the absence of LIF, yet is maximally effective 
in the presence of LIF has been suggested (Niwa, 2001; Chambers, 2004). This 
unidentified factor is thought to be important for li11iting Oct4 activity and for the 
maintenance of the pluripotent state. 
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1.3.2.2 	Sox2 
Sox2 is a HMG transcription factor which acts together with Oct4 by binding a 
composite OctlSox binding site to regulate transcription of target genes (e.g. fgf4) 
both in ES cells and in pluripotent cells in vivo (Yuan et al., 1996; Ambrosetti et al., 
1997). Functionally important Oct/Sox sites have also been found at other genes with 
ES cell specific expression including UtJl (Nishimoto et al., 1999), as well as Oct4 
(Okumura-Nakanishi et al., 2005; Chew et al., 2005) and Sox2 (Chew et al., 2005; 
Tomioka et al., 2002) themselves. Composite Oct/Sox sites are non-palindromic and 
occur with conserved comparative directionality to permit side chain interactions 
between the HMG domain of Sox and, the POU-specific domain of Oct which 
stabilise the Oct-Sox-DNA ternary complex (Williams et al., '2004; reviewed by 
Chambers, 2005). Sox2' inner cell masses cannot give rise to ES cells when 
explanted in vitro (Avilion et al., 2003). Sox2 embryos develop until E6.5, 
considerably later than defects in Oct4 embryos became apparent. It is currently 
unclear whether, this difference reflects the fact that Sox2 may be activating only a 
subset of Oct4 target genes or whether an earlier requirement for Sox2 is satisfied by 
long-lived maternal protein (Avilion et al., 2003). Whether Sox2 in necessary for ES 
self-renewal remains unclear, and experiments to acutely remove Sox2 during ES cell 
culture could address this question. Certainly forced Sox2 expression does not effect 
increased self-renewal, and rather increases the efficiency of neural differentiation in 
appropriate culture conditions (Zhao etal., 2004). 
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1.3.2.3 	Sa114 
Sa114 is a zinc finger transcription factor of the spalt family that was first identified in 
Drosophila as region specific homeotic gene (Kubnlein et al., 1994). Sa114 has 
recently been identified as an interacting partner protein of Nanog in mouse ES cells 
(Wu et al., 2006). Nanog and Sal14 can reciprocally transcriptionally activate each 
other suggesting the existence of a transcriptional feed-forward loop between Nanog 
and Sa114 (Wu et al., 2006). Nanog and Sa114 co-occupy many genomic loci 
including Nanog, Oct4, Sox2, and Esrrb suggesting Nanog and Sa114 may act 
together to regulate some target genes (Wu et al., 2006). Genetic disruption of both 
Sa114 alleles reveals a cell-autonomous requirement for Sa114 in the epiblast, and no 
Sal14 ES cell lines could be established from Sall4 intercrosses (Elling et al., 
2006). However sequential targeting of Sa114 alleles in ES cells revealed that 
proliferation compromised Sall4 clones can be obtained, albeit only at very low 
frequency (2%), due to preferential recombination at the already mutated allele 
(Sakaki-Yumoto et al., 2006). This suggests that the homozygous Sa114 mutation is 
detrimental to ES cells. This proliferation defect however is not due to modulation of 
expression of two genes previously implicated in controlling ES cell proliferation, 
Utf-1 (Nishimoto et al., 2005) and Eras (Takahashi et al., 2003), as northern analysis 
shows Utf-1 and Eras expression levels are unchanged in Sal14 ES cells (Sakaki-
Yumoto et al., 2006). Sall4also activates' Oct4 in ES cells (Zhang et al., 2006). In 
vivo siRNA reduction of Sa!14 expression in the one cell embryo results in decreased 
Oct4 expression and expansion of the Cdx2 expression domain into the 1CM (Zhang 
et al., 2006). It therefore seems Sal14 may, through Oct4, modulate Cdx2 expression 
and may be important in the first lineage determination decision in vivo. This data 
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perhaps explains why Sall4 trophoblast stem (TS) cell lines (Tanaka et al., 1998), 
yet not ES or extraembryonic endoderm stem (XEN) cell lines (Kunath et al., 2005) 
can be obtained from Sa114' blastocysts (Elling et al., 2006). 
1.3.2.4 	Nanog. 
1.3.2.4.1 	Identification of Nanog. 
Nanog was identified in two concurrent screens for functional proteins important in 
mouse ES cell self-renewal. The first involved an in silico subtraction method which 
identified Nanog as one of several transcripts specifically expressed in ES cells 
(Mitsui et al., 2003). The second strategy involved directly selecting cDNAs that 
were capable of directing self-renewal in the absence of otherwise obligatory LIF 
stimulation (Chambers et al, 2003). It was subsequently shown that Nanog over-
expression can also circumvent the requirement for BMP/Smad signalling as well as 
Stat3 activation, allowing efficient self-renewal in a completely defined minimal 
media (N21327) (Ying et al., 2003) as well as conferring resistance to pro-
differentiation stimuli (Chambers et al., 2003). 
1.3.2.4.2 	Nanog protein 
Nanog is a 305 amino acid polypeptide which, in simple terms can be considered a 
three domain protein containing a 96 residue serine rich N-terminal region, a 
divergent homeodomain, and a 150 residue C-terminal region (Mitsui et al., 2003; 
Chambers et al., 2003) (Figure 1.2). Homeodomain proteins are particularly 
interesting to the developmental biologist as they have numerous roles development 
and evolution (Gehring, 1987). The Nanog homeodomain is most closely related to 
we 
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Figure 1.2- Amino acid sequence of mouse Nanog protein. 
The coloured boxes show the boundaries of putative domains within 
Nanog. The C-terminal domain. begins at Ki 56 and is further divided due 
to the presence of the tryptophan repeat into C-N (K156-M197), tryptophan 
repeat (W198-W243), and C-C (N244-1305). 
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the NK2 family yet lies outwith this family due to the lack of characterisitic sequence 
motifs (Lints et al., 1993). Nanog protein localises to the nuclear compartment 
(Chambers, 2005), and the human Nanog homeodomain has been shown to contain a 
nuclear localisation signal (Do et al., 2006). The C-terminal half of Nanog contains 
an unusual sequence repeated ten times, characterised by a tryptophan residue 
repeated every 5 th amino acid. Orthologues of Nanog are recognisable in many 
organisms including human (Chambers et al., 2003), rat (Chambers et al., 2003), pig 
(Yang et al., 2004), and chicken (Canon et al., 2006). Furthermore, human Nanog 
protein is functionally conserved, having a reduced but detectable ability to direct 
cytokine independent self-renewal in mouse ES cells (Chambers et al., 2003). In 
Ga14 DNA binding domain fusion experiments, both the N-terminal domain and C-
terminal domain have been shown to possess transactivation potential with the latter 
shown to be more potent (Pan and Pei, 2003). Subsequently, the C-terminal domain 
was found, to contain two distinct transactivation domains; one being the 50 amino 
acid tryptophan repeat in which at least some of the tryptophan residues are 
functionally important, and the second being the C-terminally adjacent 58 residues 
(Pan and Pci, 2005). These studies were performed using both Ga14 Nanog fusions 
reported by a Ga14 responsive promoter and also a reporter driven by a multimerised 
Nanog binding site identified by SELEX (systematic evolution of ligands through 
exponential enrichment) (Pan and Pci, 2005). It will be interesting to examine 
whether the transactivation domains are functional at endogenous target genes in ES 
cells. Interestingly, the C-terminal (but not the N-terminal) transactivation potential 
is conserved in human Nanog (Oh et al., 2005). Although not yet reported, Nanog 
may also possess repressive function, possibly dependent on specific interacting 
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partners as has been shown for distinct multi-subunit complexes of Gata-1 
(Rodriguez et al., 2005). 
1.3.2.4.3 	Nanog expression in vivo 
Nanog is expressed, and has a functional role in the early mouse embryo (Mitsui et 
al., 2003; Chambers et al., 2003). Nanog mRNA can first be visualised at the 
compacted morula stage with expression being restricted to the apolar inner cells 
(Chambers et al., 2003) which, one day later will form the 1CM (inner cell mass) 
(Johnson and Ziomek, 1981). The expression of Nanog at this stage is 
complementary to that of Cdx2, which is required for the specification and 
differentiation of the trophectoderm (Strumpf et al., 2005). Nanog is expressed in the 
1CM but is down-regulated immediately prior to implantation (Chambers et al., 
2003). The in situ hybridisation data in Figure 1.3 shows Nanog expression in the 
early mouse embryo. In the early post implantation egg-cylinder stage embryo, 
Nanog mRNA is detectable as .a gradient with the highest mRNA levels in the 
proximal posterior region of the embryo (Hart et al., 2004). Nanog expression is 
rapidly down-regulated as cells delaminate and ingress through the primitive streak 
forming mesoderm (Hart et al., 2004; Morkel et al., 2003). Whether Nanog down-
regulation is required for mesoderm formation is a question that is addressed in this 
thesis. Later in development, Nanog is co-expressed with Oct4 in the pluripotent 
PGCs (primordial germ cells) (Chambers et al., 2003; Yamaguchi et al., 2005) which 
go on to generate functional gametes. Nanog expression has been reported in some 
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Figure 1.3- In situ hybridisation showing Nanog mRNA expression during 
mouse embryogenesis. Taken directly from Chambers et al (2003)(A-I), and 
Chambers' unpublished data (J+K). 
In situ hybridisation was used to detect Nanog mRNA which is visulaised as a purple signal. 
Panels show one cell (A), two cell (B), 6 cell (C), 8 cell (D), late morula (E), early 
blastocyst (F), expanded blastocyst (G), hatched blastocyst (H), implanting blastocyst (I), 
E5.5 and 6.5 embryos (J), and a transverse section through an E7.5 embryo (K). 
Nanog expression commences in the compacted morula and in maintained 
in the 1CM prior to down-regulation at implantation. Nanog is re-expressed 
in the post-implantation embryo with highest expression in the proximal 
posterior region of the embryo (J), and expression is extinguished upon de-
lamination and ingression through the primitive streak, (K). 
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generally rely on RT-PCR, the existence of Nanog retrogenes may mean this 
detection is artefactual (Robertson et al., 2006; Booth and Holland, 2004). 
1.3.2.4.4 	Consequences of Nanog mis-expression. 
Nanog was identified as a molecule able to direct cytokine independent mouse ES 
cell self-renewal, and elevated expression of Nanog endows mouse ES cells with the 
properties of increased self-renewal efficiency and resistance to pro-differentiation 
stimuli (Chambers et al., 2003). These properties are exemplified by the cell line EF4, 
(Nanog over-expressing) which is BMP4 and LIF independent, and when reverted to 
the wild-type via Crc recombinase excision of the loxP flanked additive Nanog 
transgene, also reverts to LIF and BMP dependency (Chambers et al., 2003; Ying et 
al., 2003). Quantitative western blotting shows the extent of Nanog over-expression 
necessary to release mouse ES cells from LIF dependency is 5-6 times the wild-type 
expression level (Yates and Chambers, 2005). Nanog is therefore a key mediator of 
mouse ES cell self-renewal that is normally expressed at limiting concentrations but, 
when over-expressed, can 'lock-in' ES cell identity. A paradigm for the importance 
- of transcription factors overcoming an expression level threshold has been shown in 
the haematopoeitic stem cell system in which the homeodomain protein HoxB4 
shows maximal self-renewal at high expression levels (reviewed by Klump et al., 
2005). NANOG. over-expression has also been suggested to bypass the requirement 
for feeders and conditioned media in human ES cells, although this may be due the 
irreversible gene expression profile changes that occur in these experiments (Darr et 
al., 2006). 
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Classical gene targeting of Nanog, performed in ES cells grown on a fibroblast 
feeder layer resulted in loss of pluripotency and differentiation into extra-embryonic 
endoderm cells which expressed Gata6 (Mitsui et al., 2003). In addition, Nanog 
embryos do not support an epiblast compartment with extraembryonic endoderm 
differentiation ensuing (Mitsui et al., 2003). Gata6 is normally expressed in 
(Morrisey et al., 1996), and required for (Koutsourakis et al., 1999) the developing 
primitive endoderm, and indeed forced expression of Gata6 in mouse ES cells drives 
extra-embryonic endoderm differentiation (Fujikura et al., 2002). It has therefore 
been suggested that Nanog may act to repress Gata6 in ES cells (Mitsui et al., 2003; 
Chambers and Smith, 2004; Ralston and Rossant, 2005). Coupled with the 
knowledge that Oct-4 expression is required to prevent trophectoderm differentiation, 
this may seem a neat mechanism in which two proteins, namely Oct4 and Nanog 
maintain the identity of pluripotent cells both in vitro and in vivo by preventing 
differentiation into the two alternative cell fates of trophectoderm and primitive 
endoderm, respectively. However, recent experiments involving the acute deletion of 
Nanog reveal it is non-essential for the maintenance of pluripotency in healthy 
mouse ES cell cultures (Chambers unpublished). Rather, Nanog expression appears 
to oscillate in ES cells such that transiently Nanog negative cells are provided with a 
"window of indecision" during which they may perceive environmental signalling 
cues and differentiate accordingly (Chambers unpublished). In the absence of pro-
differentiation stimuli the transiently Nanog negative cells can re-express Nanog and 
are thereby shielded from differentiation (Chambers unpublished). This explains how 
Nanog ES cells may be maintained in an undifferentiated state when adhering to a 
stringent pro-self-renewal culture regimen. Nanog is however required in vivo both 
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for the establishment of pluripotent cells in the pre-implantation epiblast (Mitsui et 
al., 2003) and for the completion of germ cell development following entry of PGCs 
to the genital ridge (Chambers unpublished). This study also suggests the re-
expression of Nanog in the post-implantation embryo may serve to protect the 
pluripotent post-implantation epiblast cells from premature differentiation. A 
complementary experimental approach shows that Nanog expression in ES cells 
plays a significant role in re-establishment of the pluripotent state when fused to 
tissue restricted non-pluripotent stem cells or terminally differentiated somatic cells 
(Silva et al., 2006). Chambers et al note that the common theme between Nanog 
enhancing reprogramming of non-pluripotent cells via cell fusion, and requirement of 
Nanog for PGC maturation is epigenetic erasure, which suggests that Nanog maybe 
key to this process (Chambers unpublished). 
1.3.2.4.5 	Regulation of Nanog 
It appears that an appropriate level of Nanog expression is required to balance 
prevention of precocious differentiation, with the need to permit differentiation upon 
receipt by the cell of appropriate environmental signals. An Oct/Sox site has been 
identified in the Nanog gene (Chambers and Smith, 2004), within 180 base pairs of 
the transcription initiation site (Chambers, 2005; Wu da and Yao, 2005). Given the 
functional importance of Oct/Sox sites in the promoters of other ES cell specific 
genes (Ambrosetti et al., 1997; Nishimoto et al., 1999; Tokuzawa et al.,- 2003) 
including Oct4 and Sox2 themselves (Okumura-Nakanishi et qi., 2005; Chew et al., 
2005; Tomioka et al., 2002) these sites were further investigated. Indeed, 
endogenous Oct4 and Sox2 are bound to the Nanog promoter in ES and EC cells 
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(Rodda et al., 2005; Kuroda et al., 2005). Moreover, transient transfection assays in 
ES and EC cells suggest that both Oct4 and Sox2 positively regulate Nanog 
expression (Rodda et al., 2005; Kuroda et al., 2005). Oct4 is not however required 
for Nanog transcription in vivo, as evidenced by Nanog expression in all blastocysts 
of an Oct4 intercross (Chambers et al., 2003). It remains unclear whether the 
apparent contradiction of in vitro data (Rodda et al., 2005; Kuroda et al., 2005) and 
in vivo data (Chambers et al., 2003) reflects a difference in OctlSox regulation of 
Nanog during establishment as opposed to maintenance of pluripotency. 
In addition to Oct4 and Sox2, the forkhead transcription factor FoxD3 can also 
activate the Nanog promoter in transient transfection assays (Pan et al., 2006). 
Chromatin immunoprecipitation experiments suggest this effect could be direct as 
epitope tagged FoxD3 can bind the Nanog promoter (Pan et al., 2006). FoxD3 
embryos are indistinguishable from the wildtype at the blastocyst stage; although 
later in development at E6.5, FoxD3 embryos have a defect in the epiblast (Hanna 
et al., 2002). This suggeststhat FoxD3 may be dispensable in cells of the 1CM yet 
required for maintenance of pluripotent epiblast cells after implantation. In ES cells, 
reciprocal positive regulation of Nanog and FoxD3 expression (Loh et al., 2006; Pan 
et al., 2006) may be important for lineage priming as FoxD3 can activate the 
endodermal genes FoxAl and FoxA2. However, precocious differentiation is 
prevented via co-repression of FoxD3 activity by a physical interaction with Oct4 
(Guo etal., 2002). 
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Clearly however, some mechanism of Nanog repression is required for epiblast cells 
and ES cells to be able to differentiate. The transcription factors p53 (Lin et al., 
2005), GCNF (Gu et al., 2005), and Tcf3 (Pereira et al., 2006) may be able to repress 
Nanog. However, whether these transcription factors can repress Nanog in self-
renewing.wildtype ES cells is unclear. p53, GCNF', and TcJ3 ES cells are all 
capable of differentiation suggesting that either additional factors, or a combination 
of these transcription factors is required for complete Nanog repression (Lin et al., 
2005; Gu et al., 2005; Pereira et al., 2006). In ES cells, LIF stimulation does not 
result in a global increase in Nanog levels (Chambers et al., 2003). Recent work 
suggests that Stat3 in combination with Brachyury (I) can directly bind and activate 
the Nanog promoter when ES cells are cultured in reduced LIF conditions in order to 
prevent mesoderm differentiation (Suzuki et al., 2006a; Suzuki et al., 2006b). 
However, under normal self-renewing conditions Brachyury and Stat3 do not 
regulate Nanog expression in ES cells (Suzuki et al., 2006b) 
Constitutive activation of canonical wnt signalling enhanced ES cell self-renewal in 
short term, high density culture (Sato et al., 2004) possibly via f3-catenin mediated 
up-regulation of Nanog expression (Takao et al., 2006). Genetic disruption of the 
wnt signalling components /3-catenin and wnt3a result in the in vivo down-regulation 
of Nanog at E6.5 and the mesoderm in these embryos does not form (Morkel et al., 
2003). Whether the wntl -catenin pathway impinges directly on Nanog in the mouse 
embryo is not yet established. 
25 
The Grb2-Mek-Erk pathway is also thought to repress Nanog expression (Hama.zaki 
et al., 2006) and this may reflect the increased Nanog expression and lack of 
primitive endoderm differentiation of Grb2 blastocysts (Chazaud et al., 2006). Such 
an Erk mediated Nanog repression may explain the observation that ES cells grown 
in the presence of Mek inhibitors exhibit enhanced self-renewal (Burdon et al., 1999). 
The various regulatory factors governing Nanog expression are depicted 
schematically in Figure 1.4. 
1.3.2.4.6 	Regulation by Nanog 
The transcriptional networks of Nanog together with Oct4 and Sox2 have begun to 
be elucidated in mouse and human ES cells, with these.three proteins co-occupying 
many genomic sites (Loh et al., 2006; Boyer et al., 2005). In fact Nanog has been 
proposed to be bound to nearly, 1500 genes in mouse ES cells. Exactly how many of 
these targets are truly dependent on Nanog binding for expression is unclear at 
present. One example of a gene co-regulated by Nanog, Oct4 and Sox2 is Esrrb, the 
orphan nuclear receptor. Esrrb appears functionally important for ES cells as specific 
RNAi mediated knock-down of Esrrb results in morphological flattening of ES cells 
concomitant with a loss of expression of alkaline phosphatase, a marker of the 
undifferentiated state (Loh et al., 2006). In addition, Nanog over-expression induces 
increased Esrrb expression (Loh et al., 2006). 
The consensus DNA sequence recognised by Nanog was identified by systematic 
evolution of ligands by exponential enrichment (SELEX) and is characterised by an 




I. I 	Nanog exons 
Figure 1.4- Schematic representation of all known transcription factors that regulate expression of the 
Nanog promoter. 
Modified from Pan and Pei (2006). Coloured shapes indicate binding sites of regulatory factors. Black rectangles 
represent Nanog exons. The binding sites are not spaced to scale. Direct binding has been demonstrated by either 
ChIP data or EMSA or both. Primary references are provided in the main text (Section 1.3.2.4.5). 
Nanog binding site has been identified in the enhancers of Gata6 and Rex] (Mitsui et 
al., 2003). Furthermore, ChIP data shows that Nanog can bind the promoter region of 
the pluripotency asscociated gene Rex] (Shi et al., 2006) and Gata6, a gene 
expressed in primitive endoderm (Wang et al., 2006). It has not yet been shown that 
Nanog binding to Gata6 results in Gata6 repression. However, such a mechanism 
could explain the primitive endoderm cell types generated upon Nanog deletion in 
the mouse embryo or by classical gene targeting in ES cells. It is possible that Nanog 
is acting both as an activator and repressor; repressing pro-differentiation genes such 
as Gata6 whilst activating pluripotency associated genes such as Rex]. 
Nanog and Oct4 have been proposed to exist in a positive feedback loop with the 
spalt family transcription factor Sa114 (Wu et al., 2006; Zhang et al., 2006). Genetic 
disruption of Sa114 is not compatible with efficient mouse ES cell self-renewal 
(Elling et al., 2006; Sakaki-Yumoto et al., 2006), suggesting the feed-forward loop 
involving Oct4, Nanog and Sa114 may be important for maintaining mouse ES cell 
self-renewal. Although LIF stimulation does not globally increase Nanog levels in 
ES cells, growth in reduced LIF concentrations may lead to transient up-regulation of 
Nanog by Brachyury and Stat3 to prevent premature mesoderm differentiation 
(Suzuki et al., 2006a). It has been proposed that this involves Nanog negatively and 
indirectly regulating Brachyury by physically sequestering the active Smadi required 
for Brachyury expression (Suzuki etal., 2006b). 
1.4 	Protein-Protein interaction technology. 
1.4.1 	Background 
A detailed understanding of the dynamic nature of the proteome is required to dissect 
cellular functions. Since 1979 when the first protein-protein interactions were 
identified (Lane and Crawford, 1979; Linzer and Levine, 1979), proteins have been 
identified in large multi-protein complexes in many systems. To characterise a 
protein of interest, detailed knowledge of its interacting partners is useful as this 
offers insight into the biological function of the protein. Many techniques have been 
devised to screen for interacting partners and these will be summarised here. These 
systems generally fall into one of two categories; (i) affinity based approaches in 
which proteins of interest are isolated from complex mixtures based on their binding 
to particular ligands. Identification of the purified protein and associated factors is 
then attained by using antibodies in a candidate based approach or, more recently, by 
mass-spectrometry. (ii) Functional complementation of a genetic system whereby 
activation of a transcription unit is dependent on protein-protein interaction between 
a bait (protein of interest), and a prey protein (unknown partner protein) e.g. yeast 2 
hybrid. 
1.4.2 	Affmity based approaches 
All these approaches involve purification of a protein of interest based on particular 
affinity properties. For identification of co-purifying proteins for which there is no 
prior knowledge, mass-spectrometry is the method of choice (depicted schematically 
in Figure 1.5). 
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Figure 1.5- Schematic depiction of affmity based purification methods. 
This schematic diagram gives an overview of the one step affinity purification procedure used in this thesis- BlO tagging. 
Nuclear extract is prepared from cells co-expressing a BlO tagged transcription factor of interest and a biotin ligase. The 
nuclear extract is incubated with immobilised streptavidin for 2h at 4oC and subsequently washed extensively. The 
specifically bound proteins are then eluted from the solid phase via boiling in Laemmli buffer or incubation with TEV 
protease. Eluted proteins are then resolved via SDS-PAGE before being subjected to in gel trypsinisation and mass-
spectrometric identification of purified peptides. This generic scheme also applies to co-immunoprecipitation or TAP tagging 
methodologies. 
1.4.2.1 	Co-inununoprecipitation 
Co-immunoprecipitation involves purification of a protein, of interest using a specific 
antibody under conditions that permit maintenance of higher order complex integrity. 
Although this can be performed using antibodies against the endogenous protein, this 
is often insufficient as these antibodies may purify different protein isoforms, 
homologues, or even non-related proteins leading to the mis-identification of partners. 
In addition, some antibodies will not be of sufficiently high affinity to identify all 
interactions. Furthermore, it has been suggested that using an antibody raised directly 
against the protein of interest in unwise due to the possibility that it will compete 
with partner proteins for interaction at the immune epitope (Monti et al., 2005 a). To 
bypass some of the problems with antibodies against endogenous proteins, fusions 
between the protein of interest and short epitope tags with highly specific affinity 
properties can be employed (Terpe, 2003). Tagged proteins have been used 
successfully to isolate many proteins from complex miitures and subsequently 
identify interacting partner proteins in a number of cell types. The use of epitope tags 
introduces additional concerns. For example, epitope tags may alter the three 
dimensional structure of the protein thus affecting function and/or interactions with 
partner proteins. This problem is illustrated by the abolition of TGF-13 induced 
Smad3 phosphorylation upon fusion of an epitope tag to the C-terminus of Smad3 
(Liu et al., 1997). Furthermore, unless targeted to the endogenous genes, the addition 
of epitope tags also necessitates introduction of a transgene which will alter the 
stoichiometry of the protein with respect to its partners which could affect the 
interactions observed (Monti et al., 2005b). One major caveat with all co-
immunoprecipitation studies is that it is difficult to unequivocally conclude that the 
31 
biochemical interaction observed is present in vivo as it has been suggested that 
many non-specific interactions may occur after cell lysis in vitro on the derivatised 
beads (Monti et al., 2005a). 
1.4.2.2 	Tandem affmity purification (TAP) tagging. 
TAP tagging provides a generic method for purification of proteins and associated 
partner proteins at (or close to) endogenous expression levels (Rigaut et al., 1999). 
The first generation of TAP tag was utilised in yeast, and identified a novel Ui 
snRNP subunit along with all previously known U 1 snRNP subunits (Rigaut et al., 
1999). Furthermore, eight times less starting material was required than for standard 
antibody mediated affinity procedures and the non-specific background proteins were 
much reduced compared to standard antibody mediated purifications (Rigaut et al., 
1999). The TAP tag is bipartite in nature, consisting of a protein A domain separated 
from a calmodulin binding protein (CBP) domain by a tobacco etch virus (TEV) 
protease site (Puig et al., 001). Cells expressing the TAP tagged protein of interest 
are lysed under native conditions and subjected to the first step of purification by 
binding to IgG beads. The bound material is cleaved from the IgG beads with TEV 
protease and bound to calmodulin coated beads prior to elution with EGTA and 
subsequent mass spectrometry analysis. A benefit of this system is the decreased 
background afforded by the two step purification as well as the fact that TEV 
protease release from the solid phase will leave any non-specific proteins in situ. 
Recently, the TAP tag system has been successfully used in a mammalian system to 
identify the protein interaction networks in a signal transduction pathway 
(Bouwmeester et al., 2004). TAP tags have also been modified to increase their 
32 
efficiency in mammalian systems by for example, introducing a Flag tag (Knuesel et 
al., 2003) or a biotin tag (Drakas et al., 2005) instead of the calmodulin binding 
protein, the latter of which is estimated to increase the yield of purified protein by 
about three fold compared to the yeast TAP tag. Widespread use of the TAP tag in 
mammalian cells lags behind yeast as there is often a low yield of the fusion protein, 
there is difficulty obtaining the required cell mass, and there is competition between 
the endogenous and tagged protein for partner proteins (Drakas et al., 2005). 
1.4.2.3 	Biotinylation (BlO) tagging. 
Biotin is a naturally occurring co-factor for many metabolic enzymes, yet is only 
active when covalently added to enzymes via the action of biotin ligase (Chapman-
Smith and Cronan, 1999). Biotin is able to bind streptavidin in the strongest non-
covalent interaction in nature (Kj-'1 015).  This property led to the generation of 
peptide tags which can be biotinylated in several cell types, but these tags were large 
and inefficiently biotinylated in mammalian cells (Parrott and Barry, 2000; Parrott 
and Barry, 2001). Recently, however, shorter tags of approximately 23 amino acids 
have been developed that can be biotinylated as efficiently as natural biotin acceptor. 
proteins (Beckett et al., 1999). 'Furthermore, it has, been demonstrated that upon 
fusion of a BlO tag to the transcription factor Gatal and co-expression in mouse 
erythroleukaemic cells with the E.coli biotin ligase BirA, biotinylated Gatal can be 
efficiently purified on immobilised streptavidin in a single step protocol (de Boer et 
a1., 2003; Rodriguez et al., 2006). Performing these experiments under non-
denaturing conditions permitted identification by mass-spectrometry of functionally 
important partner proteins present in distinct activator and repressor complexes 
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(Rodriguez et al., 2005). This approach appears to be particularly useful as it can be - 
performed in a single step, with no requirement for antibodies or for tag cleavage. 
Moreover, there are very few naturally biotinylated contaminating proteins (de Boer 
et al., 2003). Biotin tagging has subsequently been employed to purify proteins from 
ES cells and transgenic mice (Driegen et aL, 2005). 
1.4.2.4 	Mass spectrometry 
Each of the affinity purification protocols described requires protein identification 
using mass-spectrometry. Peptide mass fingerprinting is a powerful mass 
spectrometry technique which allows identification of proteins based on the mass: 
charge ratio of the ionised peptides derived from proteolytic digestion of a protein 
mixture (reviewed by Yates, 2000). Peptide mass fingerprints together with 
knowledge of the protease used to digest the protein mixture are used to search 
databases containing predicted peptide masses from all known proteins. Due to the 
exquisite resolution of mass-spectrOmetry it is possible to identify many of the 
proteins in a mixture. However, the signals produced by single step mass-
spectrometer e.g. MALDI-TOF (Matrix assisted laser desorption ionisation- time of 
flight) are often too complex for the complete identification of all proteins in a 
mixture. This is because large numbers of peptides from several proteins are co-
detected, and it is impossible to correctly identify which protein a particular peptide 
represents. In these cases innovations such as LC/MS/MS (Liquid Chromatography 
tandem mass spectrometry) are useful. LCIMS/MS first separates the protein mixture 
via liquid chromatography, before introduction to the mass spectrometer. The 
technique works by fragmenting peptide ions and obtaining sequence data from mass: 
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charge values. Individual peptides can be selected out of complex mixtures of other 
ions and analysed by fragmentation. The fragmentation chemistry is such that the 
introduced peptides collide with a gas, and the peptide is broken at peptide bonds 
producing an ion series from which sequence can be determined (Peng and Gygi, 
2001; Yates, 2000; Monti et al., 2005a). It has been suggested that mass-
spectrometry should be used only to ascertain that a product of a particular gene is 
present rather than the unequivocal identification of a particular protein (Rappsilber 
and Mann, 2002) because mass spectrometry data is only partially experimental. 
1.4.3 	Yeast two hybrid systems. 
Two hybrid systems involve functional reconstitution of a transcription factor. Some 
transcription factors can be physically separated into independent domains, for 
example the activation domain (AD) and DNA binding domain (DBD) of Gal4p 
(Keegan et al., 1986). This knowledge was exploited in yeast to show that if one 
member of an interacting partner pair is fused to Gal4p-AD and the other to Gal4p-
DBD, that Gal4p activity is reconstituted by virtue of their close physical proximity 
(Fields and Song, 1989). Subsequently, this technology has been further developed 
and is now routinely used to screen for novel interactors using a 'bait' protein of 
interest fused to the Gal4p-AD and a "prey" cDNA library from a cell-type/ tissue of 
choice fused to Gal4p-DBD (Vidal and Legrain, 1999). Vidal and Legrain (1999) 
outline the advantages and disadvantages of yeast two hybrid technology and they 
are summarised here. The yeast 2-hybrid system has the advantage of being 
performed in vivo so issues of ex vivo non-physiological interactions are diminished. 
Furthermore, large libraries containing potential interactors can be screened in a 
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single experiment. Yeast two hybrid screens also have no reliance on expensive 
antibodies or mass-spectrometry. However, there are a number of drawbacks 
including the high false positive rate, as the screen is not only for proteins that do 
interact in vivo but also for those that merely can. Moreover, as the screen reads-out 
based on transcriptional activation, some proteins in the introduced library can have 
'self-activator' activity. Additionally, yeast two hybrid systems predominantly 
identify only direct interactions rather than the whole complexes identified via 
affinity purification procedures. Finally, and of particular importance when analysing 
mammalian protein interaction, the proteins may not be correctly folded or post-
translationally modified in yeast cells. Mammalian two hybrid systems are available 
(reviewed by Lee and Lee, 2004) but are more suited to use for confirming putative 
protein-protein interaction rather than for performing screens as with the yeast 
system. 
1.5 	Aims 
The broad aims of this thesis are to perform a preliminary biochemical 
characterisation of Nanog protein and to assess the effects of Nanog over-expression 
in vivo. Experiments will be performed to assess the multimerisation capacity of 
Nanog as well as attempting to identify Nanog interacting partner proteins using a 
candidate approach. To extend the search for Nanog partner proteins, an unbiased 
biotinylation tagging strategy will be designed, constructed, and implemented, and 
preliminary confirmation of putative partner proteins performed via co-
immunoprecipitation. Additionally, the phenotypic consequences of Nanog over-
expression during development will be investigated via the design and generation of 
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a Nanog over-expressing cell line reagent that can be tracked in the mouse embryo. 
Together, these experiments should allow progress to be made in understanding the 
molecular mechanisms underlying Nanog function. 
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Chapter 2. 
Materials and Methods 
Unless otherwise stated, chemicals were obtained from Fisher, and oligonucleotides 
synthesised by Sigma. The water used for all procedures was milliQ water (Millipore) 
which was monitored for electrical resistance during purification, and used at 
1 8.2m. 
2.1 	Culture and manipulation of ES cells. 
2.1.1 	Routine culture of mouse ES cells. 
I 
ES Media 
500m1 	GMEM (Sigma). 
1 lml Sodium pyruvate/ L- Glutamine (Invitrogen) 
51 ml Foetal Calf Serum (Invitrogen). 
5.5m1 1 OOx Non-essential amino acids (Gibco). 
555 jil 0.1M 2-mercaptoethanol. (BDH) 
555 j.tl LIF (prepared by ISCR tissue culture staff) 
1X Trypsin solution 
0.1 86g EDTA was dissolved in 500m1 PBS and filter sterilised. 5m1 Chick serum 
(Sigma) and Sml trypsin (2.5%) (Invitrogen) was added and mixed. Trypsin was 
stored at -20°C and the final concentration was 0.025%. 
Sodium pyruvate/ L- Glutamine solution 
The 1 imI aliquot was made by mixing 5.5m1 Sodium pyruvate (100mM) with 5.5m1 
L-Glutamine (200mM). 
In 
Protocol 	ES cells were cultured according to (Sqiith, 1991). 
Routinely, the media was changed at least every 2 days with pre-warmed ES 
cell media. 
. Cells were routinely passaged every 3-4 days when cells were 80-90% 
confluent. 
. Tissue culture coated flasks! plates (Iwaki) were coated with 0.1% gelatin 
(Sigma)! Dulbecco PBS 20 mm. before passaging cells. 
. ES cell media was removed from the cells via aspiration. 
. Cells were washed twice with pre-warmed Dulbecco PBS (Sigma). 
. Trypsin solution was added to the cells so that the monolayer was entirely 
covered. 
The flask/ plate was placed in 37 °C! 7% CO2 incubator for -1minute. 
The flask/ plate was tapped to dislodge the cells. 
• Trypsin was neutralised by addition of 4x volume of ES cell media. 
• The cells were centrifuged at 1200rpm (250g) (ALC PK120; Annita) for 3 
mm. in universal tubes. 
• The cell pellet was resuspended in 1 Oml ES media. 
• Routinely cells were split 1:5 at each passage into pre-warmed ES cell media. 
• Cells were gassed with 5% CO2/ air and returned to the 37 °C incubator. 
39 
2.1.2 	Transfection of DNA into mouse ES cells. 
2.1.2.1 	Stable transfection. 
• ES cell media was changed at least 2h prior to transfection. 
• 9.5m1 ES cell media was added to gelatinised 100mm plates and placed in 
370C/7% CO2 incubator to equilibrate. 
. The cells were trypsinised and neutralised with ES cell media. 
• The cells were pelleted at 1200rpm (250g) for 3mm. (ALC PK120; Annita). 
•. The cell pellet was washed in pre-warmed PBS. 
• The cells were counted using a haemocytometer. 
• The cells were pelleted at 1200rpm (250g) for 3mm.. 
• The cells were resuspended such that 107  cells were in a volume of 0.7m1 
I': 
100tg of linearised (usually ScaT) DNA in a volume of 0.lml 1X PBS was 
placed in an electroporation cuvette (Biorad). 
0.7ml (107  cells) were added to the cuvette containing the DNA and mixed 
gently. 
• The cuvettes were left 3 mm. at room temperature. 
• Cells were electroporated at 0.8kV and 3tF using a GenePulser (Biorad). 
• The cells were removed with a plugged Pasteur pipette and added to 9.2m1 of 
prewarmed ES cell media. 
• 0.5m1 (5x10 5 cells) cell suspension was added to the plate and swirled to 
distribute. 
• Selection was started 24h post-transfection (see Table 2.1). 
2.1.2.2 	Transient transfection. 
. 30 minutes prior to transfection, 106  mouse ES cells were plated into a well of 
gelatinised 6 well plate in a volume of 2m1 ES cell media. 
• 3tl Lipofectamine 2000 (Invitrogen) was diluted into 250tl ES cell medium 
without FCS and incubated at room temperature for 5 minutes. 
. 3j.tg plasmid DNA was diluted into 250 j.tl  ES cell medium without FCS and 
incubated at room temperature for 5 minutes. 
• The diluted DNA and Lipofectamine 2000 were mixed and incubated at room 
temperature for 20 minutes. 
• The Lipofectamine!DNA mixture was added drop-wise to the plated ES cells 
and swirled to distribute. 
• Plates were returned to the 3 7 °C! 7%CO2 incubator. 
• Cells are replated and selection started (see Table 2.1) 24-36h post 
transfection. 
Table 2.1. Antibiotic concentrations used for drug selection in mammalian cells 
ANTIBIOTIC SUPPLIER STOCK CONC. 
WORKING 
CONC. 
G418 PAA 200mg/ml 200tg/ml 
Puromycin Sigma Smg!ml 1-2p.g!ml 
Blasticidin S HCl Invitrogen Smg!ml 5-15j.tg/ml 
Hygromycin B Roche 50mg/ml 100-200pg!ml 
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2.1.2.3 	Picking mouse ES cell colonies. 
The media was removed and the cells were washed twice with warm PBS. 5j.tl 
trypsin was taken up in a yellow tip and expelled over a colony. The colony was then 
scraped and sucked up with the yellow tip and placed into a gelatinised well of a 96 
well plate. 180jtl ES cell media was added and tituration was used to break up the 
colony. The plate was then placed in the 37 0/o! 7%CO2 incubator. 
2.1.3 	LIF independence assay. 
ForLIF independence assays of stable ES cell lines, 600 cells were plated/ well of a 
6 well plate (64 cells/cm2) in the presence or absence of LIF, and left for 6 days prior 
to inspection and staining. For LIF independence assays following transient 
transfection (lipofection), cells were routinely plated• at 5x10 4 cells per 100mm 
diameter plate (640 cells/ cm 2) and selected in appropriate antibiotics in the presence 
or absence of LIF for 10-12 days prior to alkaline phosphatase staining. 
2.1.4 	Freezing mouse ES cells. 
• -4x106 ES cells were pelleted 
• Cells were washed in freezing mix (ES cell media containing 10% DMSO) 
- 
	
	 • The pellet was then resuspended in -iml freezing mix, transferred to a 
cryotube (Nunc) and placed immediately in the -80 °C freezer. 
• The next day the cells were transferred to the liquid N2 storage tank (-170 0C). 
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2.1.5 	Thawing mouse ES cells. 
. The vial was removed from the liquid N2 and placed immediately in the 37 °C 
waterbath to thaw. 
• The thawed cells were transferred to a universal tube containing 9m1 warmed 
ES cell media. 
• The cells were pelleted via centrifugation at 1000rpm (200g) (ALC PK120; 
Annita). 
The pellet of ES cells was carefully resuspended in ES cell media, and 
transferred to a gelatinised flask, and placed in a 37 0C/7%CO2 incubator. 
2.1.6 	Staining of mouse ES cells 
2.1.6.1 	Alkaline phosphatase staining. 
An alkaline phosphatase staining kit was used (Sigma) 
FIXATIVE SOLUTION (Store at 4°C) 




400 j.il FRV alkaline solution (in kit) and 400t1 Sodium Nitrite solution (in kit) were 
mixed and incubated for 2 minutes at room temperature. The Alkaline/Nitrite was 
added to 1 8m1 dH20. Finally, 400 j.tl Napthol solution (in kit) was added. 
Protocol 
• The media was aspirated. 
• The cells were washed with warm PBS. 
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• 2m1 fixative solution was added for 45s 
• The fixative solution was removed and the cells were washed in dH 20 
• 2m1 stain was added and incubated for 25mm. at room temperature in the 
dark. 
• The stain was removed and wells were washed with dH20. 
• Plates were allowed to air dry before microscope analysis. 
2.1.6.2 	X-Gal staining of ES cells and embryos. 
PO4 Buffer (0.1M pH 7.33) 
75m1 1M disodium hydrogen orthophosphate+ 25m1 1M Sodium dihydrogen 







0.1% sodium deoxycholate 
0.02% NP-40 
0.05% BSA 
Both the fixative and wash were made up with 0.1M PO4 buffer pH7.33. 
Stain 
Dissolve 50mg X-Gal in imi dimethyl formamide. 
50m1 wash + 12mg spermidine 
82mg K3Fe(CN)6 
105mg K4Fe(CN)6 
15mM NaCl (0.25m1 3M stock) 
Mix (1) and (2), filter, and freeze down in Eppendorf tubes. 
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• The stain was thawed and spun down before use. 
• The adherent cells or the dissected embryos were rinsed in PBS, fixed for 
5mm (cells) or 60mm (embryos), washed 3x 10mm., before addition of the 
stain and incubation at 37 °C in the dark. Cells were checked for the 
appearance of a blue colour every hour (or left overnight). 
2.1.7 	Metaphase spreads of mouse ES cells. 
Mouse ES cells were plated the day before preparing the spreads (20% confluent T25 
tissue culture flask). 
• The next day cells were trypsinised and neutralised with ES cell media. The 
detached cells were pelleted by centrifugation. 
• The supernatant was removed and the cells were resuspended in -2ml 0.56% 
KC1 for 6 minutes. SOjiJ fixative (3:1, methanol: acetic acid) was added in a 
drop-wise fashion, prior to re-pelleting the cells for a further 5 mm. 
• The supematant was removed and lml fixative was added. 
• The fixed cells were then refrigerated for at least 30mm. 
• The fixed cells were re-pelleted and resuspended in 200 p1 fixative. 
• 20j.tI of fixed cells were dropped on a clean microscope slide, allowed to air 
dry, and stained with 10% Giemsa stain (BDH). 
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2.1.8 	Embryological techniques 
2.1.8.1 	Morula aggregation and embryo transfer. 
The protocols were based on those from (Nagy, 2002; Nagy, 2001) 
Aggregations and transfers were performed by ISCR staff. 
PB 1 media G2 media 
136mM NaCl 90.08mM 	NaCl 
2mM KC1 5.5mM KC1 
1mM CaCl2 0.5mM 	 NaH2PO4.2H20 
1mM KH2PO4 1mM MgSO4.7H20 
0.5mM MgC12.6H20 3.15mM 	 Glucose 
8mM Na2HPO4 11.74mM Na Lactate 
0.3mM Na pyruvate 0.1mM 	 Na pyruvate 
5.5mM Glucose 25mM NaHCO3 
1.5g/500m1 BSA 1mM 	 Glutamine 
1.8mM CaC12.2H20 
1X Essential amino acids and 1X non- 
essential amino acids (Gibco) 
Morula Aggregation 
. ES cells were trypsinised and neutralised as usual, plated in ES cell medium 
in bacterial plates, and placed in a 37°C17%CO2 incubator for -2h prior to 
aggregation. This allows cells to adhere to one another loosely forming 
strings of cells. For morula aggregation experiments ES cell lines of passage 
number <15 were used. 
Aggregation plates: Drops of G2 complete media were placed in primaria 
dishes, and covered with mineral oil (Sigma). An indentation was made in the 
dish at the centre of each drop using a Hungarian darning needle (ND-09; 
from BLS Ltd). 
The aggregation plates were placed at 37 0C/7%CO2 to equilibrate. 
• The oviducts from pregnant (E2.5) F 1 female mice were cut out, the fat was 
trimmed off and the oviducts were flushed with PB1 media using a flattened 
needle into a 60mm dish of PB1. 
• The zona pellucida was removed from the embryos by washing in Acid 
Tyrode's solution. 
• Each morula was picked up using a drawn Pasteur mouth pipette and placed 
into an indent in the aggregation plate. 
. ES cells clumps were then added to each indent containing a morula ('-8cells/ 
morula). Before adding the ES cells they were washed in a large drop of G2. 
Aggregation plates were then incubated at 3 7 °C! 7% CO2 overnight. 
Transfer of embryos 
• The next day, embryos were transferred to 2.5dpc CBA/ BL/6 (F 1 hybrid) 
pseudopregnant, females. 
• The anaesthetic Avertin (2.5%) was given via intra-peritoneal injection with 
the dose being dependent on mouse size (0.015-0.0 17 ml!g body weight) 
• A dorsal incision was made in the abdominal cavity and the ovary was 
exposed. Ovary stimulation was monitored by the presence of red dots which 
report the vascularisation of the corpus luteum. 
• The uterine horn was pierced with a small needle. 
• A fine glass needle was used to introduce the embryos into the uterine horn. 
• The skin was sealed with wound clips. 
• After the procedure the animal was given a painkilling injection of Caprofen 
(4j.tg/g body weight). 
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. At the desired time point the animal was sacrificed via cervical dislocation 
and embryos were photographed and stained as appropriate. 
2.1.8.2 	Sectioning of embryos 
Embryos were embedded in 100% paraffin (BDH) and left to set. 
• Serial sections were taken through the embryo at 6 micron. intervals using a 
microtome (Anglia Scientific 0325) 
• These sections were floated on a 37 °C water bath containing sterile dH20. 
• The sections were lifted onto microscope slides and allowed to dry before 
microscopic examination. 
2.1.9 	FACS analysis 
Cells were trypsinised as described (section 2.1 .1) and resuspended in ice cold PBS! 
5% FCS at a density of1x10 6 cells/mi. cells were analysed using the FACScalibur 
apparatus (Becton Dickinson). 
EK 
2.2 	Biochemical Techniques. 
2.2.1 	Preparation of nuclear extract. 
Buffer A 	 10mM HEPES/ KOH pH7.9 
1.5mM M902 
1OmMKC1 
+ EDTA free complete protease inhibitor cocktail (Roche) 
Buffer C 	 20mM HEPES/ KOH pH7.9 




+ EDTA free complete protease inhibitor cocktail (Roche) 





+ EDTA free complete protease inhibitor cocktail (Roche) 
For 25 150cm2 plates of 80% confluent mouse ES cells; 
. Media was supplemented with 0.1 tg/ml biotin (Sigma) 24h before lysis. 
. Media was aspirated and cells were washed with 5m1 room temperature PBS. 
. 2m1 trypsin was added and the plates were incubated at 37 °C for -1mm. 
Trypsin was neutralised with 8m1 ES cell media. 
Three plates worth of cells were pooled in 1 universal tube. 
. The cells were pelleted via centrifugation at 1200rpm (250g) in a benchtop 
centrifuge (ALC PK120; Annita) 
The pellets were washed in PBS and pooled. 
The pooled cells were pelleted at 1200rpm (250g) (ALC PK120; Annita) 
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• The cells were carefully resuspended in 50m1 ice cold Buffer A in a 50m1 
Coming tube. 
• The cells were iysed by incubation on ice for 20 mm. 
• The cells were vortexed for 90s-120s. 
• 1 O1.Ll  of cell suspension was mixed with 101.11 Unna Stain/ methyl pyronin (a 
gift from J. Strouboulis), pipetted onto a microscope slide and covered with a 
cover slip. The cells were examined under the light microscope (the free 
nuclei stain a pale blue colour). When >90% of the nuclei were free from 
cytoplasm the protocol was continued. If <90% of cells were lysed, vortexing 
was repeated. 
• The nuclei were pelleted via centrifugation at 4 °C at 340g (Sigma 4K1 5 
centrifuge). 
The supematant (cytoplasmic fraction) was removed and discarded. 
The pellet (nuclei) was resuspended in 6m1 ice cold buffer C. 
• 2.2M HENG was added drop-wise until the DNA precipitated. 
• The Coming tube was rotated at 4 °C for 30mm. 
The liquid was decanted into a SW40. 1 tube (Beckman), ultracentrifuged for 
60min at 4°C at 40000 rpm (198,000g) using a pre-chilled SW41T-4 rotor in 
a BeckmanL7-65 ultracentrifuge. 
• The supernatant is the nuclear extract which was split into lml aliquots in 
non-stick microcentrifuge tubes (Alpha Laboratories), snap frozen and stored 
at -80°C. 
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• The salt concentration is calculated by comparing the sample nuclear extract 
to a dilution series of KC1 in the concentration range 100-500mM using an 
AKTA FPLC system (Amersham). 
• Protein concentration was calculated using a ND 1000 spectrophotometer 
(Nanodrop). 
2.2.2 	Binding biotinylated material to streptavidin beads and 
preparation for mass-spectrometry. 
Solutions required; 
1M HENG 





1M HENG/ 0% Glycerol 









OM HENG! 0% Glycerol 
10mM HEPES/ KOH pH7.9 
1.5mM M902 
0.25mM EDTA 
Using these solutions it was possible to easily make HENG buffers of desired KC1 
and glycerol concentration without affecting the concentration of the other 
components 
Bead Wash Buffer 
250mM HENG Buffer 
0.3% NP-40 
2x Laemmli Buffer 
125mM Tris pH6.8 
25% Glycerol 
4% SDS 
0.01% bromophenol blue 
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50X Protease inhibitor 




RNAseA (lOOmg/ml; Roche), 
10% NP-40 (Sigma) 
Protocol 
. Nuclear extract aliquots were thawed on ice 
Approximately 15mg of nuclear extract was added to a 50 ml Corning tube 
and made up to a final volume of 30m1 with HENG buffer. The final 
concentration should be 100mM KC1/ 7-12% Glycerol. NP-40 was added to a 
final concentration of 0.3%, MgC12 to a final concentration of 10mM and 
protease inhibitors at 1X. 
. A 1 OOpi aliquot was removed and stored at -20 °C (for nuclease efficiency 
assay). 
80.tl RNAseA or 1 OOj.il Benzonase (Novagen; 1 25U/ mg protein) was added. 
• The diluted nuclear extract was incubated on ice for 2h. 
• 200j.tl Dynabeads M-280 (Invitrogen) were blocked with 200ng/.tl chicken 
egg extract (Sigma) in PBS for lh at room temperature in a rotary incubator. 
• Block buffer was removed using a magnetic rack (Dynal-MPCS). 
• The beads were added to the diluted nuclear extract and incubated at 4 °C with 
tumbling for 2h. 
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• The beads were pelleted via centrifugation at 4 °C for 5min at 340g (Sigma 
4K1 5 centrifuge). 
The supernatant was removed and a imi aliquot stored at -20 °C (for western 
analysis, and a lOOp.l aliquot stored at -20 °C (for nuclease efficiency assay). 
• The beads were transferred to a fresh microcentrifuge tube and washed 5x 
5mm. with -1 ml bead wash buffer. 
. Either; The beads were boiled in 30j.tl 2x Laemmli Sample buffer. 1 .tl was 
retained for western analysis. 
Or; The bound material was trypsinised on the beads (see later). 
• Bound material was subjected to SDS-PAGE on a 4-12% Bis-Tris NuPage 
gel in MOPS running buffer (Invitrogen) for 70min at 200V. 
The gel was stained with colloidal blue stain kit (Invitrogen). 
• Each lane was cut into 20 slices and each slice cut into 3 pieces, and 
submitted for in gel tryptic digests and mass-spectrometry at Erasmus MC 
(Rotterdam). 
On bead trypsinisation (based on Rybak et al., 2005) 
• Beads were washed once in 50mM Ammonium bicarbonate then resuspended 
in 250p.l 50mM Ammonium bicarbonate. 
Sequencing grade trypsin (Roche) was reconstituted in 50mM Ammonium 
bicarbonate and added to the bead suspension at 60nglmg input protein. 
• The beads were incubated overnight at 37 °C in a rotary incubator. 
• The beads were inimobilised using the magnetic rack, the supernatant 
(trypsinised material) was transferred to a fresh microcentrifuge tube and 
stored at -20°C prior to mass-spectrometry. 
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Boiling the M-280 beads (post trypsinisation) in Laenmili buffer followed by 
western analysis can confirm that bound material has been efficiently 
digested. 
Routinely 1% of the input, bound, and unbound material was retained for western 
analysis. Imrnmunoblotting with both a-Nanog and streptavidin-HRP can provide an 
estimate of purification efficiency. 
Nuclease activity was monitored by treating the 1 OOjil aliquots of the binding 
mixture (pre and post nuclease) with proteinase K, phenol chloroform extracting the 
nucleic acid, and adding DNA loading dye prior to electrophoresis on a fresh 1% 
TBE agarose gel. Degradation of nucleic acid was assessed by viewing the gel under 
UV transillumination. 
2.23 	Mass spectrometry 
2.2.3.1 Preparation of samples for Mass-Spectrometry. 
Performed by Jeroen Demmers at the Erasmus MC (Rotterdam) as part of a 
collaboration with J. Strouboulis and colleagues. Protocol taken from (Rodriguez et 
al., 2006). 
Following electrophoresis by SDS-PAGE the gel was stained overnight with 
Colloidal Blue, according to the manufacturer's instructions. 
. The gel was destained in several changes of ddH20 until the background (i.e. 
the non-protein containing part of the gel) was completely destained. This 
usually takes several hours (i.e. more than 12 hours). 
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. The destained gel was photographed to provide a record of the purification 
experiment. 
. 20-25 microfuge tubes were rinsed in 60% acetonitrile. 
. The entire lane were cut out lengthwise and divided into at least 20 gel slices. 
Each gel slice was cut into 3 pieces and set of three pieces was placed in a 
separate tube. 
. Each gel slice was destained in 100tl of destaining solution (25mM 
ammonium bicarbonate in 50% acetonitrile) for 20-30mm. This step was 
repeated until the gel slice became completely destained (usually 3-4 times). 
Alternatively, gel slices can be destained overnight at 4oC. 
. Each gel slice was dehydrated in 1 00.tl of 100% acetonitrile for 5-1 0min at 
room 
temperature. The plug became hard and white at this step. 
The gel slices were reduced with freshly prepared 6.5mM DTT solution for 
45-60mm at 37°C. 
. TIe solution was discarded and proteins in the gel slices were alkylated by 
adding 100.d of 54 mM iodoacetamide solution and incubating for 60min at 
room temperature in the dark. 
- 	. The solution was discarded and the gel slices were washed in 1 OOi.d of gel 
slice destaining solution for 15 min at room temperature. This step was 
repeated once more. 
The washing solution was discarded and the gel slices were dried in 1 OOj.tl of 
100% acetonitrile for 1 0mm. The solution was again discarded and the gel 
slices were dried at room temperature. 
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• Proteins were in-gel digested in 1 5p,l of 10 ng/p.l modified trypsin at (diluted 
from the 1 OOx stock in 50 mM animonium bicarbonate) for 30 min on ice. 15 
l of 50 mM ammonium bicarbonate were added to the samples followed by 
overnight incubation at 3 7°C. 
Samples were equilibrated to room temperature. 30j.il  of 2% acetonitrile in 
0.1% formic acid were added to the samples and incubated at room 
temperature for 15 mm. The samples were then vortexed briefly and 
sonicated for 1 minute. 
. The supernatants were collected in separate tubes and the remaining gel slices 
were treated with 30tl of 50% acetonitrile in 0.1% formic acid and incubated 
as above. Samples were again vortexed and sonicated as above and the 
supernatants were collected and pooled with the corresponding supernatants 
the previous step. 
The samples were vacuum dried in a vacuum centrifuge for 45-60 minutes. 
• The eluted peptides were now ready for analysis by mass spectrometry. 
2.2.3.2 	Mass-Spectrometry analysis. 
Performed by Jeroen Demmers at the Erasmus MC (Rotterdam) as part of a 
collaboration with John Strouboulis and colleagues. 
Nanoflow LC-MS/MS was performed on an 1100 series capillary LC system 
(Agilent Technologies) coupled to an LTQ linear ion trap mass spectrometer 
(Thermo) operating in positive mode and equipped with a nanospray source. Peptide 
mixtures were trapped on a ReproSil Cl 8 reversed phase column (Dr Maisch GmbH; 
we 
column dimensions 1.5 cm x  100 .tm, packed in-house) at a flow rate of 8 p.11mm. 
Peptide separation was performed on ReproSil Cl 8 reversed phase column (Dr 
Maisch GmbH; column dimensions 15 cm x  50 p.m, packed in-house) using a linear 
gradient from 0 to 80% B (A = 0.1 M acetic acid; B = 80% (v/v) acetonitrile, 0.1 M 
acetic acid) in 70 min and at a constant flow rate of 200 nllmin using a splitter. The 
column eluent was directly sprayed into, the ESI source of the mass spectrometer. 
Mass spectra were acquired in continuum mode; fragmentation of the peptides was 
performed in data-dependent mode. Peak lists were automatically created from raw 
data files using the Mascot Distiller software (version 2.1; MatrixScience). The 
Mascot search algorithm (version 2.1, MatrixScience) was used for searching against 
the NCBInr database (release NCBInr_20061209.fasta; taxonomy: Mus musculus). 
The peptide tolerance was typically set to 2 Da and the fragment ion tolerance to 0.8 
Da. A maximum number of 2 missed cleavages by trypsin were allowed and 
carbamidomethylated cysteine and oxidized methionine were set as fixed and 
variable modifications, respectively. The Mascot score cut-off value for a positive 
protein hit was set to 60. Individual peptide MS/MS spectra with Mowse scores 
below 40 were checked manually and either interpreted as valid identifications or 
discarded. 
2.2.4 	Phenol:Chloroform extraction from nuclear extracts. 
• 100111 extract was diluted in 400p.l PBS and Sp.l  proteinase K (lOmg/ml; 
Sigma), and 15p.l 20% SDS were added. This was incubated overnight at 
55°C. 
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• 500.tl Phenol: Chloroform: Isoamyl alcohol (25:24:1; Fluka) was added to 
the overnight proteinase K digest and shaken vigorously. 
• The material was spun for 3 mm. at full speed in a microcentrifuge 
(13,000rpm in a Biofuge pico centrifuge, Heraeus). 
• The aqueous phase was transferred to a fresh microcentrifuge tube and 0.7 
volumes of propan-2-ol and SOjil SM NaCl were added prior to vortexing. 
• The material was spun down for 10 mm. at full speed at 4 °C in a 
microcentrifuge. 
The pellet was washed in ice cold 70% Ethanol and allowed to air dry. 
The pellet was resuspended in 30 j.tl 1X DNA loading buffer. 
2.2.5 	Size exclusion chromatography. (Rodriguez et al., 2006) 
Column running buffer 	 2x Laemmli Sample Buffer 







125mM Tris pH6.8 
25% Glycerol 
0.0 1% Bromophenol blue. 
5% 2- mercaptoethanol 
• Nuclear extract was thawed on ice and microcentrifuged at full speed for 5 
minutes at 4°C. 
• The pump (AKTA FPLC; Amersham) and the Superose 6 colunm 
(Amersham) were washed with colunm running buffer. Running program was 
set as follows: Flow rate, 100tl1min; Sample volume loop, 2001fl; Fraction 
volume, 500j.tl; Elution length, 1 column volume of column running buffer; 
Alarm pressure, 0.5MPa. 
. The calibration standards (Amersham) were run through the column to 
establish the elution volume of protein complexes. 
The sample was injected onto the column (200tl =-600j.tg nuclear extract). 
NB. Injected volume must not exceed 1% of the total column volume (24m1). 
• 500.tl fractions were collected. 
The protein fractions were precipitated with Tricloroacetic acid (Sigma). 
125.tl 100% TCA was added to each 500j.tl fraction, incubated on ice for lh. 
Precipitated protein was spun in a microcentrifuge at full speed for 15 
minutes at 4°C, washed in 1% TCA, re-pelleted, washed in ice cold acetone, 
re-pelleted, and finally boiled in 50}.tl Laemmli sample buffer. 
• lOjil of all even numbered fractions were subjected to SDS-PAGE, 
immunoblotting, and probing with a-Nanog antibody. 
2.2.6 	Histone tail binding protocols 
• Streptavidin M-280 beads (Invitrogen) (50tL/reaction) were blocked with 
200ng/ul chicken egg extract (Sigma) in PBS for lh at room temperature. 
• 2.tg of either unmodified or K4 dimethylated, biotinylated H3 peptide tails 
(NEB) were bound to 50.tl blocked beads in non-stick microcentrifuge tubes 
(Alpha Labs) in 100mM HENG buffer (see 2.2.1), 0.3% NP-40, 10% 
Glycerol, mini-complete protese inhibitors (Roche), 1mM PMSF, in a volume 
of 500.tl. A bead only negative control was also performed to control for non-
specific background binding. 
• The reaction was incubated at 4 °C for 3h with rotation. 
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• After the biotinylated peptide had pre-incubated with the beads, the unbound 
peptide was washed away via 3 washes with 300mM HENG! complete 
EDTA free protease inhibitor (Roche)! 1mM PMSF, using the magnetic rack 
to immobilise the beads at each wash. 
. The immobilised peptides (and bead only control) were added 3 tubes of 
diluted ES cell nuclear extract (300j.tg protein, in 100mM HENG buffer, 
0.3% NP-40, 10% glycerol, EDTA free complete protease inhibitor (Roche), 
1mM PMSF) in a volume of 500 p1 and incubated for 2h at 4 °C with tumbling. 
• The beads were washed 8 times with 300mM HENG containing EDTA free 
complete protease inhibitor (Roche), 1mM PMSF. 
• The beads were boiled in 50tl 2x Laemmli buffer for 10mm. and either 
stored at -20°C or subjected to SDS-PAGE. 
2.2.7 	SDS-PAGE Electrophoresis and Western Blotting. 
Running Buffer: 	MOPS Running Buffer (Invitrogen) 
Transfer Buffer: 	25mM Tris, 0.21M Glycine, 20% Methanol. 
TBS: 	 10mM Tris pH7.6-8.0, 150mM NaCl. 
Western wash Buffer: 	0.5M NaCl, 0.3% Triton X-100- made up in lBS. 
Western stripping Buffer: 62.5mM Tris pH6.8, 2%SDS. 
2X Laemmli Buffer: 	125mM Tris pH6.8, 4% SDS, 25% Glycerol, 0.01% 
bromophenol blue, 5% 2-mercaptoethanol. 
• All samples are prepared in Laemmli buffer prior to loading. To prepare 
whole cell lysates, 1x10 6 cells were lysed in 200p1 1X Laemmli buffer. 
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• Both the upper and lower chamber of the XCellSurelock module (Invitrogen) 
were filled with running buffer, and 500j.tl antioxidant reagent (Invitrogen) 
was added to the upper chamber. 
• Routinely, lOj.tl of samples were loaded onto 4-12% Bis-Tris gels 
(Invitrogen). 10.tl of 'See Blue Plus 2' protein size ladder (Invitrogen) was 
loaded. Electrophoretic separation was performed at 200V for —70 minutes. 
This provides resolution of proteins in the 20-200kDa range. - 
• The gel was removed from the housing and submerged in ice cold transfer 
buffer and the gel foot was cut off. 
• The transfer sandwich was assembled (as shown) below the surface of ice 
cold transfer buffer to minimise the risk of trapping air bubbles. 
WESTERN TRANSFER SANDWICH 
3mm Whatman paper 	 PROTRAN Nitrocellulose 
Sponge 	
Membrane (Schleicher and Schuell) 
• G • 
CATHODE 	




• - • 
Protein Movement 
• Transfer was performed at 4 °C at 395mA constant for 70 minutes. 
• The transfer sandwich was disassembled and transfer efficiency monitored by 
visually checking that the size markers were on the membrane and not 
remaining in the gel. 
• The membrane was washed briefly in TBS/ 0.05% NP-40. 
• The membrane was blocked overnight in 10% Non- fat dry Milk in TBS/ 
0.05% NP-40. 
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• The membrane was incubated for 2h at room temperature with the primary 
antibody diluted (Table 2.2) in 5% Non- fat dry milk in TBS/ 0.15% NP-40. 
• The membrane was washed 3x 1 5mm. in western wash buffer. 
• The membrane was tumbled for lh at room temperature with the secondary 
antibody diluted (Table 2.2) in 5% Non-fat dry milk in TBS/ 0.15% NP-40. 
• The membrane was washed 3x 1 5mm. in western wash buffer. 
• The membrane incubated with Super-Signal West Pico reagent (Pierce) for 
5min at room temperature. 
• The membrane was wrapped in cling film and exposed to Hyperfilm 
(Amersham) for lOs- 30min depending on the signal strength. 
• Film was developed using a SRX-1O1A developer (Konica-Minolta). 
Stripping Western Blot Membranes 
The western blot nitrocellulose membrane was incubated with stripping buffer in a 
sealed container at 70°C for 40 mm. The stripping buffer was thouroughly washed 
away before re-applying the blocking solution. 
Table 2.2 Antibodies used for western blotting 






0506 (Nanog) Produced in house N/A 1:3000 Rabbit-HRP 
a Oct-4-c-10 Santa Cruz Sc5279 1:1000 Mouse-HRP 
a HA Covance MMS-101P 1:2000 Mouse-HRP 
• Flag-M2 Sigma F3 165 1:4000 Mouse-HRP 
• HDAC2 Upstate 05-8 14 1:1000 Mouse-HRP 
a SHP-2 Santa Cruz Sc280 1:2000 Rabbit-HRP 
Streptavidin-HRP NEL NEL750 1:10,000 N/A 
a STAT3 BD Transduction 610189 1:1000 Rabbit-HRP 
a Sa114 Gift from M.Trier N/A 1:500 Rabbit-HRP 
a mouse-HRP Amersham NA93 1 1:2000 N/A 
a rabbit-HRP Amersham NA934 1:2000 N/A 
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2.2.8 	Immunoprecipitation protocols 
2.2.8.1 	Standard immunoprecipitation from mammalian cells. 
Lysis Buffer (Stored at 4 °C) 
0.5% NP-40 
50mM Tris pH8.0 
150mM NaCl 
(Mini complete protease 
inhibitor tablet; Roche) 
2x Laemmli Sample Buffer 
4%SDS 
125mM Tris pH6.8 
25% Glycerol 
0.0 1% Bromophenol blue 
5% 2-mercaptoethanol (added fresh) 
For transient transfection experiments, lxi 06  cells were plated 24h post transfection, 
the media was changed daily and the cells were lysed 72h post transfection. For 
stable cell lines, 107  cells were plated and lysed 24h post plating. 
DAY 1 
. The cells were grown in 100mm tissue culture plates (Iwaki) and the media 
changed 2h prior to lysis. 
. The media was aspirated and cells were washed twice in ice cold PBS. 
. 1 .2ml Lysis Buffer was added to plates and rocked for 30min at 4 °C. 
. The lysates were transferred to non-stick 1 .5ml microcentrifuge tube (Alpha 
Laboratories). 
. Lysates were spun at 13,000rpm at 4 °C in a microcentrifuge (Micro 24S, 
Sorvall) 
. The supernatant was transferred to a fresh non-stick microcentrifuge tube. 
• 25jil lysate was removed and mixed with 25 pJ  2x Laemmli sample buffer, 
boiled for 5min and stored at -20 °C. This was used as an input sample. 
• 5,tg antibody added to lysate and incubated overnight at 4 °C. 
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DAY 2 
• For each immunoprecipitation experiment 20p.l (10.tl packed bead volume) 
protein A or protein G sepharose beads (Amersham) were blocked with 
200ng/j.il Chicken Egg Albumin (Sigma) in PBS for lh at room temperature. 
• The beads were washed once in lysis buffer before being added to the 
immunopreciptitates and tumbled at 4 °C for 1 h to collect the immune 
comp1exes 
• The beads were washed 5 times with 500tl lysis buffer. 
• After the 5th  wash, all traces of lysis buffer were carefully removed before 
adding 301.il 2x Laemmli Buffer, boiling for 5 mm, and either storing at -20 °C 
or subjecting to SDS-PAGE. 
2.2.8.2 	Dephosphorylation of immunoprecipitated Nanog. 
• Nanog was immunoprecipitated from EF4 cell lysates as described (2.2.8.1) 
using 5p.g of a-7506 (Nanog) antibody. 
• Before adding the protein A sepharose beads, the IF mixture was split into 4 
equal aliquots of 300p1 each. 
1 Oj.tl packed bead volume of protein A sepharose beads were added to each 
tube and rotated at 4°C for lh. 
• The beads were then washed three times with 250.tl lysis buffer. 
• Three of the tubes were washed with lx phosphatase buffer (provided by the 
manufacturer), and 1 tube was washed again with lysis buffer only. 
• The beads in the 3 tubes washed in phosphatase buffer were resuspended in 
50.il phosphatase buffer and 5j.tl, 2.5pl,  or 0.il of either Shrimp Alkaline 
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phosphatase (1U/j.tl; Roche) or Antarctic phosphatase (5U/pJ; NEB) were 
added. The beads in the remaining tube were resuspended in 50pi lysis buffer 
with no enzyme. 
• The beads were incubated at 37 °C for 1 5mm. briefly spun down, washed a 
final time with lysis buffer and boiled in 30p1 Laemmli buffer for 5mm. 
before storing at -20°C or subjecting to SDS-PAGE. 
2.3 	Molecular biology techniques. 
2.3.1 	Nucleic Acid Isolation. 
2.3.1.1 	Plasmid preparation from bacterial cells. 
Plasmid DNA was prepared from overnight bacterial cultures grown in LB broth 
containing the appropriate antibiotic. Miniprep and Maxiprep kits (Qiagen) were 
used to prepare 50j.tI of -100ngItl DNA and 400.il of -2mg/ml DNA, respectively. 
DNA concentration was quantified using a ND-bOO spectrophotometer (Nanodrop). 
2.3.1.2 	RNA extraction from ES cells. 
RNA was extracted from ES cells using the RNAEasy kit (Qiagen) according to the 
manufacturer's instructions 
2.3.1.3 	First strand cDNA synthesis. 
cDNA was synthesised from RNA using the superscript® II reverse transcriptase 
(Invitrogen) according to the manufacturer's instructions. 
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2.3.2 	DNA Manipulation. 
2.3.2.1 	Agarose gel electrophoresis. 
For an analytical 1% TBE gel; 2g agarose (Cambrex) was added to 200m1 
0.5X TBE buffer (45mM Tris- Borate, 1mM EDTA). This was heated in a 
microwave on full power for —2min until the agarose was completed 
dissolved. 
. The agarose was allowed to cool to below 60°C and 6p.l of Ethidium bromide 
(1 Omg/ml stock) was added. 
• Gels were cast in a gel casting tray, and once set were routinely run in 0.5X 
TBE buffer at 1 OOV in a gel tank, with the DNA in 1X Ficoll Blue DNA 
loading buffer (6X stock; 15% w/v Ficoll 400 (Amersham) in dH 20/0.02% 
bromophenol blue (BDH)). 
• Restriction fragments lengths were visualised using a GeneFlash Imager 
(Syngene). 
Preparative gels were prepared and run in lx TAE buffer (40mM Tris-acetate, 
2mM EDTA). 
2.3.2.2 	1 Restriction endonuclease digestion. 
DNA digestions were performed using restriction endonucleases from Roche and 
NEB and are performed in the buffers provided by the manufacturers. 
2.3.2.3 	Blunt ending of cohesive ends. 
To a 200 jil digest volume, 6.6jil 1mM dNTP's (final conc. 33j.iM) and 41fl 
(5U/p.l) Klenow fragment (NEB) of DNA polymerase were added. 
• The reaction was incubated at 25°C for 1 5mm. 
• The reaction was inactivated at 75°C for 5 mm. and a final concentration of 
10mM EDTA was added. 
2.3.2.4 	Construct Building. 
2.3.2.4.1 	Purification of restriction DNA fragments 
Routinely, 1 Otg plasmid DNA was digested with the relevant restriction 
endonucleases (New England Biolabs and Roche) in the manufacturer's 
buffer. NB. If the two enzymes used to release a desired fragment were not 
compatible with a given buffer, an ethanol precipitation step was performed 
after a single enzyme digestion and the precipitated DNA was resuspended in 
the second buffer before adding the second restriction enzyme. 
• Fragments were separated on TAE agarose gels (1% for fragments >1kb, 2% 
for fragments < 1kb), visualised via long wavelength UV transillumination 
(UVP), and the desired fragment was excised with a clean scalpel blade. 
• The DNA was extracted from the gel slice using the QIAEX II kit (Qiagen) 
according to the manufacturer's instructions. 
2.3.2.4.2 	Ligation. 
• Ligation reactions were routinely performed using either T4 ligase or 
QuickLigase (NEB) in a volume of 20pd, according to the manufacturer's 
instructions. Ligation reactions were set up with vector: insert in a 1:3 molar 
ratio using bOng of the vector (largest) fragment. 
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6tl of the ligation reaction was used to transform 50.il DH5a E.coli 
(Invitrogen). 
2.3.2.4.3 	Screening for correct ligation products. 
• 	300ng Miniprep DNA was digested with a panel of (usually 2 or 3) 
restriction endonucleases which would give an unambiguous restriction 
fragment length pattern upon agarose gel electrophoresis. 
High purity maxiprep (Qiagen) DNA was produced prior to transfection into 
mammalian cells. 
2.3.3 	Transformation of plasmid DNA into E.coli. 
Firstly, Luria Broth (LB) agar (1.5% w/v agar in LB, 1% w/v tryptone (Difco), 0.5% 
w/v yeast extract (Difco), 5mM NaCl) was melted, appropriate antibiotics added 
once agar had cooled to below 60 °C, and plates were poured. 
• A vial of DH5a E.coli (Invitrogen) was thawed on ice. 
• -lOng plasmid (or 6jil of a ligation reaction) DNA was added to 50il 
DH5a E.coli and flicked gently to mix. 
• The mixture was incubated on ice for 30mm. 
• The bacteria were heat shocked in a 37 °C heat block for 30sec., and 
returned to ice for 2mm. 
• 950.tl LB broth was added and shaken at 200rpm at 37 °C for lh in an 
orbital shaker. 
M. 
• For known plasmid DNA; 1 Oil and lOOp 1 of transformation mix was 
plated out on 100mm plate containing LB Agar and the appropriate 
antibiotic (see Table 2.3). For ligation products, 100j.il and all of the rest 
were plated out and incubated at 37 °C overnight. 
Transformation efficiency was monitored by transfecting a known 
amount (5 picograms) pUC19 plasmid. 
Table 2.3 Antibiotic concentrations for selection of transformants in E. coli.. 
ANTIBIOTIC STOCK CONC. WORKING CONC. 
Ampicillin lOOmg/ml in dH20 50.tg/ml 
Carbenicillin 100mg/mi in dH20 50j.tg/ml 
Kanamycin 1 Omg/ml in dH20 20j.tg/ml 
Zeocin lOOmg/ml in dH20 25tg/ml 
2.3.4 	Ethanol precipitation of DNA. 
• DNA was precipitated by adding 2.5 volumes 100% Ethanol, 1/10 volume 
5M NaCl,. and storing at -20°C for at least 30mm. 
• DNA was spun at full speed in a microcentrifuge for 20min at 4 °C. 
• The pellet was washed in 70% ice cold Ethanol and allowed to air dry. 
• Depending on the experiment, the DNA was either resuspended in a buffer 
for restriction digestion or in milliQ water if being used for transfection into 
mammalian cells. 
2.3.5 	Polymerase Chain Reaction (PCR). 
Reactions were performed using Phusion (Finnzymes), a high fidelity Taq DNA 
polymerase. 
For each 50pi reaction the following was used; 
DNA template 	(200ng cDNAlreaction) 
300nM oligo 1 
300nM oligo 2 
200p.M dNTP's 
lx PCR Buffer (Supplied by manufacturer) 
0.5j.tl Phusion (5U/j.tl) 
make up to a final volume of 50.tl with milliQ dH 20. 
The following program was used on a GeneAmp®9700 thermocycler (Applied 
Biosystems) to amplify cDNA templates. 
98°C 30s 
98°C lOs 
Tm+3°C lower primer .. 25 cycles 
72°C 3 Os/kb 	J 
72°C 1 0mm 
See oligonucleotide appendix for details of primers sequences. 
3 tl of PCR reaction mixture was subjected to TBE agarose gel electrophoresis to 
visualise the PCR product. If a single discrete band was seen then TOPO cloning was 
performed. 
2.3.7 	Cloning of blunt end PCR products. 
The Zero Blunt® TOPO® cloning kit was used (Invitrogen). TOPO cloning provides 
a quick and efficient method to clone blunt ended PCR products such as those 
produced by Phusion Taq polymerase. The reaction was carried out according to the 
manufacturer's protocol. The pCR®-Blunt II- TOPO® vector contains EcoRI 
flanking the insert site allowing a convenient first screen to analyse correct 
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transformants via EcoRI digestion. Cloned PCR products were then verified by DNA 
sequencing at the School of Biological Sciences Sequencing Service- University of 
Edinburgh. Sequence data was analysed using Seqman software. 
2.3.8 	Mutagenesis of plasmid DNA 
The template plasmid for the mutagenesis performed in this thesis was IPC 35 (see 




200mM Tris pH7.4 
20mM MgCl2 
500mM NaCl 
Ratio of template: oligo = 10:1. 
The following were combined on ice in a 1 .5m1 tube; 
1.3j.il lp.M oligo 1 
1.31.il ltMoligo2 
1 .tl. i OX annealing buffer. 
1.3.tl ssDNA 1PC35 (200ng) 
5.1 p1 milliQ H20 
The annealing reaction was mixed gently, spun down, and placed in a beaker 
containing 500m1 dH20 at 70°C. The beaker was removed from the water 
bath and allowed to cool to room temperature. 
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Synthesis 
The following were combined on ice, adding the hybridisation mix last. 
lOjtl Hybridisation mixture 





2.5 units T4 DNA ligase (NEB) 
2 units T4 polymerase 
+mifliQ dH20 to a final volume of lOOp,l. 
The synthesis reaction was incubated for 5 minutes on ice, followed by 5 
minutes at room temperature, and finally 2h at 3 7 °C. The reaction was 
stopped via addition of 3.tl 0.5M EDTA. 
. DH5a E. coli were transformed with 1 Oj.d of the synthesis reaction, plated on 
LB agar plates containing 50tg/ml carbenicillin, and incubated at 37 °C 
overnight. 
• The next day, 12 bacterial colonies were picked in to LB broth containing 
50g/ml ampicillin and incubated overnight at 37 °C with shaking. 
• The next day minipreps were prepared and suitable restriction digests were 
performed to screen for the putative mutant DNA molecule. These were then 
verified by DNA sequencing at the School of Biological Sciences Sequencing 
Service (SBSSS) and sequence data was analysed using Seqman software. 
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Chapter 3. 
Biochemical Characterisation of Nanog. 
3.1 	Introduction 
Nanog has been identified as a key regulator of pluripotency. (Chambers et al., 2003; 
Mitsui et al., 2003) However, the precise mechanism of Nanog action remains 
unclear. A complete dissection of the molecular mechanisms by which Nanog acts 
will involve identification of upstream regulators and downstream target genes. In 
addition, a thorough biochemical characterisation of Nanog and any associated 
partner proteins required for Nanog function will also be required. 
The ability of a given transcription factor to regulate gene expression depends on a 
number of biochemical factors including post-translational modification, 
accessibility to the target DNA sequence and, potentially, inclusion in higher-order 
multi-protein complex(es). Homeodomain containing proteins bind specifically to 
DNA sequences with the consensus ATTA and act as sequence specific transcription 
factors that have myriad roles in development and evolution (reviewed by Gehring, 
1987). The homeodomain is a60 amino acid amino sequence that contains three a 
helices folded around a hydrophobic core with a flexible arm extending from the N-
terminus (reviewed by Wolberger, 1996). Examples are known in which 
homeodomaiff proteins bind to DNA as monomers, such Antennapaedia in 
Drosophila (Billeter et al., .1993), hetero-dimers, such as the MATa1 and MATa in 
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yeast (Li et al., 1995), or homo-dimers, such as the paired class homeodomains 
(Wilson et al., 1995). 
In simplistic terms Nanog can be thought of as a 305 residue protein containing three 
domains; a centrally located homeodomain flanked by a serine rich N-terminus and 
the C-terminus (Figure 3.1). The Nanog homeodomain is most closely related to the 
NK2 family of homeodomain proteins sharing 50% identity across the homeodornain 
to mouse members of this family (Chambers et al., 2003). NK2 family members are 
characterised by the presence of a sequence conforming to the consensus 
PARRIAVPVLVRDGKPCL located 15 residues C-terminal to the homeodomain as 
well as a conserved tyrosine residue within DNA binding a-helix of the 
homeodomain (Lints et al., 1993). As Nanog lacks these signature motifs it cannot be 
classified as a member of the NK2 family. In fact, outwith the homeodomain there is 
little homology to other proteins that can be used to infer biological function. The 
Nanog C-terminal domain can be further subdivided due to the presence of a 
centrally located pentapeptide repeat in which a tryptophan is present at every 5th 
residue. The C-terminal domain is likely to be of functional importance as it has been 
shown to possess two transactivation domains as judged by Ga14-fusion luciferase 
assays (Pan and Pci, 2003; Pan and Pei, 2005). Furthermore, the tryptophan residues 
have been shown to be implicit to this transactivation, although these experiments 
were not performed in ES cells (Pan and Pci, 2005). In addition, Nanog can 
transactivate a reporter driven by its cognate binding sequence in non-pluripotent 
cells (Pan and Pci, 2005). Whether Nanog can transactivate endogenous genes in ES 
cells is not clear. N-terminal to the homeodomain, Nanog contains a sequence which 
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Figure 3.1- Amino acid sequence of mouse Nanog protein. 
The coloured boxes show the boundaries of putative domains within 
Nanog. The C-terminal domain begins at K156 and is further divided due 
to the presence of the tryptophan repeat into C-N (K156-M197), tryptophan 
repeat (W198-W243), and C-C (N244-1305). 
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has homology to a sequence of unknown function within the linker region of Smad4 
(Hart et al., 2004). To begin biochemical characterisation of Nanog, experiments are 
described below which assess the multimerisation capacity of Nanog, post-
translational modification of Nanog protein, as well as a candidate based approach to 
identify Nanog interacting proteins. 
3.2 	Nanog multimerises through sequences within the C-terminal domain. 
To assess whether Nanog protein could multimerise, transient transfections were 
performed using two Nanog plasmids with distinct epitope tags fused to the N-
terminus (Figure 3.2). This allows subsequent immunoprecipitates collected with an 
antibody against one of the tags to be examined by immunoblotting for the presence 
of Nanog tagged by the second epitope. Whole cell lysates were prepared in 0.5% 
NP-40, 50mM Tris pH8.0, 150mM NaCl and (Flag) 3Nanog was immunoprecipitated 
with a-Flag-M2 antibody. The immunoprecipitates were subjected to SDS-PAGE 
followed by immunoblotting and detection with a-HA antibody. Experiments in 
E14/T mouse ES cells (Aubert et al., 2002) show that indeed Nanog is capable of 
multimerising with itself (Figure 3.3). In addition, as a similar interaction was 
obtained following transfection of COS-7 cells (Figure 3.3), showing Nanog 
multimerisation does not depend on additional proteins present in mouse ES cells yet 
absent from African green monkey kidney fibroblasts. Furthermore, the C-terminus 
of Nanog is absolutely required for this interaction as (HA) 3NanogAC is not co-
immunoprecipitated with (Flag) 3Nanog (Figure 3.4). However, truncations lacking 





155 	198 	243 	305 
Full-length (1PC37) (flag)3 	N-term 	HD 4WI WR 
Full-length (IPC38) (HA) 3 WR 
AN (1PC78) (HA)3 \/'\/\,/\/ - 	WR 
AC (IPC79) (HA)3 
AHD(1PC168) (HA)3 WR 
AC49 (IPC 178) (HA)3 WR 
AC20 (IPC 177) (HA)3 WR 
C-term (IPC 86) (HA)3 WR 
AWR (1PC328) (HA)3 • 	/\\/ 
Figure 3.2- Schematic representation of epitope tagged Nanog 
deletion mutants. 
Numbers refer to the amino acid residue. N-term- N-terminal region; 
HD- homeodomain; WR- Tryptophan repeat; C-term- C-terminal region. 
IPC numbers are plasmid database reference number. 
\/\,/\t\/ Indicates the deleted region. 
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Lysate WB: a HA 51 kDa - 	- 
IP: a Flag, WB: aFlag 
E14/T COS7 
Figure 3.3- Nanog is able to multimerise with itself in ES cells and COS-7 
cells 
Co-transfections of (Flag) 3Nanog and (HA) 3Nanog into El 4/T ES cells and 
COS-7 cells were performed. a-Flag-M2 immunoprecipitates were 
prepared and immune complexes separated by SDS-PAGE. The immunoblots 
were probed with u-HA antibody.. Further details of the protocol are provided in 
Materials and Methods (section 2.2.8.1). 
Constructs are schematically depicted in Figure 3.2 
ig 
(Flag)3Nanog 	 (Flag)1Nanog 
	 01 . 
0 0 	 0 0 	 N 
0 	 C)L) U e Z 	C..) C.) C..) 
z z < < z z < < < < < 
< <<<<<< << <<<<< 
a-Flag Ab IP  
51kDa 
I?: a Flag, 	 39kDa 
WB:aHA 
- 	 I 28kDa 
Lysate WB: 	 — 	 — — 
- 51kDa 
a HA 	 - 39kDa 
- 28kDa 
IP: a Flag,  
WB: a Flag 
E14/T 	 COS-7 
Figure 3.4- The C-terminal domain of Nanog is necessary for multimerisation 
in ES cells and COS-7 cells in transient co-transfection experiments. 
Transfections were performed and processed as described in Figure 3.3 using the 
deletion mutants indicated and diagrammed in Figure 3.2. 
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(Figure 3.4), suggesting that the site of interaction lies between the end of the 
homeodomain at K156 and L256. 
To determine whether the multimerisation capacity of Nanog could localise to the C-
terminal domain, further transient co-transfections of COS-7 cells were performed. 
Immunoprecipitation with the a-Flag-M2 antibody followed by SDS-PAGE and 
immunoblotting with a-HA antibody indicated that under these conditions (0.5%NP-
40, 50mM Tris pH8.0, 150mM NaCl), the C-terminal domain can interact with a 
second Nanog molecule (Figure 3.5). Taken together these data show that the C-
terminal domain of Nanog is not only required but also sufficient for Nanog 
multimerisation. 
3.3 	The role of the Nanog tryptophan repeat. 
3.3.1 The tryptophan repeat is necessary for Nanog multimerisation. 
The preceding experiments indicated that the region between K156 and L256 was 
responsible for Nanog mulitmerisation. As the tryptophan repeat lies in this region, a 
mutant was generated lacking this repeat sequence; (HA) 3NanogAWr (see plasmid 
appendix for cloning strategy). Transient co-transfection experiments using E14/T 
ES and COS-7 cells demonstrated that (HA) 3NanogAWr could not be co-
immunoprecipitated with (Flag) 3Nanog. This indicates that residues within the 
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Figure 3.5- The C-terminal domain of Nanog is sufficient to interact with 
a second molecule of Nanog in transient COS-7 cell transfections. 
Co-transfections of (Flag) 3Nanog and (HA) 3Nanog deletion mutants into 
COS-7 cells were performed as indicated. Cells were lysed 
(0.5%NP-40, 50mM Tris pH8.0, 150mM NaCl), ct-Flag-M2 
immunoprecipitates were prepared, immune complexes separated by 
SDS-PAGE and immunoblotted. The immunoblots were probed 
with a-HA. Further details of the protocol are found in the materials and 
methods (section 2.2.8.1). 
E31 
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Figure 3.6- The tryptophan repeat of Nanog is necessary for Nanog-
Nanog interaction in transient ES and COS-7 cell transfections. 
Co-transfections of (Flag) 3 Nanog and (HA) 3Nanog deletion mutants into 
E14/T ES cells and COS-7 cells were performed as indicated. a-Flag-M2 
immunoprecipitates were prepared and immune complexes separated by 
SDS-PAGE and immunoblotted. The immunoblots were probed with a-
HA antibody. Details of the immunoprecipitation protocol are found in 
material and methods 2.2.8.1 
M. 
3.3.2 The tryptophan repeat is functionally important in mouse ES cells. 
In addition to being required for multimerisation, the Nanog tryptophan repeat is 
required for transactivator function of Nanog (Pan and Pei, 2005). This conclusion 
rests on experiments conducted in HEK293 cells in which a luciferase reporter under 
the control of multimerised Ga14 DNA binding sites was co-transfected with fusion 
proteins formed between the Ga14 DNA binding domain and fragments of Nanog. 
Mutation of tryptophan residues indicated at least some of the tryptophan residues 
are required for function. However, the importance of the tryptophan repeat for 
Nanog function in ES cells is not known. To assess this, E14/T cells were super-
transfected (Aubert et al., 2002; Gassmarm et al., 1995) with either (I-IA)3Nanog, 
(HA) 3NanogA C, GFP, or (HA)3 NanogA Wr and transfectants selected in puromycin 
in the presence or absence of LIF. Colonies were photographed after ten days clonal 
expansion, and stained for alkaline phosphatase activity the following day. For 
example undifferentiated, mixed, and differentiated colonies see Figure 4.4a. As 
expected, full length Nanog expression provides the highest proportion (91%) of 
uniformly undifferentiated colonies in the presence of LIF. A high proportion (>80%) 
of colonies expressing either GFP or (HA)3Nanogzl Wr are also uniformly 
undifferentiated in the presence of LIF but these colonies differ qualitatively from 
those expressing (HA)3Nanog. The latter form raised colonies that are highly 
refractile under phase contrast microscopy (Figure 3.7a). In contrast, GFP expressing 
colonies appear flatter and (HA)3NanogA Wr expressing colonies are either very small 
or show some peripheral differentiation when grown in the presence of LIF (Figure 
3.7a). Interestingly, in the presence of LIF, (HA)3NanogAC expressing colonies 
show a much higher proportion of mixed colonies (5 7%) compared to the other 
M. 
constructs suggesting it may have a dominant negative effect on Nanog action. Upon 
cytokine withdrawal, 57% of colonies expressing (HA)3Nanog remain uniformly 
undifferentiated whereas the only 7% of (HA)3NanogA Wr colonies are 
undifferentiated. The inability of the mutant Nanog molecules to efficiently direct 
LIF independent self-renewal can also be seen by visually inspecting the AP stained 
plates without microscopy (Figure 3.7b) which shows the gross differences between 
full-length (HA)3Nanog and' the mutant molecules. No uniformly undifferentiated 
colonies expressing GFP and (HA) 3Nanog4 C were observed in the absence of LIF. 
Taken together these results indicate that the Nanog C-terminal domain is required 
for ES cell self-renewal and that the tryptophan repeat constitutes a significant part of 
this requirement. However, these experiments also suggest that additional motifs 
within the C-terminal domain but outwith the homeodomain are likely to be 
important for Nanog function. 
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Figure 3.7- Functional assessment of tryptophan repeat in E14/T ES cells. 
El 4/T ES cells were transiently transfected with the constructs indicated: 
(HA) 3 AC(IPC 79), (HA) 3 Nanog (IPC 38), GFP (AGS 684), (I-IA) 3NanogAW-
repeat (IPC 328); 5x104 cells plated at a density of 640 cells/cm 2 and cultured in 
the presence and absence of LIF in 2.xg/ml puromycin. After II days clonal 
growth, the cells were photographed under phase microscopy (a), before 
alkaline phosphatase staining, (b). 
3.4 	Post-translational modification of Nanog in mouse ES cells 
3.4.1 	Post-translational modifications 
Protein function depends not only on the primary amino acid sequence but also on 
post-translational modifications and how these affect quaternary structure. Many 
transcription factors exhibit post-translational modification including ubiquitination, 
sumoylation, which inhibits transcription factor activity (Gill, 2005), acetylation, 
methylation, and phosphorylation. Post-translational modification can alter protein 
function. For example, the phosphorylatable transcription factor Stat3 exists in an 
inactive state in the cytoplasm when unphosphorylated (Stahl et al., 1995). 
Following phosphorylation, Stat3 dimerises and translocates to the nucleus, the site 
of transcriptional activity (IhIe, 1996). In this section an experiment is presented 
investigating the post-translational modification of Nanog protein. 
3.4.2 Nanog is a phosphorylated protein 
Nanog has a predicted molecular weight of 351cDa although it migrates much slower 
than predicted upon SDS-PAGE. An antibody raised against amino acids 2-16 of 
mouse Nanog (Chambers, 2005) recognises three bands that migrate with an 
apparent molecular weight NO  of -.42kDa on immunoblots of mouse ES cell lysates. 
It is known that post-translational modifications can affect the migration of proteins 
during electrophoresis. To investigate whether these bands of retarded migration 
were due to phosphorylation of Nanog, Nanog immunoprecipitates were prepared 
from the Nanog over-expressing cell line EF4 (Chambers et al., 2003) using anti-
Nanog antibody (Chambers, 2005). These immunopreciptitates were then washed 
extensively and treated with two independent phosphatases whilst immobilised on 
- 	 — r 
- 
AntP 	 SAP 
Ig 	 OEM 
Nanog iiawww - 
Figure 3.8- Nanog is a phosphoprotein in mouse ES cells. 
(Taken from Yates and Chambers, 2005) 
EF4 cells (1.2x107) cultured in the presence of LIF, were lysed in 1.2m1 
lysis buffer (0.5%NP-40, 150mM NaCl, 50mM Tris pH8.0), and u-Nanog 
immunoprecipitates were prepared. The immune complexes were collected 
on protein A sepharose beads and washed in lysis buffer (wash 1), followed 
by washing in manufacturer's phosphatase buffer (wash 2). Finally, the 
immunoprecipitates were subjected to on-bead phosphatase treatment with 
increasing concentrations of either antarctic phosphatase (Ant F; NEB) or 
Shrimp alkaline phosphatase (SAP; Roche) as indicated. Note the collapse 
of the triplet signal to a single band in the phosphatase treated samples; Ig 
is the heavy chain immunoglobulin. For a detailed protocol see section 
2.2.8.2 of this thesis. 
M. 
the solid phase beads. Subsequent immunoblotting analysis with anti-Nanog 
antibody revealed that the triplet signal normally observed had collapsed to a single 
band upon treatment with either antarctic phosphatase or shrimp alkaline 
phosphatase (Figure 3.8), (Yates and Chambers, 2005). 
3.5 	Nanog partner proteins: a candidate approach 
A major goal towards delineation of the mechanism of Nanog action is to identify 
Nanog partner proteins in mouse ES cells. At the outset of this project no. such 
partner proteins of Nanog had been identified. Therefore potential partner proteins 
were examined in a candidate based approach. Interactions were examined between 
Nanog and two other key regulators of ES self-renewal, Stat3 and Oct4. As Stat3, 
Oct4, and Nanog are all transcription factors with important roles in ES cell self-
renewal, a simple hypothesis is that these molecules might act together in a complex 
on target genes. 
3.5.1 	Stat3 
The functional expression cloning of Nanog depended upon the ability of Nanog to 
direct ES cell self-renewal in the absence of LIF. However, the self-renewal 
efficiency of ES cells over-expressing Nanog is enhanced if the cells are treated with 
LIF. Stat3 is known to be a downstream effector of LIF signalling important for ES 
cell self-renewal (Matsuda et al., 1999; Niwa et al., 1998). As Stat3 does not appear 
to be a downstream transcriptional target of Nanog (Chambers et al., 2003) the co-
operative effect of Nanog and Stat3 on ES cell self-renewal could result from a direct 
interaction between Nanog and Stat3. Nanog protein was immunoprecipitated from 
EF4 cells using anti-Nanog antibody (Chambers, 2005). The immunoprecipitates 
were subjected to SDS-PAGE and immunoblots probed with anti-Stat3 antibody. No 




Over-expression of Oct4 results in differentiation into a mixture of cell types that 
express markers of endoderm and mesoderm (Niwa et al., 2000). This cellular 
differentiation is similar both morphologically and in terms of marker expression to 
that seen upon LIF withdrawal. This similarity in phenotype caused by these 
treatments led to the proposition that a binding partner of Oct4 existed that was 
present in limiting amounts and that was maximally active in cells stimulated by LIF 
(Niwa, 2001). As Nanog fits both these criteria and as the pro-differentiative effect of 
Oct4 over-expression is attenuated in ES cells over-expressing Nanog (Chambers 
unpublished) a direct interaction between Nanog and Oct4 seemed feasible. Nanog 
protein was immunoprecipitated from EF4 cells using anti-Nanog antibody 
(Chambers, 2005). The immunoprecipitates were subjected to SDS-PAGE and 
immunoblots probed with anti-Oct4. No interaction between Nanog and Oct4 was 
observed under the conditions tested (Figure 3.9). 
3.5.3 	Generation of (Flag) 30ct4: (HA)3Nanog expressing cell line. 
The failure to detect an interaction between Nanog and either Oct4 or Stat3 described 
in the previous section could be due to the low affinity between the 













Figure 3.9 Nanog does not interact with Stat3 or Oct4 in mouse ES cells. 
Nanog was immumnoprecipitated from from EF4 cells using anti Nanog 
antibody and subjected to SDS-PAGE. After transfer to nitrocellulose 
immunoblots were probed with anti -Oct4-C-10, anti-Stat3, and anti-Nanog 
antibodies. For details of the immunoprecipitation protocol see 2.2.8.1 
all 
immunoprecipitating antibody could disrupt the interaction being sought. To 
circumvent such potential problems, immunoprecipitations were performed using 
antibodies against haemagglutinin (HA) and the Flag peptide in conjunction with 
trimerised epitope tags, as these reagents have been optimised for 
immunoprecipitation and immunoblotting applications. Having the epitope tag in 
triplicate increases the avidity of the antibody- antigen interaction, a property 
particularly important in immunoprecipitation procedures. An ES cell line carrying 
epitope tagged Nanog and Oct-4 transgenes was generated as a reagent to further 
examine possible Nanog-Oct4 and Nanog-Stat3 interactions. The cell line was based 
on the ZHBTc4. 1 cell line (Niwa et al., 2000) which has two null Oct-4 alleles but 
can be sustained in the undifferentiated state by the expression• of doxycycline 
repressible Oct4 transgene. In cell culture, growth without doxycycline activates the 
transgene and thus the ES cell phenotype is maintained. To generate a derivative cell 
line expressing (Flag) 30ct4 protein, ZHBTc4. 1 cells were transfected with a 
(Flag) 30ct4 transgene and selected in 1 ig/ml puromycin in the presence of 
doxycycline. Under these conditions cells will differentiate down the 
trophectodermal lineage unless (Flag) 30ct4 is expressed at the appropriate level. The 
fact that undifferentiated clones were obtained shows that the fusion of the (Flag) 3 
epitope tag to the N-terminus of Oct4 does not affect Oct4 function. One of the 
(Flag)30ct4 clones obtained, clone c6, was then then transfected with a (HA)3Nanog 
transgene and selected in G4 18. A schematic diagram of the 
(F1a9)30ct4:(I-IA)3Nanog cell line is shown (Figure 3.10a). Immunoblotting of 
(Flag) 30ct4 clone c6 whole cell lysates detects (Flag)30ct4 protein, and in 
(HA) 3Nanog derivative lines, the size shifted (HA) 3Nanog protein is observed with 
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Figure 3.10 (Flag) 30ct4: (HA) 3Nanog cell line generation. 
Schematic depiction of (Flag)30cr4: (HA)3Nanog cell line. ZHBTc4. I 
cells were stably transfected with (Flag) 3 Oct4IRESpac and selected 
with puromycin in the presence of doxycycline to generate (Flag) 30ct4 
parental cells. Clone c6 was then stably transfected with 
(HA) 3NanogIRES/3-geo and selected in G41 8. 
(Flag) 3 0ct4: (HA) 3Nanog whole cell lysates were resolved by SDS-
PAGE, immunoblotted, and probed with the indicated antibodies. 
SHP-2 acts as a loading control. Subsequent immunoprecipitation 
experiments were performed using clone 2B4. 
92 
the expected retarded migration relative to the endogenous protein (+ 4kDa) (Figure 
3.1 Ob). As the (Flag)30ct4 cells are grown in doxycycline, all the Oct4 protein in 
the cell is Flag tagged, whereas the HA tagged Nanog represents approximately one 
third of the total Nanog protein. 
3.5.4 Nanog does not interact with 004 or Stat3 in (Flag)30ct4: (HA)3Nanog 
ES cells. 
(HA)3Nanog was immunoprecipitated from (Flag)3 Oct4: (HA)3Nanog ES cell lysates 
using anti-HA antibody. The immunoprecipitates were resolved by SDS-PAGE, 
immunoblotted, and probed with anti-Stat3 and anti-Flag antibodies. The results 
show that (HA)3Nanog is clearly enriched in the anti-HA immunoprecipitates, 
however (Flag)30ct4 and Stat3 do not co-immunoprecipitate with (HA) 3Nanog under 
these conditions (0.5 1/oNP-40, 50mM Tris pH7.5, 150mM NaCl) (Figure 3.11). 
3.6 	5a114 interaction studies in mouse ES cells. 
3.6.1 Sa114 physically interacts with Nanog and Oct4 
During the course of this study an interaction between Nanog and the Spalt like Zinc 
finger protein Sal14 was described in ES cells (Wu et al., 2006). This interaction has 
been confirmed by detecting the presence of Sal14 protein in Nanog 
immunoprecipitates from EF4 ES cells (Figure 3. 12a). The domain within Nanog 
responsible for the interaction with Sal14 was identified as the homeodomain (Wu et 
al., 2006). Comparing the Nanog homeodomain sequence with all other known 
homeodomain sequences identifies a motif (SLQQ), located at the N-terminal end of 
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Figure 3.11 Nanog does not interact with Stat3 or 004 in 
(Flag)30ct4. (HA)3Nanog cells. 
(HA)3Nanog was immunoprecipitated from (Flag) 3 0ct4: (HA) 3Nanog 
cell lysates using anti-HA antibody and subjected to SDS-PAGE. After transfer 
to nitrocellulose, immunoblots were probed with anti -Flag and anti-Stat3. For 
details of the immunoprecipitation protocol see 2.2.8.1. 
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Figure 3.12- Sa114 interacts with Nanog and Oct4 
1x107 FF4 ES cells were lysed in 1.2m1 lysis buffer (0.5% NP-40, 50mM Tris p118.0, 150mM 
NaCl). Nanog was immunoprecipitated using anti-Nanog antibody and immune complexes were 
collected on protein A sepharose. After extensive washing in lysis buffer, the beads were boiled 
in Laemmli buffer and bound proteins were resolved by SDS-PAGE prior to immunoblotting 
with anti- Sal14 antibody. 
lxi 06  Nanog/T (super-transfectable Nanog over-expressing cells) were transiently transfected 
with pPyCAG(Flag) 30ct4 expression construct. —72h post-transfection cells were lysed in 1 .2m1 
lysis buffer (0.5% NP-40, 50mM Tris pH8.0, 150mM NaCl). Sa114 was immunoprecipitated 
using anti-Sal14 antibody and immune complexes were collected on protein A sepharose. After 
extensive washing in lysis buffer, the beads were boiled in Laemmli buffer and bound proteins 
were resolved by SDS-PAGE prior to immunoblotting with anti- Flag antibody. 
lx 106  E14/T ES cells were transiently transfected with (HA) 3Nanog or indicated Nanog mutant 
expression constructs. 72h post-transfection, cells were lysed in 1 .2m1 lysis buffer (0.5% NP-40, 
50mM Tris pH8.0, 150mM NaCl). Sal14 was immuno-precipitated using anti-Sa114 antibody and 
immune complexes were collected on protein A sepharose. After extensive washing in lysis 
buffer, the beads were boiled in Laemmli buffer and bound proteins were resolved by SDS-
PAGE prior to immuno-blotting with anti- HA antibody. Aliquots of cell lysates were subjected 
to SDS-PAGE followed by immunoblotting to illustrate (HA) 3Nanog expression from all 
constructs. 
lxiO6 E14/T ES cells were transiently transfected with the constructs indicated-, Nanog (1PC 
38), GFP (AGS 684), SLQQ>SAAQ (IPC 120). 24h after transfection the cell were trypsinised 
and re-plated at 640 cells/cm2 in the presence or absence of LW with selection in 2ig/m1 
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Figure 3.13- Model showing the position of the TSEE motif in human Octi 
homeodomain corresponding to the SLQQ motif in the 004 and Nanog. 
Multiple sequence alignment of the human Oct 1, mouse Nanog, mouse 
Oct4, human Nanog, rat nanog, human Oct4, and mouse Nkx2.5 homeodomains. 
Performed using ClustalW vi .83). SLQQ motif or analogous sequence is 
Highlighted in the blue box. 
Crystal structure of human Octi bound to DNA (adapted from Remenyi 
et a!, 2003). Image produced using PyMol software. The DNA is coloured in purple 
and protein in green. The TS [- motif can be seen in the second a helix. 
A higher magnification of the Octi Ti motif showing the serine and 
glutamate side chains projecting into space. 
that these sequences are involved in interaction of Nanog andOct4 with a common 
partner. The most relevant protein for which a structure has been determined is Octi 
(Remenyi et al., 2003). Alignment of Oct4, Nanog, and Octi homeodomain amino 
acid sequences reveals that the human Octi homeodomain contains a TSEE  motif at 
the position of SLQQ in Oct4 and Nanog (Figure 3.13a). Mapping the SLQQ motif 
onto the three dimensional structure of Octl (Remenyi et al., 2003) suggests that 
these residues protrude from the homeodomain along the helical axis (Figure 3.13b). 
The position of Octi S406 and E407 are labelled on Figure 3.13c and these residues 
correspond to the central LQ of the SLQQ domain in Oct4 and Nanog. The leucine 
residue is hydrophobic compared to the hydrophilic serine residue at the analogous 
position in Oct 1, and an uncharged glutamine is found in the SLQQ motif in place of 
the acidic glutamate residue in TSEE. These considerations predict that if the SLQQ 
motif is involved in the Sal14 interaction, then Oct4 should also interact with Sa114. 
To determine whether Sal14 and Oct4 physically interact, a (Flag) 30ct4 expression 
plasmid was transiently transfected into NanoglT ES cells (supertransfectable EF4 
derivatives). Sal14 immunoprecipitates prepared using anti-5a114 antibody (Elling et 
al., 2006) were immunoblotted and probed with anti-Flag antibody. A co-
immunoprecipitating band corresponding to (Flag) 30ct4 protein is specifically 
observed in the Sa114 immunoprecipitate (Figure 3.12b) This suggests that Oct4 can 
physically interact with Sa114 in mouse ES cells. 
3.6.2 The Nanog SLQQ motif mediates Sa114 interaction. 
These considerations prompted an analysis of whether the site of Sa114 interaction 
with Nanog is the SLQQ motif in the homeodomain. To this end E14/T cells were 
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transiently transfected with (HA) 3Nanog, (HA) 3Nanog N51A (a putative DNA 
binding mutant), or (HA) 3NanogSLQQ>SAAQ. Co-immunoprecipitation experiments 
were carried out (according to protocol 2.2.8.1) with the anti-Sa114 antibody (Elling 
et al., 2006), immunoprecipitates were subjected to SDS-PAGE, and subsequent 
immunoblots probed with anti-HA antibody. These experiments show that full length 
Nanog and the N5 1 A mutant are able to interact with Sa114 with comparable 
efficiency but the NanogSLQQ>SAAQ mutant is dramatically impaired in this 
ability (Figure 3.1 2c). 
3.6.3 SLQQ>SAAQ function in mouse ES cells. 
To assess whether this perturbation in Nanog-Sa114 interaction has consequences for 
mouse ES cell self-renewal. El 4/T cells were transiently transfected with either 
(HA) 3Nanog, (HA) 3 Nanog SLQQ>SAAQ, or GFP and clonally expanded in the 
presence or absence of LIF for 12 days in puromycin selection. The resultant 
colonies were then photographed and stained for alkaline phosphatase (Figure 3.12d). 
As expected the full length Nanog was able to direct clonal ES cell self-renewal in 
the absence of LIF, whereas the colonies expressing GFP terminally differentiated in 
the absence of LIF. Interestingly, colonies expressing (HA) 3NanogSLQQ>SAAQ did 
not differentiate in the absence of LIF but, formed minute rounded colonies similar to 
those found in the presence of LIF with this mutant. This suggests that the Nanog 
SLQQ>SAAQ mutation may not affect ES self-renewal per se but rather have an 
effect on ES cell proliferation. 
3.7 	Discussion 
3.7.1 Nanog multimerisation 
The Nanog C-terminus is necessary and sufficient for Nanog multimerisation, and 
the domain mediating interaction has been identified as the tryptophan repeat 
sequence (198W- 243W) (Figure 3.6). However, it remains to be determined whether 
Nanog is an obligate multimer. If so, does Nanog solely form homo-multimers or 
could multimerisation with other proteins have functional significance? Recently a 
family of proteins has been identified called the pentapeptide repeat proteins which 
have either a leucine or phenylalanine residue repeated every 5 1h  amino acid 
(reviewed by Vetting et al., 2006). A crystal structure of one of the family members, 
MfpA from M. tuberculosum, has revealed that this protein consists of mainly right-
handed n-helix that has eight coils of 4 sides each which stack on top of one another 
(Hegde et al., 2005). MfpA acts to mimic DNA and dock with DNA gyrase, thus 
preventing the DNA-DNA gyrase interaction and providing resistance to 
fluroquinilones (Hegde et al., 2005). The tryptophan repeat may be able to adopt this 
unusual stacked coil structure (2.5 coils) as the tryptophan is a hydrophobic aromatic 
residue similar to phenylalanine. If this were the case Nanog might act as DNA 
mimic either to recruit DNA binding proteins to gene targets or to titrate particular 
transcription factors away from the DNA providing an indirect mechanism for 
regulating transcription. The latter hypothesis is particularly relevant given the 
proposal that Nanog may act to limit the action of differentiation inducing 
transcription factors (Chambers and Smith, 2004). Mutant Nanog proteins lacking 
only the tryptophan repeat or the C-C domain are not impaired in transactivation of a 
reporter driven by a multimerised Nanog binding site (Pan and Pei, 2005). However, 
deletion of both the tryptophan repeat and the C-C domain abolished transactivation 
activity in this assay. These data suggests that it is unlikely the tryptophan repeat 
provides additional DNA binding specificity per se at the cognate Nanog binding site. 
However, it remains unclear whether these conclusions hold true at endogenous 
genes targets, as these experiments were not performed in ES cells. Moreover, the 
requirements for transactivation may differ if Nanog binds to sites distal from the 
promoter of endogenous target genes. 
The fact that the Nanog-Nanog interaction can be seen in COS-7 cells (Figure 3.3 
and 3.4) suggests that the interaction is independent of any ES cell-specific partner 
protein or indeed any mouse specific protein. Whether the Nanog-Nanog interaction 
is direct is however another matter. It is possible that a partner protein is required to 
bridge two molecules of Nanog, and an orthologous protein provides this link in 
COS-7 cells. In vitro translation experiments using the low complexity of nuclear 
proteins present in rabbit reticulocyte lysates could be used to further investigate this. 
It is also possible that the multimerisation of Nanog is dependent on DNA, and future 
experiments performed in the presence of DNAse or Benzonase to digest the DNA 
could address this possibility. 
In addition to the identification of the Nanog C-terminus as the domain that is both 
necessary and sufficient for Nanog multimerisation, one can infer from these data 
that the interaction is homotypic. This is because in each set of co-
immunoprecipitates there is one full-length (Flag) 3Nanog molecule, therefore if the 
C-terminus was interacting with the N-terminus or the homeodomain then 
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(HA)3NanogAC would co- immunoprecipitate with full-length Nanog; an interaction 
that has never been observed. 
Considering the functional data (Figure 3.7) in the context of the multimerisation 
data, one can hypothesize that the decreased self-renewal efficiency of 
(HA)3NanogA Wr and non-function of (HA)3NanogAC are due to an inability to 
multimerise with other Nanog molecules, a process that could be important for 
Nanog function. This suggests that Nanog may function as a homo-multimer or 
larger multimer, either alone or as part of a higher order multi-protein complex. 
Alternatively, if the tryptophan repeat sequence can indeed act as a DNA mimic, the 
impaired function of the mutant Nanog could be due to inability to sequester 
differentiation inducing transcription factors away from gene targets. 
(HA)3Nanogzi Wr does however direct limited self-renewal in the absence of LIF in 
contrast to the complete lack of self-renewing colonies obtained upon GFP 
expression. It is possible that (HA)3NanogAWr could up-regulate endogenous Nanog 
expression leading to the limited self-renewal observed. Alternatively, it is possible 
that (HA) 3NanogAWr acts on target genes in multimers with a small amount of 
endogenous Nanog protein, not detectable by co-immunoprecipitation studies. By 
performing the functional assessment of (HA) 3NanogAWr in Nanoe ES cells 
(Chambers unpublished) the importance of the tryptophan repeat can be more 
robustly monitored, as all the Nanog protein in the cell will be mutant. 
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3.7.2 Nanogpost-trans1ationa1 modification 
Nanog is a phosphoprotein but what might the function of this phosphorylation event 
be? It is possible that phosphorylation may alter the DNA binding properties of 
Nanog as has been described for Nkx2.5 which exhibits increased DNA binding 
ability upon phosphorylation of the homeodomain (Kasahara and Izumo, 1999). 
Alternatively or additionally, phosphorylation may be important for interaction with 
partner proteins. To address these issues it is first necessary to identify the residue(s) 
phosphorylated. This could be achieved by immunopurification of Nanog from 
mouse ES cell lysates followed by mass-spectrometric (MS) analysis of tryptic 
digests of the purified material. MS can permit identification of which tryptic 
peptides are phosphorylated and at which residues. This knowledge would inform 
inhibitor experiments if the phosphorylated residue(s) sit in a well chäracterised 
kinase recognition sequences for which an inhibitor is available. More rigorously, 
site directed mutagenesis of the phosphorylatable residue to alanine and subsequent 
expression of the mutant Nanog in. ES cells would permit investigation of the 
functional relevance of the particular phosphorylation event. 
3.7.3 	Nanog partner proteins: a candidate approach. 
Oct4 and Stat3 do not interact with Nanog, at least not under the conditions used in 
the experiments described in this chapter (Figure 3.9). The simplest explanation for 
this negative data is that Nanog does not interact with either of these molecules. 
However, co-immunoprecipitation procedures are dependent on the particular lysiS 
and binding conditions used, and it quite possible that by using less stringent lysis 
procedures, interactions would have been detected, particularly if these were weak or 
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transient in nature. Recently in contradiction to the data shown here, an MS based 
screen for Nanog interacting proteins in ES cells identified Oct4 and provided 
biochemical data to support this interaction (Wang et al., 2006). It is unclear why a 
Nanog-Oct4 interaction was not also detected in the experiments described here 
(Figure 3.9). There are a number of technical differences between the experiments 
described in this chapter and those performed by Wang et a! (2006) which may 
explain the difference in the co-immunoprecipitation data. The lysis and purification 
conditions used vary from 350mM NaC1/0.3% NP-40 (Wang et a! 2006) to 1 50mM 
NaC1/0.5% NP-40 (this chapter). It is possible that the increase in detergent 
concentration is not compatible with maintenance of an Oct4-Nanog interaction. The 
experiments to examine a possible Oct4-Nanog interaction performed in this chapter 
used stable. ES cells lines, whereas the presence of Oct4 in Nanog 
immunoprecipitates detected by Wang et a! (2006) were achieved via transient 
transfection of epitope tagged Oct4. Furthermore, the two studies employed different 
antibodies for both the immunoprecipitation and detection of partner proteins on 
immunoblots. Also, the experiments in this chapter use cell lines based onEl4Tg2a 
or CGR8 ES cells whereas the experiments of Wang et a! (2006) use Ji ES cells. 
Any one, or a combination of these variables, may explain the detection of an Oct4-
Nanog interaction by Wang et a! (2006), yet lack of detection in this thesis. 
Oct4 and Nanog are both specifically expressed in the pluripotent tissues of the early 
mouse embryo as well as pluripotent ES cells and are considered markers of 
pluripotency. However, consequences of their ablation lead to quite different 
phenotypes both in ES cells and in the mouse embryo. Oct4 deletion leads to 
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trophectodermal differentiation of both the 1CM and mouse ES cells (Niwa et a!;, 
2000; Nichols et al., 1998). Nanog plays an important role in determination of 
pluripotent tissues (Mitsui et al., 2003), and the efficiency of self-renewal (Chambers 
et al., 2003), however Nanog is not absolutely essential for maintenance of 
pluripotency (Chambers unpublished). These data suggest that Oct4 and Nanog sit at 
different places in the circuitry responsible for pluripotency. It is therefore possible 
that Oct4 and Nanog act together on a subset of transcriptional targets involved in 
initiating a pluripotency program. Indeed recent ChIP based screens show that Oct4 
and Nanog co-occupy the promoters of many genes in both mouse and human ES 
cells (Loh et al., 2006; Boyer et al., 2005). It is possible that Nanog and Oct4 are in 
the same complex acting at these common target genes, which could explain the 
interaction seen by Wang et al (2006). Alternatively, Oct4 and Nanog could be 
binding at common targets but in different complexes. However, taking into account 
the distinct null phenotypes, it is likely that Oct4 and Nanog regulate some genes 
independently of one another to control distinct cell-fate decisions. 
The fact that Stat3 is not found to interact with Nanog in the experiments in this 
chapter (Figure 3.9) is consistent with the data of Wang et a! (2006) and the MS 
based screen described in chapter 5 of this thesis. Considered together, it is likely 
that Stat3 does not interact with Nanog in mouse ES cells, at least not in a complex 
that can be purified by standard immunoaffinity purification protocols. It is known 
that maximal ES cell self-renewal efficiency is achieved upon Nanog over-
expression and LIF stimulation (Chambers et al., 2003). This is possibly achieved by 
Nanog and Stat3 acting on either different target genes or different parts of the 
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promoter of a common target gene(s). Instrumental in Nanog and Stat3 function in 
ES cells is active Smadl, which has been found to physically interact with Stat3 
(Ying et al., 2003) and Nanog (Suzuki et al., 2006b). These two complexes may act 
in a circuit to maintain maximal self-renewal efficiency with Nanog binding Smadi 
to block BMP induced ES cell differentiation (Suzuki et al., 2006b), and active 
Smadl interacting with Stat3 to co-regulate LIF and BMP transcriptional targets. 
This proposed mechanism would explain how elevated Nanog levels coupled with 
LIF stimulation yields pure ES cell cultures with very few of the normally observed 
differentiated cells. However, the possibility remains that Nanog, Stat3 and Smadi, 
are found together in a transient or unstable complex that is not amenable to 
examination by immunoprecipitation procedures. It may be possible to explore this 
possibility further using cross-linking agents to stabilise the unstable native complex. 
3.7.4 Sa114 interactions in ES cells. 
In this chapter the SLQQ motif of Nanog has been mapped as being involved in Sa114 
interaction and Oct4 has been preliminarily identified as a Sa114 partner protein 
(Figure 3.12). This Oct4-Sa114 interaction was also detected in the MS screen for 
Oct4 partners (Wang et al., 2006). Given that Oct4 is the only homeodomain in the 
mouse genome other than Nanog to possess such an SLQQ motif in a similar 
position in the homeodomain, one can hypothesise that the SLQQ also mediates 
Oct4-Sa114 interactions. Sa114 is known to be a transcriptional regulator of Oct4' 
transcription (Zhang et al., 2006). Whether Sa114 acts on target genes as part of an 
Oct4 or Nanog containing complex has not been demonstrated although data 
suggesting co-occupancy of many genomic sites by Sa114 and Nanog may make this 
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a likely possibility (Wu et al., 2006). Likewise, ChIP data suggests Sa114 can be 
precipitated at the Nanog promoter in ES cells and is able to activate the distal Nanog 
enhancer in luciferase assays (Wu et al., 2006). Nanog also acts with Sa114 to activate 
Sa114 transcription in ES cells (Wu et al., 2006). Taken together, it appears that Sa114 
acts to maintain the expression of Nanog and Oct4 in ES cells. Consistent with this, 
Sa114 deletion has been shown to be detrimental to ES cell self-renewal (Elling et al., 
2006; Sakaki-Yumoto et al., 2006). In one case ES cells lacking S6114 could not be 
generated by acutely inactivating Sa114 in ES cells (Elling et al., 2006). A separate 
study isolated Sa114 ES cells at a very low frequency. Sall4 ES cells proliferated 
much slower than Sa114 heterozygote ES cells although they appear to retain 
pluripotentiality as judged by their wide contribution to E7.5 chimaeric embryos. 
(Sakaki-Yumoto et al., 2006). 
The crystal structure of human Octi homeodomain in conjunction with the Octi 
DNA binding site was used to further understand the nature of the Nanog-Sa114 
interaction mediated by SLQQ motif. The crystal structure of the human Octi 
homeodomain (Remenyi et al., 2003), identifies the position of the TSEE motif 
(positioned analogously to the SLQQ motif) as being exposed on the protein surface 
and positioned along the DNA helical axis (Figure 3.13). The evolutionary 
differences between the TSEE motif of Octi and the SLQQ motif of Nanog likely 
alter both protein interacting capabilities and potential interactions between the 
SLQQ and the DNA backbone. Notwithstanding the chemical differences between 
the Octi TSEE motif and the Oct4/Nanog SLQQ motif, the spatial information from 
the Octi homeodomain crystal structure predicts that the SLQQ is located in an 
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exposed position in the nucleoplasm likely to be accessible to interacting partner 
proteins, such as Sa114 and possibly additional molecules. 
At the simplest level it would be predicted that if the (HA)Nanog 3 SLQQ>SAAQ 
mutant acted to abolish a Sa114 interaction, ES cell self-renewal would be unaffected 
by this mutant in the presence of LIF as endogenous Nanog would continue to 
interact with Sa114. However, the decreased colony size of the SLQQ>SAAQ 
mutants suggests a different or additional mechanism is at play. It is possible that the 
(HA)3NanogSLQQ>SAAQ protein is interacting with endogenous Nanog (as this 
mutant has an intact C-terminal domain) and acting to titrate endogenous Nanog 
from Sa114 (or other partner protein) containing complexes reducing the functional 
output of Sa114 (or other partner protein) in the cell. Future experiments, performing 
the functional assessment of (HA) 3Nan0gSLQQ>SAAQ in Nanog ES cells would 
enable this to be addressed as all the Nanog in the cell would be the SAAQ mutant. 
In addition, whether the decreased colony size is solely due to abolition of the Sa114 
interaction will require identification and mutational analysis of the interacting 
residues in Sa114. Published data shows that Sa114 does indeed have a role in 
proliferation of mouse ES cells as Sa114 ES cells grow slower than wild-type cells 
(Sakaki-Yumoto et al., 2006). This is intriguing since Nanog ES cells also 
proliferate more slowly than wildtype cells (Chambers unpublished). Therefore the 
contention that the Nanog-Sall4 complex is a key regulator in mouse ES cells is 
feasible and that the colonies formed by (HA) 3NanogSLQQ>SAAQ over-expression 
could indeed be due to disruption of this interaction. Again whether the Sa114 
interaction with Nanog is mediated directly by the SLQQ motif is unclear. It is 
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possible that there is a bridging molecule or complex that is SLQQ dependent. In 
vitro experiments using protein synthesised either in E.coli or rabbit reticulocyte 
lysate would allow assessment of whether the interaction is direct. 
3.8 Summary. 
This chapter has described experiments that begin a biochemical characterisation of 
Nanog protein in ES cells. Nanog has been shown to be phosphorylated in ES cells 
and to multimerise through sequences within the tryptophan repeat. Furthermore, the 
published Nanog-Sa114 interaction has been confirmed and the SLQQ motif within 
the Nanog homeodomain has been mapped as the key motif in this interaction which 
has functional significance in ES cells. In addition, preliminary biochemical data 
shows the identification of an Oct4-Sa114 interaction in ES cells. Negative data from 
candidate based co-immunoprecipitation experiments have shown that Oct4 and 
Stat3 do not interact with Nanog under the conditions used, and importantly this 
instructed an unbiased screening approach to Nanog partner protein identification 
described in chapter 5 of this thesis. 
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Chapter 4. 
Investigation of the in vivo consequences of Nanog over-
expression during mouse development. 
4.1 	Introduction 
During embryogenesis, Nanog mRNA is expressed from the morula stage and is 
down-regulated shortly prior to implantation (Chambers et aL, 2003). In the early 
post-implantation embryo (E6.5-E7.5), Nanog mRNA forms a gradient of expression 
with highest levels at the proximal posterior region of the egg cylinder embryo. 
Moreover, Nanog mRNA is restricted to the ectoderm and is rapidly eliminated as 
cells de-laminate and enter the primitive streak (Hart et aL, 2004). In this chapter, the 
consequence of over-expressing Nanog on in vivo differentiation is addressed. To 
this end, a mouse ES cell line has been generated in which a loxP flanked Nanog 
transgene is expressed from the CAG cassette (Niwa et al., 1991) and in which 
Nanog expression can be monitored through the use of an IRES linked (Mountford et 
at., 1994) lacZ reporter. The generation of chimaeric embryos using this cell line can 
be visualised by the constitutive expression of a fluorescent protein from a separate 
additive transgene, thus allowing visualisation of the fate of these Nanog over-
expressing cells in vivo. Exclusion of GFP expressing cells from a particular lineage 
would suggest that continued Nanog expression is incompatible with differentiation 
into that lineage. This could also be apparent by the lack of 3-galactosidase activity; 
however a 3-galactosidase negative phenotype could also result from artifactual 
silencing of the Nanog transgene due to site of integration effects. The presence of a 
DsRed2 ORF downstream of the loxP flanked Nanog transgene allows for control 
over such artefacts following Crc excision and allows any phenotype to be rigorously 
assigned to Nanog over-expression by Nanog removal. If Nanog over-expression is 
directly responsible for a differentiation block, then the restoration of differentiation 
potential in the Cre-reverted DsRed2 cells should allow generation of cellular 
derivatives in the lineage not populated by the Nanog over-expressing ES cell line. 
The information that can be obtained by monitoring -galactosidase/ DsRed2 
expression in the embryo is summarised in Table 4.1. In this way, the effect of 
elevating Nanog expression on epithelialisation of the epiblast and mesoderm 
formation can be addressed. 
Table 4.1- Summary of the information to be gained by tracking Nanog expression 
in ES cell: morula aggregated embryos. 
-GALACTOSIDASE DSRED2 INFO GAINED 
+ve +ve No effect of Nanog over-expression 
-ye +ve Nanog over-expressing cells excluded from 
lineage_'X' 
-ye -ye Transgene silenced 
+ve -ye 
4.2 	Generation of loxP flanked Nanog expression plasmid. 
The construct used in this study consists of the strong CAG cassette (Niwa et al., 
1991) driving a loxP flanked NanogIRESf-geo cassette (Figure 4.1). After Crc 
mediated recombination of the loxP flanked cassette, DsRed2 becomes constitutively 
expressed. The construct is derived from an analogous plasmid containing a loxP 
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Figure 4.1- Schematic representaion of loxP flanked Nanog expression 
plasmid (IPC 154) 
Schematic diagram of IPC 154 and affect of Crc recombinase expression. 
Figure 4.2- Functional test of loxP flanked Nanog construct (IPC 154) 
Transient co-transfection of IPC 154 with Cre recombinase or empty vector 
(MT) into LRK-1 ES cells. 24 hours post transfection cells were photographed 
under fluorescent microscopy prior to staining with X-Gal to visualise the 3-
galactosidase expression. 
flanked NanoglRESpac cassette that expresses GFP upon Cre recombination (Chambers 
et al., 2003). IPC 154 was constructed in two cloning steps, first to generate IPC 138,. 
and subsequently IPC 154. Details of the cloning strategy and maps are presented in the 
plasmid appendix. 
	
4.3 	Functional assessment of the loxP flanked Nanog expression plasmid. 
Before generating stable ES cell clones using plasmid IPC 154, a functional test was 
performed to ensure f-galactosidase expression could be visualised via X-Gal staining 
and that co-expression with Cre recombinase results in correct excision of the 
NanogIRES3-geo cassette to give visible DsRed2 expression. Plasmid DNA was co-
transfected with either a Cre recombinase expression plasmid (AGS 844) or a 
corresponding empty vector (AGS 564) into super-transfectable ES cells (Chambers et 
al., 2003). Twenty-four hours after transfection, the cells were examined under 
fluorescent microscopy, photographed, fixed and then stained with X-Gal (Figure 4.2). 
IPC 154 transfectants expressed /3-galactosidase in the absence but not the presence of 
co-transfection with a Cre plasmid. The reciprocal pattern was observed for expression 
of DsRed2. These data shows that the construct functions as designed and therefore 
stable transfectants were generated. 
4.4 	Generation of taugfp cells stably expressing IPC 154. 
To enable visualisation of cells carrying the Nanog transgene in chimaeric mice, a cell 
line constitutively expressing an easily detectable marker protein is required. One such 
line is taugfp ES cells in which constitutive expression is directed by the CAG cassette 
(Ying et al., 2003). These cells express a form of GFP that is localised to microtubules 
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due to fusion of GFP with tau protein (Pratt et al., 2000). Taugfp ES cells were stably 
transfected with IPC 154 plasmid. Selection was then applied to the cells at 600 j.tg/ml 
G41 8 in the presence or absence of LIF. To attempt to select for integration sites 
directing high transgene expression a G4 18 concentration three times higher than usual 
was used. The number of undifferentiated colonies obtained was dependent on the 
addition of exogenous LIF. In the presence of LIF, colonies were obtained at a 
frequency of >2x10 whereas in the absence of LIF the frequency was --2x10 5 . Many 
colonies obtained in the absence of LIF displayed some differentiated cells at the 
periphery. Fourteen days after transfection, -70 colonies selected in the absence of LIF 
were picked and expanded. Clonal expansion of these colonies was performed in 
absence of LIF in an effort to select only transfectants robustly expressing Nanog above 
the threshold level required for cytokine independent self-renewal. 
4.5 	LIF independence of IPC 154 stable transfectants. 
Several independent clones (TFOG clones; augfi,: floxed QRF -geo) were cultured at 
clonal density (1 2Ocells/cm 2) for two passages in the presence of hLIF-05 (Vemallis et 
al., 1997), a mutant form of human LIF which antagonises LIF function. Three out of 
the five clones tested maintained an undifferentiated morphology during this rigorous 
LIF independence assay and were used in further experiments. To assess whether 
transgenic Nanog was expressed uniformly in all cells of a given clone, cultures were 
stained with X-Gal to visualise 3-galactosidase activity (Figure 4.3a). Only clone BB8 
shows uniform X-Gal staining and this clone is also the most intensely blue stained. 
















Bright Field  
Figure 4.3- X-Gal staining and Cre reversion of TFOG clones 
Three independent TFOG clones stained with X-Gal to visualise transgene 
expression both before and after culture with hLIF-05. 
TFOGBB8c2, a Cre reverted derivative of TFOGBB8 which expresses visible 
levels DsRed2, cultured for 6 days at clonal density in the presence and absence 
of LIF. 
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the expression level is lower than clone 13138 (Figure 4.3a). Clone 13138 (pre-hLIF-05) 
was transiently transfected with Cre recombinase and 24h after transfection, cells were 
replated at clonal density in the absence of G4 18. Correctly reverted cell lines were 
identified by revertion to G41 8 sensitivity and expression of visible levels of DsRed2 
protein (13138c clones). DsRed2 positive! G41 8 sensitive revertant clones were selected 
and expanded (Figure 4.3b). Further LIF independence assays were performed by 
plating taugfp parental cells, B138, and Cre reverted 13138 derivatives clones (13138c) in 
the presence and absence of LIF at a clonal density for 6 days prior to alkaline 
phosphatase staining (Figure 4.4). As expected, the taugfp cells formed ES cell colonies 
in a LIF dependent manner, whereas EF4 cells, an independent Nanog over-expressing 
ES cell line (Chambers et al., 2003), could form uniformly undifferentiated alkaline 
positive colonies in the complete absence of LIF. 13138 cells have a reduced LIF 
dependence but are not as robustly LIF independent as EF4 cells. When cultured at 
clonal density in 1OU!ml LIF for 6 days, 42% of 13138 (pre hLIF-05) colonies are 
undifferentiated compared to only 2% of taugfp colonies. It has previously been shown 
that the degree of elevated Nanog protein in EF4 cells is 5-6 times endogenous levels 
(Yates and Chambers, 2005). Immunoblotting of taugfp parental cell and TFOG B138 
cell lysates reveals that Nanog is expressed at 2-3 times parental cell levels (Figure 4.5). 
Unexpectedly, 13138 cells have differing LIF dependencies, dependent on whether they 
had been previously passaged with hLIF-05. Importantly however, Cre recombinase 
treatment of the 13138 cells (clones BB8c2 and BB8cI 1) reverted them to a LIF 



































Figure 4.4- LIF dependency of TFOG BB8 clones and Cre derivatives. 
Examples of undifferentiated, mixed, and differentiated colonies stained 
for alkaline phosphatase activity. 
The indicated cell lines were plated at 64 cells/cm 2 (clonal density) and 
cultured in varying LIF concentrations for 6 days. Cells were then stained for 
alkaline phosphatase (AP) activity and the stained colonies scored as AP positive 
uniformly undifferentiated (Undiff) colonies, mixed colonies containing AP 
positive and negative cells, or AP negative differentiated (Dim colonies. 
This data is from a single experiment. 
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Figure 4.5- Quantification of Nanog protein levels in BB8 cells. 
taugfp parental cell lysate and increasing amounts of TFOG BB8 cell lysate 
(pre hLIF05) were separated by SDS-PAGE and immunoblotted. Blots were 
probed with anti-Nanog and anti-SHP-2 antibodies. By comparing the levels 
of SHP-2 and cross-referencing to the Nanog levels, an estimate 
of Nanog over-expression level can be gained. Red boxes show equivalently 
loaded lanes. BB8 cells (pre hLIF-05) express 2-3 times the endogenous 
(taugfp) Nanog levels. 
40-38-40-40 
IFOG BBS pre hLIF-05 	TFOG BB8 post hLIF-05 
Figure 4.6- Metaphase spreads of BB8 cells 
Metaphase spreads of BB8 cells. The chromosomes are stained 
with Giemsa stain. The red dots mark individual chromosomes. 
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4.6 	BB8 cells are not grossly karyotypically abnormal. 
Metaphase spreads of BB8 cells (both pre and post hLIF-05) were performed and the 
chromosome number counted (Figure 4.6) These results suggest that the altered LIF 
dependence of BB8 cells before and after expansion in hLIF-05 is not due to gross 
aneuploidy. 
4.7 	BB8 cells contribute widely to mouse embryos. 
To assess the ability of BB8 cells to form mesoderm in the developing mouse embryo, 
BB8 cells were aggregated with E2.5 morulae and aggregated embryos were transferred 
to pseudopregnant CBAIvas females as described in Methods (section 2.1.8.1). The 
developing embryos were dissected at three time points, E7.5, E8.5, and E9.5, and 
chimaerism assessed by visual inspection of GFP expression (Table 4.2). The BB8 
chimaeric embryos were stained for 3-galactosidase activity to report the location of 
Nanog transgene expression and example embryos at E7.5 (Figure 4.7) and E9.5 (Figure 
4.8) are shown. No overt difference between the parental cell chimaeras and the BB8 
cell chimaeras was observed. One difference that can be seen at E7.5 is that there are no 
X-Gal positive cells in the extra-embryonic mesoderm in the BB8 chimaeras whereas 
the taugip parental cells readily populate this lineage (Figure 4.7). However, the sample 
size for both taugfp and BB8 chimaeric embryos is small (n=3) with only one of the 
taugfp embryos showing good contribution to the extra-embryonic mesoderm. All the 
BB8 chimaeric embryos appear show a lack of GFP X-Gal' cells in the extra-
embryonic mesoderm. 
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Figure 4.7- Contribution of taugfp and BB8 cells to E7.5 mouse embryos. 
Taugfp (parental wildtype) ES cells or 13138 (Nanog over-expressing) ES cells were aggregated with E2.5 inorulae. 
The next day embryos were transferred to 2.5 days post coitum CBAI BL/6 (Fl hybrid) pseudopregnant females. At 
E7.5, embryos were dissected and chimaerism assessed via fluorescence microscopy to visualise GFP expression, 
prior to staining with X-Gal to report transgenic Nanog expression. 
Blood Island 
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Figure 4.8- Contribution of taugfp and BB8 cells to E9.5 mouse embryos. 
Taugfp or BB8 ES cells were aggregated with morulae and transferred to 
pseudopregnant females. At E9.5, embryos were dissected and chimaerism 
(GFP) visualised by fluorescence microscopy prior to staining with X-Gal to 
report transgenic Nanog expression. 
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Table 4.2- Table showing number of chimaeric embryos at E7.5. E8.5. and E9.5. 
taugfp I 	TFOGBB8 
E7.5 
Chimaeric 3 3 
Non-chimaeric 2 (1 was "runty") 0 
Resorbed 1 4 
TOTAL 6 7 
E8.5 
Chimaeric 0 3 
Non-chimaeric 0 
Resorbed 0 
TOTAL 0 5 
E9.5 
Chimaeric 1 5 
Non-chimaenc 3+ 1 empty yolk sac 1 
Resorbed 2 10 
TOTAL 7 16 
To determine whether Nanog over-expressing cells were capable of contributing to 
mesoderm, X-Gal stained embryos were embedded in paraffin wax and 6tm transverse 
sections were prepared. BB8 Nanog over-expressing cells do populate the mesoderm, 
indicating that forced Nanog expression does not prevent movement of cells through the 
primitive streak (Figure 4.9). 
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Figure 4.9— Transverse sections of E7.5 BB8 aggregation embryos 
stained with X-GaI. 
The embryos pictured in Figure 4.7 were embedded in paraffin, 
transversely sectioned (6j.tm sections), and photographed. Two 
representative sections clearly showing BB8 cell contribution to the 
mesoderm are shown. 
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4.8 	Discussion 
4.8.1 IPC 154 construct. 
The design of the revertible Nanog over-expression construct has a number of key 
attributes. The strong constitutive CAG cassette consists of the cytomegalovirus 
immediate early enhancer, the chicken 13-actin promoter and a chimaeric f3-globin intron. 
This element directs high level transgene expression in mammalian cells (Niwa et al., 
1991). Flanking the NanogIRES3-geo cassette with loxP sites allows any observed 
phenotype to be unambiguously assigned to Nanog over-expression if the Crc reverted 
DsRed2 expressing cells revert to the wild type phenotype. The stable cell lines 
generated harbour randomly integrated transgene DNA. Although some loci are 
constitutively expressed such as Rosa26 (Zambrowicz et al., 1997), it is known that 
particular loci can be silenced in a particular somatic lineage or chromosomal location, 
for example in telomeric regions (Pedram et al., 2006). If Nanog over-expressing BB8 
cells do not contribute to a particular lineage in vivo, the DsRed2 expressing Cre 
revertants provide a useful reagent to show that the transgene integration site is indeed 
transcriptionally active, and therefore any lineage blocking phenotype is due directly to 
elevated Nanog levels. 
4.8.2 LIF dependency of Nanog over-expressing BB8 cells. 
13138 cells have a decreased dependency on the normally obligatory LIF signalling 
pathway, however, they are not robustly LIF independent (Figure 4.4). BB8 colonies 
cultured at clonal density are not all uniformly alkaline phosphatase positive and 
morphologically completely undifferentiated. EF4 cells, an independent Nanog over- 
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expressing ES cell line (Chambers et al., 2003) when treated in parallel to the BB8 cells 
maintain the undifferentiated state in the complete absence of LIF (Figure 4.4). The 
Nanog transgene is expressed uniformly (non-mosaically) in all cells in the cultures 
(Figure 4.3). Comparison of EF4 and EF4Cre revertant cell lysates reveals Nanog 
protein is 5-6 times wild-type in the LIF independent EF4 cells (Yates and Chambers, 
2005). Nanog protein levels in BB8 cells are 2-3 the parental taugfp levels (Figure 4.5), 
which, although sufficient for reduced LIF dependency, is not sufficient for complete 
release from cytokine dependence (Figure 4.4). Crossing a threshold of expression is 
also important for other homeodomain proteins to effect particular self-renewal or 
differentiation functions in a stem cell system. For example, in the haematopoetic stem 
cell (HSC) system, increased HoxB4 expression has been shown to increase the 
expansion of HSC's in vitro (Antonchuk et al., 2002) and in vivo (Sauvageau et al., 
1995; Thorsteinsdottir et al., 1999). Furthermore, differing doses of HoxB4 expression 
have been shown to effect differentiation into different haematopoetic lineages, with the 
highest achievable levels of over-expression favouring self-renewal over differentiation 
C. 
(reviewed by Kiump et al., 2005). It is not however a general rule that homeodomain 
proteins important in stem cell regulation increase self-renewal efficiency when over-
expressed. This is exemplified by Oct4 which is a master regulator of mouse ES cell 
self-renewal (Nichols et al., 1998) but when the thrershold of 150% of wildtype level is 
surpassed, differentiation ensues (Niwa et al., 2000). The immunoblot (Figure 4.5) and 
clonal expansion assays (Figure 4.4) show the -6 fold increase in Nanog protein levels 
required for true LIF independent self-renewal are not reached in the BB8 cells. This 
raises the question of how self-renewing colonies were obtained during selection in the 
absence of LIF. These cultures contain a mixed population of cells which themselves 
124 
produce LIF, meaning diffusible LIF is present in the ES cell media. This may reduce 
the transgenic Nanog levels required to generate undifferentiated colonies. Even with 
regular media changes, (every 2 days during selection) LIF may be present at effective 
concentrations. This is particularly likely to be the case as the primary colonies will be 
growing on a matrix associated form of LIF deposited by the initially plated 
untransfected cells (Rathjen et al., 1990). If this experiment was to be repeated, one 
possibility may be to include hLIF-05, the LIF antagonist, in the culture media during 
selection, to increase the probability of only high Nanog expressing undifferentiated 
colonies being obtained in these stringent culture conditions. To date, all published 
Nanog over-expressing, LW independent cell lines were generated using the strong 
CAG promoter (Niwa et al., 1991) combined with puromycin drug selection, which 
selects for high level transgene expression (Chambers et al., 2003; Loh et al., 2006; 
Mitsui et al., 2003). To illustrate this point, immunoblotting of the. (HA) 3Nanog: 
(Flag) 30ct4 cell line (Figure 3.10) reveals that the (HA) 3Nanog, which was selected in 
G41 8, constitutes only -'one third of the total Nanog protein in the cell. Furthermore, 
LIF independency assays reveal that these cell lines are totally LIF dependent (data not 
shown). It can therefore be appreciated that the choice of drug selection used in this 
study may not be ideal togenerate LIF independent ES cell clones. 
One unexpected set of data is that the LIF dependency of the 13138 cells differs 
dependent on whether they have been cultured in the presence of hLIF-05 (Figure 4.4). 
13138 cells post hLIF-05 treatment are less dependent on LIF, with 80% of colonies 
adopting a uniformly undifferentiated morphology at 1 OU/ml LIF compared with only 
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40% of clone 13138 'pre-hLIF-05' colonies. It is possible that a sub-population of higher-
expressing cells were selected during culture with hLIF-05, or that a karyotypic change 
occurred which provided a self-renewal advantage. To assess the possibility of 
aneuploidy in 13138 cells, metaphase spreads and chromosome counts were performed 
(Figure 4.6), and it was found that B138 cells both 'pre' and 'post' exposure to hLIF-05 
were karyotypically normal as judged by chromosome counting. It is possible however 
that a more subtle pro-self-renewal karyotypic alteration is present in the post hLIF-05 
13138 cells that will only be revealed by detailed karyotypic analysis using a high 
resolution technique such as comparative genomic hybridisation (CGH). In this regard, 
it is worth noting that some clones derived from selections in the absence of LIF 
following transfection with Nanog transgenes, have apparently accumulated at least 
three copies of the endogenous Nanog gene (Ian Chambers, personal communication). 
If these experiments were to be repeated, two alternative approaches could be taken to 
elevate transgene expression levels, and these are outlined here and in Figure 4.10. 
Approach 1: One reason that neo (-geo) cassette was employed is that it allows 
expression of the transgene to be visualised, and a second is that the parental taugfp 
cells already have puromycin resistance (Ying et al., 2003). In future experiments, 
higher level transgene expression may be achieved using a parental GFP: h ygromycinR 
ES cell line and use a construct analogous to IPC 154 with a puromycinRfluorescent 
protein fusion (e.g. CFP- cyan fluorescent protein- puromycin-N-acetyl transferase 
fusion) replacing the 3-geo. This would permit high level transgene expression, whilst 
retaining the key attributes of the construct, namely, a visible report on Nanog 
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expression and Cre-revertabiltiy. However, this may be dependent on the puromycinR 
fluorescent protein fusion being as active as puromycinR  (puromycin acetyl transferase). 
Approach 2: A second approach, to increase transgenic Nanog expression is to include 
a pre-selection cassette similar to that described in chapter 5 of this thesis for construct 
IPC 206. Anfrt flanked DsRed2IRESBsdr cassette can be introduced upstream of the 5' 
loxP site in IPC 154. Initial selection of transfectants in blasticidin would be followed 
by single cell fluorescent activated cell sorting (FACS) of the highest DsRed2 
expressing cells followed by clonal expansion. Fip recombinase expression can then be 
used to excise this 'pre-selection' cassette and induce NanogIRES3-geo expression. The 
resultant clones would be analogous to BB8 cells yet may express higher transgene 
levels. An additional benefit offered by this type of plasmid is that the expression of the 
fluorescent protein could be monitored in the absence of drug selection to analyse the 
stability of the transgene integration site. Monitoring fluorescent protein stability during 
in vitro differentiation would help in choosing clones likely to maintain transgene 
expression in chimaeric embryos. A final advantage of this latter approach is that it 
avoids direct selection for Nanog activity, which as noted above, can result in 
accumulation of additional copies of the Nanog gene. 
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Figure 4.10- Schematic depiction of 2 alternative approaches to generate 
high level Nanog transgene expression. 
For details of both approaches see section 4.8.2 
4.8.3 BBS cells contribution to mouse embryos. 
ES cells are able to contribute widely to all tissues of the developing mouse embryo 
(Beddington and Robertson, 1989). In vitro, elevated Nanog expression causes ES cells 
to be refractory to differentiation even in the presence of potent pro-differentiation 
stimuli (Chambers et al., 2003). As Nanog mRNA can be detected at E6.5 and E7.5 in 
the posterior region of the egg cylinder embryo yet not in the primitive streak (Morkel 
et al., 2003; Hart et al., 2004), it was hypothesised that Nanog over-expressing cells in 
the epiblast may be unable to form mesoderm during gastrulation. A further possibility, 
based on the decrease in Nanog mRNA expression immediately prior to implantation 
was that Nanog down-regulation might be required for the epithelialisation Of the 
epiblast. The experiments carried out in this chapter aimed to assess whether elevated 
Nanog levels in the epiblast led to altered developmental potency and, in particular, 
whether Nanog over-expression precluded mesoderm formation. The embryos 
generated by morula aggregation with BB8 cells (pre-hLIF-05) do not appear overtly 
different to the taugfp parental cell control embryos (Figure 4.7+ 4.8). The visualisation 
of -galactosidase activity in the mesoderm (Figure 4.9) shows that 2-3 times 
endogenous levels of Nanog does not block mesoderm formation. Furthermore, this data 
shows that Nanog down-regulation is not required for formation of the mesoderm. From 
analysis of Nanog chimaeric embryos, it can be seen that Nanog cells are able to 
generate mesoderm (Chambers unpublished) however this ability could be due to 
wildtype cells rescuing the mesoderm forming ability of Nanog cells through release 
of soluble factors. Little is known about the regulation of Nanog in vivo, although both 
Wnt3 and fl-catenin embryos show that Nanog mRNA is abolished in the proximal 
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posterior region of the embryonic ectoderm at E6.5 (Morkel et al., 2003). Tcf3 is a 
DNA binding protein effector of Wnt signalling which acts as an activator upon 0-
catenin stabilisation, but as a repressor in the absence of stabilized 13-catenin (Pereira et 
al., 2006). Recently, Tcf3 has been shown to repress Nanog expression in mouse ES 
cells and this activity is dependent on DNA binding (Pereira et al., 2006). Interestingly, 
the level of elevation of Nanog protein in Tcf3 ES cells is around two fold. TcJ3 
embryos exhibit defects during gastrulation and anterior-posterior axis formation 
(Merrill et al., 2004), and it is possible that this is in part due to an inability to repress 
Nanog. One can hypothesise that the abolished Nanog mRNA in Wnt3 and fl-catenin 
embryos could be due to the repressor activity of Tcf3 in this context. However, given 
the data in this chapter, additional or alternative mechanism(s) must be functioning to 
achieve the TcJ3 phenotype, as maintained Nanog expression is compatible with 
mesoderm formation (Figure 4.9). Brachyury (I), an early marker of mesoderm 
expressed in the primitive streak, is also a direct transcriptional target of Wnt/ 0-catenin 
pathway (Arnold etal., 2000; Galceran et al., 2001; Yamaguchi et al., 1999). Brachyury 
has been shown to bind the Nanog promoter in ChIP assays in ES cells (Suzuki et al., 
2006b), and Nanog has been proposed to protect against precocious mesoderm 
differentiation in vitro (Suzuki et al., 2006a). However, the consensus T-box 
recognition DNA sequence identified in the Nanog promoter may also be bound by 
other T-box containing proteins such as Eomesodermin (Conlon et al., 2001). It may be 
that Brachyury and Nanog are both responsive to Wnt signalling and exist in a feedback 
loop in the proximal posterior region of the egg cylinder embryo and together control 
mesodermal differentiation in the primitive streak. The level of Nanog in the 13138 cells 
however, may not be sufficient to tip the balance in favour retaining epiblast identity. In 
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this respect, it is possible that there is an upper threshold expression level that needs to 
be surpassed in order for Nanog to elicit a differentiation blocking phenotype in vivo, 
similar to that observed in vitro. To address this question, a further batch of ES cell 
clones for embryo aggregation could be generated which express Nanog at higher levels 
to give robust LIF independence using either of the approaches described in Figure 4.10. 
It is also possible that the Nanog protein is non-functional in the 13138 derived cells that 
ingress through the primitive streak, as the sub-cellular localisation of Nanog may 
change from nuclear to cytoplasmic. Indeed, there are precedents for homeodomain 
proteins altering sub-cellular localisation dependent on the environmental signals 
perceived. For example, HoxA9 is translocated to the nuclear compartment in primitive 
haematopoetic cells upon thrombopoictin (TPO) stimulation, yet is detected in the 
cytoplasm upon TPO starvation (Kirito et al., 2004). Whether an analogous mechanism 
is occurring with Nanog in BB8 derived cells could be addressed by double antibody 
staining 13138 chimaeric embryo transverse sections at E7.5 with anti-Nanog and anti-
GFP antibodies, and examining the localisation of Nanog protein in cells in the 
embryonic ectoderm compared to the mesoderm. 
Although the BB8 cell progeny are clearly able to generate embryonic mesoderm 
(Figure 4.9), it was noted that at E7.5 no extra-embryonic mesoderm had been formed 
(Figure 4.7). The taugfp parental cells can clearly generate extra-embryonic mesoderm. 
However, the sample sizes are too small for conclusions to be drawn and due to time 
constraints the possible extra-embryonic mesoderm phenotype was not further explored. 
The fact that X-Gal positive blood islands in the yolk sac at E9.5 are visible (Figure 4.8), 
shows that extra-embryonic mesoderm tissue can ultimately be generated by 13138 
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cellular progeny, although there may be a delay in formation of this lineage, possibly 
due to elevated Nanog expression. To further address the possibility that increased 
levels of Nanog cause a delay in extra-embryonic mesoderm formation the DsRed Crc 
reverted cells (Figure 4.3b) could be employed. Contribution of DsRed2 cells to the 
extraembryonic mesoderm at E7.5 would suggest that elevation of Nanog levels delays 
this differentiatiation event. 
Analysis of maintained expression of another ES cell master regulator of pluripotency, 
Oct4, has been performed (Ramos-Mejia et al., 2005). Oct4 is expressed in the 
unfertilised egg, cleavage stage mouse embryos (Palmieri et al., 1994; Scholer et aL, 
1990a), the epiblast, and is down regulated at E7.5, with the only remaining Oct4 cells 
later in development being primordial germ cells. Transgenic animals engineered to 
express Oct4 constitutively throughout embryogenesis do not have an early embryonic 
phenotype. Rather, mid-hindbrain patterning is altered at E8.O and forebrain 
development is compromised at E9.5 (Ramos-Mejia et al., 2005). The lack of early 
phenotype may be a function of the low expression level of the transgenic Oct4 (about 
50% that of ES cells). Alternatively, it may be that forced Oct4 expression has no effect 
on early post-implantation embryos. However this seems unlikely given the 
differentiation to mesoderm and endoderm that occurs upon modest levels of Oct4 over-




This chapter has described the generation of a Crc-revertible Nanog over-expressing 
construct (IPC 154), functional testing of the construct, and generation of ES cell lines 
expressing this construct. The ES cells have been characterised in terms of both LIF 
dependency in vitro, and their developmental potency in vivo. No overt differences were 
observed between taugfp parental cell derived embryos and the BB8 cell derived 
embryos. Alternative strategies have been suggested to further examine this question by 
increasing Nanog expression levels using additive transgenes. 
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Chapter 5. 
A biotin tagging strategy to identify Nanog interacting 
proteins. 
5.1 	Introduction 
As discussed in section 1.4, a wide range of methodologies are available to examine 
protein-protein interactions. These technologies generally include purifying the protein 
of interest using either antibodies to endogenous proteins, or epitope tags with particular 
binding properties (Terpe, 2003), followed by identification of co-purified partner 
proteins by mass-spectrometry (Rappsilber and Mann, 2002; Yates, 2000). Alternative 
methods rely on a genetic system for partner protein identification such as the yeast-2-
hybrid (reviewed by Luban and Goff, 1995; Fields and Song, 1989). To identify 
proteins interacting with Nanog in ES cells, an unbiased proteomic screen for Nanog 
interacting proteins was performed. The advantages and disadvantages of each potential 
approach were considered (outlined in section 1.4) before selecting a biotin tagging 
strategy. This approach was chosen as the interaction between streptavidin and biotin is 
the strongest non-covalent bond found in nature (K cj-10 15M). Moreover, this approach 
circumvents the requirement for antibodies which are often insufficient for purification 
from complex protein mixtures. In addition, the purification can be performed in a 
simple single step procedure with no requirement for intermediate steps or enzymatic 
cleavage of the epitope tag. Importantly, the tagged Nanog can be purified under native 
conditions from ES cells, a context in which Nanog partner proteins are most likely to 
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be present. Finally, Nanog (and partner proteins) will be appropriately post-
translationally modified in ES cells which could be critical for detection of some 
protein-protein interactions. 
A paradigm for the use of this system is provided in a haematopoetic cell culture system 
in which biotin tagging has been successfully employed to purify a transcription factor, 
Gatal, and the associated interacting proteins in a single step (de Boer et al., 2003). 
The identification of partner proteins then instructed further functional experiments to 
analyse the mechanism of action of Gatal (Rodriguez et al., 2005). The use of the BlO 
tag has not been restricted to one study but has been used successfully to purify Ldb 1 
complexes from MEL cells (Meier et al., 2006) and BlO tagged Oct6 can be purified 
from mouse ES cells (Driegen et al., 2005). 
The experiments described here include the generation of both an inducible BIO Nanog 
expression plasmid and a mouse ES cell line co-expressing BirA biotin ligase and the 
BlO Nanog transgene, functional characterisation of the cell line, gel filtration of Nanog 
containing complexes, pilot experiments to test the streptavidin purification protocol, 
large scale purification of Nanog complexes for mass spectrometry analysis, and 
validatory co-immunoprecipitation of three Nanog partner proteins. 
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5.2 	Generation of puromycin sensitive BirA ES cells. 
A mouse ES cell line expressing the E. Co/i BirA biotin ligase was kindly provided by 
D. Meijer (Erasmus MC, Rotterdam; (Driegen et al., 2005)). BirA ES cells express 
BirA biotin ligase from the ROSA26 locus and the targeting construct also contains a 
loxP flanked pgk puro selection cassette (Driegen et al., 2005). Before this cell line 
coulcf be transfected and clones selected with puromycin, the loxP flanked pgk puro 
cassette was removed by transient Cre recombinase expression, clonal expansion of 
transfected cells, and duplicate plating in the presence and absence of puromycin to 
identify puromycin sensitive BirA ES cell clones. The puromycin sensitive clones were 
used for subsequent transfections with the BlO Nanog construct (1PC206). 
5.3 	Generation and functional validation of a BlO Nanog expression plasmid. 
The BlO Nanog expression plasmid (Figure 5.1) was constructed as described in the 
plasmid appendix. To verify that plasmid '1PC206 had the desired properties, E14/T ES 
cells were transiently transfected either with 1PC206 alone or in combination with with 
a Cre recombinase expression plasmid. The next day, the single and double transfected 
cells were replated and selected with 2Wml  puromycin or 1O,.tg/ml blasticidin, 
respectively. After 10 days culture in either the presence or absence of LIF, colonies 
were photographed (Figure 5.2). 1PC206:Cre co-transfections gave rise to blasticidin 
resistant, DsRed2 LIF independent ES cell colonies, whereas 1PC206 single 
transfectants were DsRed2, puromycin resistant, and LIF dependent (Figure 5.2). 
These data indicate that 1PC206 functions as designed, with the loxP flanked 
DsRed2IRESpac cassette being efficiently excised upon Cre recombination, inducing 
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Figure 5.1 A schematic representation of 1PC206. 
+LIF 	 -LIF 
Figure 5.2 Functional test of 1PC206 in E14/T ES cell transient transfections. 
1PC206 was transfected either alone or in combination with a Cre recombinase 
plasmid into El 4/T ES cells and selected in puromycin (single transfectants) or 
blasticidin (co-transfectants). Photographs were taken 10 days post transfection. 
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BlO Nanog expression above the threshold (5 times endogenous) necessary to direct 
self-renewal independently of LIF stimulation. 
	
5.4 	Generation of BirA: BlO Nanog ES cells. 
Puromycin sensitive BirA ES cells were stably transfected with plasmid 1PC206 and 
selected in 1 .Ojtg/ml puromycin. Fourteen days after transfection, DsRed2 expression 
was visualised by fluorescent microscopy. Colonies with strong and uniform expression 
of DsRed2 protein in all cells were picked and expanded. FACS analysis revealed that 
of three clones analysed (BirA:206 clones B3, B4, and B5), all expressed DsRed2 and 
clone B5 had the highest and most uniform expression level (Figure 5.3). To induce 
BlO Nanog expression, clone B5 was transiently transfected with a Cre recombinase 
expression plasmid. Twenty-four hours after transfection cells were trypsinised, replated 
at very low (-6 cells/cm 2), and selected with 5tg/ml blasticidin in the absence of LIF. 
After 10 days clonal expansion, individual self-renewing DsRed2 clones were picked 
(B5Cre clones), expanded and stock vials frozen. 
5.5 	Functional assessment of BlO Nanog. 
The selection of B5Cre (BirA: BlO Nanog) clones in the absence of LIF shows that the 
level of RIO Nanog expression is sufficient to permit LIF independent self-renewal. To 
confirm this LIF independent phenotype, cells were plated at clonal density and selected 
in the presence or absence of LIF for 6 days followed by alkaline phosphatase staining 
(Figure 5.4b). Qualitatively, the colonies formed by BlO Nanog expressing cells are 
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Figure 5.3- FACS analysis of stable 1PC206 clones. 
FACS analysis shows that BirA:1PC206 stably transfected clones B3, B4, and 
and B5 are DsRed2 positive. Percentages show the proportion of cells falling 
within the indicated gate. 
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undifferentiated cells) and exhibit no differentiation at the periphery of colonies in the 
presence of LIF, and very little differentiation upon LIF withdrawal. In contrast, BirA 
parental cells growing in LIF supplemented media form colonies containing some 
differentiated cells, and in the absence of LIF the colonies were flatter in morphology, 
differentiated, and do not express alkaline phosphatase (Figure 5.4b). Colony counting 
show that close to 100% of the colonies of all the BlO Nanog cell lines generated 
remain uniformly undifferentiated after 6 days clonal expansion in the absence of LIF 
(Figure 5.4c). This suggests that RIO Nanog would be expressed at -5-6 times 
endogenous levels as this level of over-expression is reported to provide robust cytokine 
independence (Yates and Chambers, 2005). Indeed, immunoblotting of BirA and 
BirA:BIO Nanog nuclear extracts shows the presence of an intense band of retarded 
migration specifically in the BlO Nanog lane corresponding to the expected size of BlO 
Nanog protein (endogenous Nanog + -4kDa; Figure 5.4a). This functional data further 
indicates that the fusion of the BlO tag to the N-terminus of Nanog does not affect its 
function, as judged by LIF independence assays. For the rest of this chapter experiments 
involve the use of clone BirA:IPC206B5Cre2, hereafter referred to as BirA:BIO Nanog 
cells. 
5.6 	Nanog is present in complexes of a broad molecular weight range. 
At the outset of this project, it was not known if Nanog had any partner proteins, 
whether it could multimerise, or whether it was present in higher order multi-protein 
complexes. To ascertain whether Nanog is present in high molecular weight complexes 
in mouse ES cells, gel filtration experiments were performed. Nuclear extracts from 
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Figure 5.4 FunctionaL assessment of BirA:BIO Nanog cells. 
Immunoblot analysis of BirA and BirA:BIONanog nuclear extracts with 
anti-Nanog antibody reveals a size shifted band specifically in the 
BirA:BIO Nanog lane. 
BirA and BirA:BIO Nanog clones were plated at clonal density, cultured 
in the presence or absence of LIF, and stained for alkaline phosphatase 
activity after 6 days. Representative colonies are shown. 
The number of uniformly undifferentiated, mixed, and completely 
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Figure 5.5 Size exclusion chromatography of Nanog in mouse ES cell nuclear 
extracts. 
Nuclear extracts from B1rA and BirA:BIO Nanog cells were fractionated using a 
Superose 6 colunm (Amersham). 500 j.il fractions were collected, precipitated using 
TCA and resuspended in Laemmli sample buffer. The first 14 fractions correspond 
to the void volume, V 0 . Even numbered fractions from 14-36 were subjected to 
SDS-PAGE followed by immunoblotting and probing with anti-Nanog antibody. 
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to size exclusion chromatography using a Superose 6 column. Fractions were collected, 
proteins precipitated with TCA, and resolved by SDS-PAGE. Immunoblotting with an 
anti-Nanog antibody reveals that Nanog is present in complexes of a broad range of 
molecular weights from approximately 1 4OkDa to upwards of 1 MDa in weight (Figure 
5.5). Crucially, the addition of the BlO tag to Nanog does not disrupt its ability to 
integrate into these large complexes. However, the presence of BlO Nanog in fractions 
close to the size of monomeric Nanog suggests that available interaction sites are 
titrated out by the level of Nanog over-expressed in BirA:BIO Nanog cells. 
5.7 	BlO Nanog is efficiently biotinylated and can be captured on streptavidin 
coated beads. 
To assess whether BlO Nanog could be purified using the high affinity of streptavidin 
for biotin, BIrA and BIrA :BIQ Nanog nuclear extracts were incubated with streptavidin 
coated paramagnetic beads as described in Methods. Immunoblotting with both an anti-
Nanog antibody (Chambers, 2005) and streptavidin-HRP was used to analyse the input 
sample, bound material and the unbound fraction. As these samples were equivalently 
loaded, an estimate of binding efficiency could be made. Routinely, approximately 50% 
of the biotinylated BlO Nanog can be captured (Figure 5.6b), although the captured 
fraction can reach 100% (Figure 5.6a). As the BlO Nanog purification was rarely 100% 
efficient, gel filtration analysis on the unbound fraction was performed. This permits 
visualisation of whether either a proportion of all the different Nanog containing 
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Figure 5.6 BlO Nanog is efficiently biotinylated in vivo and can be captured on 
streptavidm coated beads. 
(a,b) Nuclear extracts were prepared from BirA (wildtype parental) and BiAr: BJO 
Nanog (Nanog over-expressing) ES cells and incubated with streptavidin coated 
beads as described in Materials and Methods (Section 2.2). Bound proteins were 
resolved via SDS-PAGE prior to immunoblotting. Equivalent starting amounts of 
material were losaded into adjacent lanes labelled input (I), bound (B) and unbound 
(U). It is possible to capture 100% of BlO Nanog (a). Routinely however, around a 
50% capture efficiency is obtained (b). Immunoblots were probed with the indicated 
antibodies. 
(c) Size exclusion chromatography (Superose 6) of the unbound fraction following a 
streptavidin capture of BirA: BlO Nanog nuclear extracts was performed. Fractions 
were precipitated with TCA, boiled in Laemmli buffer, and subjected to SDS-PAGE. 
Subsequent immunoblotting with a Nanog antibody reveals that the majority of 




refractory to capture (Figure 5.6c). This data indicates that it is predominantly the very 
high molecular weight complexes in fraction 16 (>1 MDa) that have not been captured. 
These data show that the BlO Nanog capture should allow identification of Nanog 
partner proteins in a wide range of complex molecular weights. 
5.8 	Large Scale BlO Nanog purification for mass spectrometry analysis. 
The streptavidin capture protocol was scaled up to purify enough material for MS 
analysis. Routinely the purifications are performed on nuclear extract containing 15mg 
protein with a final concentration of 100mM KC1 and 0.3% NP-40 (see Methods). After 
the purification procedure, —95% of the bound material is subjected to either SDS-
PAGE and stained with colloidal blue protein stain (Figure 5.7) or to on-bead 
trypsinisation. Prior to submitting the purified material for MS, a small amount of 
bound material is equivalently loaded with input and unbound material for immunoblot 
analysis to retrospectively monitor the purification efficiency (example is shown in 
Figure 5.7a). If? 50% of the BlO Nanog has been captured this is deemed sufficient to 
warrant MS analysis. In addition, the efficiency of nuclease treatment (RNAsCAI 
Benzonase) treatment is assessed by analysing nuclear extracts before and after nuclease 
treatment via agarose gel electrophoresis and ethidium bromide staining. A typical 
analysis shows that the nucleic acid has been digested (Figure 5.7c) meaning that any 
interactions detected by MS are likely to be protein- protein interactions that are stable 
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Figure 5.7 Example of large scale purification of BlO Nanog containing complexes. 
Large Scale capture (15mg starting extract) of BirA and BirA. RIO Nanog nuclear 
extracts was performed according to the Materials and Methods (Section 2.2). Bound 
proteins were equivalently loaded, input (1%), bound (1% and 3%), and unbound (1%) 
fractions and resolved via SDS-PAGE. After immunoblotting, identical membranes were 
probed with anti- Nanog and streptavidin-HRP. 
Large Scale capture (15mg starting extract) of BirA and BirA. RIO Nanog nuclear 
extracts was performed according to the Materials and Methods (Section 2.2). ---50tg 
nuclear extract (input lane) and bound material (from —1 5mg starting nuclear extract) 
was resolved by SDS-PAGE prior to staining with colloidal blue. 
Nuclear extracts were treated with Benzonase and RNAseA during streptavidin capture. 
0.33% of binding reaction was removed both before and after addition of nucleases. 
Phenol:chloroform extraction of nucleic acid was performed and samples were 
resuspended in DNA loading dye. Nucleic acids were visualized via agarose gel 
electrophoresis/ Ethidium Bromide staining. 	 146 
5.9 	Mass spectrometry analysis of BlO Nanog purifications. 
The large scale purification of BlO Nanog was performed four times (details in 
Materials and Methods 2.2.2), and the conditions for each of the purifications are 
summarised in Table 5.1. Nano LC-MS/MS was performed on the purified material as 
described in Materials and Method 2.2.3. The primary criteria for considering a mass 
spectrometry identified protein as a putative Nanog partner is that it is present in the list 
of proteins purified from the BirA:BIO Nanog nuclear extracts yet absent from the BirA 
parental cell control purifications. Encouragingly, it was found that in all four 
purification experiments (MS 1-4), Nanog peptides are only detected from the BirA:BIO 
Nanog purifications and are never detected in the BirA parental cell controls (Table 5.1). 
This gives confidence that the subtraction of BirA parental cell background from the 
BirA:BIO Nanog protein lists should not remove potential partner proteins from 
consideration. Ideally these peptides should be identified in more than one independent 
purification 
Table 5.1- A summary of conditions used for each large scale BlO Nanog purification. 








MSI IN GEL RNAseA 250mM HENG/ 0.3 0/6 NP40 12 
MS2 IN GEL RNAseA 250mM HENG/ 0.3% NP40 9 
MS3 ON BEAD RNAseA 500mM HENG/ 0.3% NP-40 2 
MS4 IN GEL RNAseA and Benzonase 250mM HENG/ 0.3% NP40 9 
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5.10 Preliminary co-immunoprecipitation experiments to confirm interactions of 
MS identified proteins. 
Details of the peptides identified in the mass-spectrometry analysis of BirA:BIO Nanog 
cells, yet absent in the BirA control purifications are provided in Table 5.2. This table 
contains details of proteins identified in all four, three out of four, or two out of four of 
the BlO Nanog purifications. Due to the fact that Nanog itself was the only protein 
specifically identified in all four purifications, further investigation of potential partner 
proteins could not be limited to these proteins co-purifying in all experiments. Therefore, 
proteins that were identified in more than one of the BlO Nanog purifications (either 
absolutely or enriched compared to background), that were identified by multiple 
peptide hits, or had biological rationale for being a Nanog partner were further 
investigated. Nanog has been shown to possess transactivation potential (Pan and Pei, 
2003; Pan and Pei, 2005) and as such may associate with other proteins associated with 
transcriptional activation. To ascertain whether the proteins identified are genuine 
Nanog partners, co-immunoprecipitation experiments were performed as this remains 
the gold-standard for biochemical validation of protein-protein interactions. These 
experiments are however often limited by the availability of good antibodies 
Firstly, a putative interaction with Esrrb was investigated as it acts as a transcription 
factor and appears to be transcriptionally regulated by Nanog. Furthermore, Esrrb 
knock-down via RNAi leads to differentiation of ES cells (Loh et al., 2006) suggesting 
a possible role in maintaining pluripotency. Secondly, HDAC2 (histone deacetylase 2) 
was followed up due to the fact that HDAC2 is able to modify chromatin and is 
involved in gene repression. Finally, a possible interaction with the WD40 repeat 
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Table 5.2- List of proteins identified in BlO Nanog purifications. 
The peptides listed in these tables are identified in the BlO Nanog purifications 
indicated and absent from the BirA background controls. 
Peptides identified in 4 purifications 
Gene Identifier Name Present on purifications 
]] gi[31338864 lmmeoboxfranscriptionfacthrNanog(Manmunculus) MS1. MS2, MS3, MS4 
Peptides identified in 3 of the 4 purifications 
Gene Identifier Name Present on purification 
gil45272166 Nanog variant protein lb [Man muecalusi MS1.MS2.MS3 
gi(56201283 NM4OGISTM1 (Man muscctus mOloeeinus] MS1.MS2.MS3 
gi[20987847 Hnrpl protein [Man manculuo] MS1MS2.M53 
gfl26378644 unnamed protein product [Man muscutan[ MS1 ,MS2.MS4 
gi12760632 protein L[Musmusculus[ MSI,MS2MS3 
gi71681342 Heficase, lyinpiroid npedllc [Man muscutus[ MS1,MS2.MS4 
9i131560812 breast cancer 1 (Man manoitun[ MSI.MS2,MS4 
9i14097808 Brcal (Man muscutus] MS1 ,M82.M54 
gil46329772 Breast cancer I [Man musculan[ MS1 .MS2,MS4 
9u1969172 breast/ovarian cancer nuncepbbibty protein tromotog MS1,MS2.MS4 
Peptides identified in 2 of the 4 purifications 
Gene Identifier Name Present on purification 
gi[32966256 narrog (Man mtmatusI MS1.MS2 
gi[12859782 unnamed protein product [Man muncutan[ MS1 .MS2 
gi(26354819 unnamed protein producl [Manmancutus[ MS1.MS2 
gu112847921 unnamed protein product (Man manculan[ MS1.MS3 
gi[29126987 Hypotheticst protein L0066184 [Man manrodan[ MSl.MS2 
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91154912 unnamed protein product [Mus munarlus[ MS1,MS4 
911200246 pyruvate casboxlane MS1.MS4 
91126347787 unnamed protein product [Mus munculus[ MS1 .MS3 
91)63547292 PRZOICTED: similar to 405 dbonomal protein S2 (Mus munculus) MS1.MS2 
91163594486 PRSOICTED: similar to 405 ribonamsi protein 52 mnnfonm 1 [Mun 
muncrilaoj  
MS1.MS4 
91115919908 unnamed protein product (Mus musaitus) MS1.MS4 
g28302223 Hypothetical protein L0C432987 [Mun manuritus) MS1.MS3 
911495128 mCBP[Musmusculus] MSI.MS4 
9111568657 testicular antigen (Man mimcutus[ MSI.MS2 
91116554827 WD repeal domain S (tiomo eaeewJ MS1M54 
91118204899 Nucteolar protein SA [Mao manculas] MSI.MS2 
91126348689 unnamed protein product (Man munculus) MS1MS2 
gi126353478 unnamed protein product (Mon muncutun) M51.M52 
91126353514 unnamed protein product [Mao muoculus[ MS1.MS2 
91)38614350 Cp protein [Man musuctus] MS1.MS2 
91112232371 helicaoe, lympbroid specific [Man musculus[ MS1.MS4 
gi[15489014 Nsun2 protein [Man muscelus] MS1.MS4 
gill 903238 type II intermediate filament of hair keratin (Man musculus[ MS1 .MS2 
91)19353961 Wdr74 protein [Mon musculus[ MS1 .MS4 
91126335199 unnamed protein product(Mus munculus) MS1.M52 
gi)26338343 unnamed protein product [Mao munculus] MSI.MS2 
91)26341620 unnamed protein product [Mao munculun[ M51.M52 
gi)26344922 unnamed protein product [Man musculus[ MSI.MS4 
gi[27883856 low density lipoprotein receptor-related protein 4 [Man musculan] MS1,MS4 
gi)30047838 MutS homolog 2 [Man muoculun[ MS1,MS4 
91131542461 NOL1INOP2JSun domain family 2 (Mao munculus[ MS1 ,M54 
91137994713 Krt1-13 protein [Mao munculus[ MS1 .MS2 
9i1471 17264 Low-density lipoprotein receptor-related protein 4 precursor (LDLR 
dan)  
MS1 .MS2 
91155153885 Similar to glyceraldehyde-3-phosphate dehydrogenase (Mao 
munculus)  
MS1.MS4 
gi)726086 MutS lromolog 2 MS1.MS4 
gi112847667 unnamed protein product [Musmunculun[ MSI,M52 
gi)12848426 unnamed protein product [Mao musculus[ MS1,MS4 
gi112862002 unnamed protein product(Mus musculus[ MS1MS2 
gi)1304155 pokeweed aggtutinin-tilnding protein [Mao munculus] MS1 ,M54 
gill 3272554 cytokeratin KRT2-6HF [Mao musculus[ MS1 M53 
gi[13386238 kerafin complex 1, acidic, gene 4 [Mao musculus[ MS1MS2 
91)13529464 Nadeolin [Mao munculus[ MS1.MS2 
91113542636 Cdc2a protein [Mao musculus] MS1.MS4 
gi115214716 Rps9 protein [Mao musculus[ MSl .M53 
gi)21759414 Exonome complex exonuctease RRP43 (Riboenmal RNA- 
processing protein 43) (Exosoroe component 8)  
MS1.MS4 
gi)2228746 DighI horoolog (Mao muscutus) MS1.M54 
gi(2407195 putative RNA helicase and RNA dependent ATPane (Man musculuo[ MSl .MS3 
gi)263251 14 unnamed protein product [Mao musculus[ MS1.MS2 
gi)26327461 unnamed protein product (Mao manculus[ MS1,MS2 
gi126327475 unnamed protein product [Mao muscolus[ MS1,MS2 
gi(26341628 unnamed protein product (Man rouncutus[ MS1 MS2 
gi)26986202 SMC5 protein [Mao muoculas) MS1.MS4 
gi(27777677 deooyribose-phonphate aldolasodike (Mao muocutus) MS1.M54 
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9112809537 beta prune ceatomer protein [Mus muocrius] MS1.M$4 
gi(28548933 PREDICTED: acoenme component 7 unborn 1 [Mus mtmartus] MS1,M$4 
91129611663 exoenme complex exonuctease RRP41 (Mus menrortun) MS1 .MS4 
91130962875 Exosome component 7 (Mus munailus] MSI,MS4 
91131542366 cell division cyde 2 homolog A [Mus munrodus] MS1.1664 
9i132822838 1700021 tO9Rik protein [Men musrortus] MS1.M$2 
91137359764 mKIAA9578 protein (Mus muncutus) 	 - MS1.MS4 
81137359778 mKIAti01116 protein [Mus munroitun( MEl ,MS4 
91139104489 mKL°A0594 protein [Mun muncutun( MEl ,MS4 
9114097873 elF3-p44 (Mus musailus] MS1.MS4 
gi(45595709 Exosc8 protein [Mao muscutus] MS1.MS4 
gi)50360 unnamed protein product [Mus munculun( MEl .MS4 
91)50510377 mKIAA0136 protein [Mus musailus] MS1.MS4 
91151704904 PREDICTED: eirn5ar to Elongation factor 1-gamma (EF-1-gamma) 
(eEF-18 gamma) isoform 1 (Mun rnunculun 
MEl ,MS4 
gi153454 nudeolin (Mus munculus] MS1 .MS2 
9i158477264 Unknoanr (protein for MGC:102174) [Mus muncutus( MS1 .MS2 
gi160359868 mKIAA4013 protein [Mus munculus] MS1 .MS4 
9116754488 keratn complex 2. baeic. gene 61, [Mus munculus( MS1.MS3 
gi167972435 DEAD (Asp-Gtu-Ate-Asp) box polypeptide 49 [Men muoceluo( MS1,1664 
91172679679 Krtl-24 protein (Men musculus) MSI.MS2 
91)8393684 keratn, hair. add 	5 (Men musculus( MS1,MS2 
911988214 breast/ovarian cancersuncephbrlity frornotog MSI.MS2 
91128972888 mIQAA3005 protein [Men musculus( MS2.MS3 
gi[53733821 Tubulin, alpha 1,(Men muoculus( MS2,MS3 
gill 7512384 BC031593 protein [Men musculus( MS2.MS3 
gi)22096212 Tranncnpton factor 20 (Stiomelynin 1 PDGF-responsive clamant- 
binding protein) (SPRE-trinding prote  
M52.MS3 
911387399 epidemiat keratin type I MS2.M54 
gi(12849997 unnamed protein product (Men menculen] MS2,MS4 
91126330478 unnamed protein product [Men menculen( MS2.MS4 
gi126353010 unnamed protein product [Men menculen( MS2.MS4 
gi130931 339 Transcnptionat represuor NAC1 [Men muocuten( MS2.MS4 
gi137675525 AHNAX [Men mencuten] MS2.MS4 
91(3851579 nb000mal protein L8 [Men musculus( MS2.MS4 
91150510329 ml(JM0020 protein [Men muncutus] MS2.MS4 
91(40510873 mKtP1298 protein [Men muscuten( MS2,MS4 
gi)62185779 Nudeoponn 107 [Men mencuten] MS2,MS4 
gi)62201695 Rpt14 protein (Men menculen) MS2.MS4 
91112853471 unnamed protein product [Men musculen( MS2,MS3 
91(1401337 Mrellb MS2.MS4 
81123274262 Orcll protein (Men menculen) MS2.MS4 
gi126340418 unnamed protein product [Men munculen( MS2.MS3 
gi(27693623 Unknororr (protein for IMAGE:4481097) [Men mencuten( MS2.MS4 
gi127808676 SWI/SNF-retuted matrbc-ansociatad actlrr-dependent regulator of 
chmmahn uubfamity D roronber 1 (SWt/  
MS2.MS4 
91(46399229 Ewmg sarcoma breakpoint regIon I (Men menmilen) MS2.MS4 
91150510319 mKtri0002 protein (Men menarlen] MS2.MS4 
91151261317 Smarodi protein[Musmunculen( MS2.MS4 
gi)5295992 cftaperonin contatinng TCP-1 theta uubueit (Men rousculen( MS2.MS4 
91156206934 Ewmg sarcoma horootog (Men muncuten) MS2.M84 
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9i156206935 Eng sarma homolog (Moo muscutus( MS2.MS4 
gi(37748194 DEAD (Aop-Glu-Ala-Aop) box poypcpbde 21 (MoO musailus] MS3.MS4 
g166T7757 nbonudeic actd tending protein SI (Moo musroitus] MS3.MS4 
9i1110625918 tromeobox Uansaiptten Ir Nazrog tbis mramdtro] MS3.MS4 
gi112852157 unnamed protein product (Mus musorlus( M53.MS4 
gi(26349459 unnamed protein product (MoO muoxutus) MS3,MS4 
gij26334713 unnamed protein product [Moo moocubun] MS3.MS4 
gi(62471421 Orfx[Musmuncutus] MS3.MS4 
152 
protein Wdr5 was investigated. Wdr5 is a part of the MLL/ Trithorax complex capable 
of modifying histone H3 at residue K4, a modification associated with transcriptional 
activation (Wysocka et al., 2005). 
5.10.1 Nanog-Esrrb interaction 
El 4/T ES cells were transiently transfected with (Flag) 3Nanog expression vector (IPC 
37) and after 3 days in culture whole cell lysates prepared. A rabbit polyclonal antibody. 
to Esrrb (obtained from Abcam- ab19331) was used to immunoprecipitate (IP) Esrrb 
protein. The (Flag) 3Nanog expression vector allowed the use of mouse anti-Flag 
antibody for Nanog detection. This circumvents cross reactivity between the rabbit anti-
Esrrb and rabbit anti-Nanog antibody routinely used for Nanog detection obscuring 
potentially interesting data. Esrrb immunoprecipitates were subjected to SDS-PAGE 
electrophoresis, immunoblotted and probed with mouse anti-Flag antibody. The 
immunoblot shows there is a discrete band corresponding to (Flag) 3Nanog specifically 
in the Esrrb immunoprecipitate that is absent from the mock immunoprecipitate (Figure 
5.8). This promising preliminary data suggests that Esrrb is a bona fide Nanog partner 
protein. 
5.10.2 Nanog- HDAC2 interaction. 
Nanog immunoprecipitates were prepared from EF4 (Nanog over-expressing) cells 
(Chambers et al., 2003) using anti-Nanog antibody (Chambers, 2005). The 
immunoprecipitate was subjected to SDS-PAGE, immunoblotted, and probed with an 
anti-HDAC2 antibody. Again a specific signal was observed only in the Nanog IP lane 
which suggests that Nanog and HDAC2 can be found in complex together (Figure 5.9). 
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5.10.3 Nanog-WdrS interaction 
To investigate the potential Wdr5-Nanog interaction, two approaches were undertaken. 
To assess whether WdrS and Nanog interact in ES cells, (Flag) 3Wdr5 (IPC 328) was 
constructed (see plasmid appendix for cloning strategy) and transiently transfected into 
E14/T cells. After 72h in culture, lysates were made, Nanog was immunoprecipitated, 
and immunoprecipitates were resolved by SDS-PAGE. Immunoblotting revealed that 
(Flag)3Wdr5 is specifically present in Nanog immunoprecipitates suggesting 
confirmation of this protein-protein interaction (Figure 5.1 Ob). A histone tail peptide 
binding experiment was performed as Wdr5 has been shown to bind preferentially to 
histone H3 dimethylated at lysine 4 (H3K4(me)2) (Wysocka et al., 2005). A similar 
binding specificity for Nanog would support a model in which Nanog is bridged by 
Wdr5 to H3K4(me)2. Streptavidin immobilised biotinylated histone H3 tail peptides 
either unmodified or dimethylated at lysine 4 were incubated with ES cell nuclear 
extracts and assayed for their ability to interact with both Nanog and Wdr5. The 
immunoblot data (Figure 5.10a) shows that Nanog can bind the histone tails, and is 
indiscriminate in binding preference for unmodified or dimethylated H3K4. WdrS 
however shows preference for dimethylated H3K4 in accordance with published data in 






Figure 5.8- Co- immunoprecipitation of Nanog with Esrrb. 
Whole ES cell lysate was prepared from E14/T ES cells expressing 
(Flag) 3Nanog. Esrrb immunoprecipitates were prepared using anti-Esrrb 
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Figure 5.9- Co- immunoprecipitation of Nanog with HDAC2. 
Whole cell lysate was prepared from EF4 ES cells. Nanog 
immunoprecipitates were prepared using anti-Nanog antibody, 
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Figure 5.10- Nanog interacts with histone H3 tails and Wdr5. 
Incubation of streptavidin immobilised biotinylated histone H3 tails with 
ES cell nuclear extract reveals Nanog can bind H3 tails regardless of the K4 
modification, whereas dimethylated H3K4 is the preferred binding substrate 
for Wdr5 as judged by immunoblotting with anti-Wdr5 and anti-Nanog 
antibody. 
Nanog immunoprecipitates were prepared from ES cells transiently 






At the outset of the experiments described in this chapter there were no known Nanog 
interacting proteins. Given the failure of the candidate approach to partner identification 
described in Chapter 3, a biotinylation strategy was employed as a single step procedure 
to identify Nanog partner proteins in mouse ES cells in an unbiased manner. This 
chapter has described the design, generation and use of a biotinylation tagging strategy 
to identify Nanog partner proteins in mouse ES cells. Here the technical aspects of the 
experiments will be discussed prior to discussion of the results in the context of relevant 
published data. 
5.11.2 	Technical aspects. 
5.11.2.1 	Plasmid design. 
The design of plasmid IPC 206 (Figure 5.1) has 2 major advantages over a more simple 
expression plasmid such as pPyCAG BIONanogIRESpac (1PC203). Firstly, the level of 
transgene expression can be quantified by FACS analysis to identify the highest 
expressing clones, which should then correlate to Nanog over-expression and cytokine 
independence upon transient Cre recombinase co-expression. Having a cell line 
expressing the maximal amount of BlO Nanog possible should yield the highest 
possible number of tryptic Nanog peptides and partner protein peptides by MS analysis. 
The BirA:BIO Nanog ES cell line therefore. provides a useful reagent for the proposed 
proteomic screen. This type of construct with a "pre-selection cassette" would also be 
useful in other studies in which maximal expression of a cDNA is required. Secondly, 
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based on the work in chapter 4 of this thesis, it can be seen that transgenic Nanog 
expression can be mosaic in nature. Using 1PC206, fluorescent microscopy can be 
employed to identify colonies uniformly expressing DsRed2 protein in all cells. 
5.11.2.2 	Nanog is present in complexes of a broad molecular weight range. 
Many eukaryotic proteins do not exert their action alone but rather act as part of 
complexes containing many different proteins. Some proteins, such as components of 
the spliceosome machinery are found in multi-protein complexes of discrete molecular 
weights (Reed et al., 1988) whereas others such as the haematopoetic transcription 
factor Gatal are found in a number of distinct complexes (Rodriguez et al., 2005). Size 
exclusion chromatography reveals Nanog is found in a range of different molecular 
weight complexes, a profile also seen by others (Wang et al., 2006). The BirA:BIO 
Nanog ES cell line generated in this study expresses BlO Nanog at elevated levels in the 
population compared to genetically unmanipulated ES cells, thus permitting cytokine 
independent self-renewal. Importantly, Nanog is present in the same profile of 
molecular weight complexes in both the parental BirA cell line and the BlO Nanog cell 
line from —140KDa to complexes upwards of 1MDa in size (Figure 5.5). This shows the 
BlO Nanog protein can form the same complexes as endogenous Nanog. Moreover, 
these data give confidence that there are a number of Nanog interacting molecules 
awaiting identification. Fraction 14 (Vo, void volume) contains no Nanog protein 
suggesting that Nanog is not forming large non-specific aggregates in solution and, one 
can infer therefore, that the Nanog protein present in fractions 16-36 is in bona fide 
functionally relevant multi-protein complexes. 
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5.11.2.3 	BlO Nanog is efficiently biotinylated and captured. 
Pilot experiments show that BlO Nanog protein can be efficiently purified by 
streptavidin coated magnetic beads. Routinely, the purification efficiency was found to 
be 50-60% of total and that this represents a wide range of Nanog containing complexes, 
but with the highest molecular weight complexes been inefficiently captured (Figure 
5.5c). The sub-optimal purification efficiency is not due to low BirA activity 
(biotinylation efficiency), as biotinylated Nanog is observed in the unbound fraction. It 
is possible that the high molecular weight complexes are refractory to capture as the 
BlO epitope could be buried within the complex rendering it inaccessible to the 
streptavidin coated beads. In future experiments, purification efficiency could be 
increased by (a) increasing detergent concentration although this may lead to the loss of 
some associated partner proteins, or (b), producing a C-terminal BlO tag fusion which 
may be more amenable to capture by streptavidin coated beads. The BlO Nanog 
purifications were performed in the presence of nucleases for a number of reasons. 
Previous streptavidin purifications of BlO tagged transcription factors identify RNA 
binding proteins as abundant background proteins (de Boer et al., 2003; Meier et al., 
2006). Furthermore, false positive identification of interacting proteins may occur if the 
two proteins are simply bound to same fragment of DNA but at a distance of several 
kilobases apart. Of course, DNA may be a crucial factor in the formation and stability of 
the ternary multi-protein complex, therefore ideally, purifications should be performed 
in both the presence and absence and absence of nucleases. 
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5.11.2.4 	Large scale BlO Nanog purification and MS analysis. 
One would expect the banding pattern of bound material from BirA and BirA: BlO 
Nanog cell nuclear extracts to vary dramatically upon colloidal blue protein staining of 
SDS-PAGE gel as specific Nanog partners should be enriched from only the BlO Nanog 
nuclear extracts. This however is not the case with a huge background visible in the 
BirA nuclear extracts (Figure 5.7b). Comparing the background bound material (BirA 
parental cells) from ES cells (this study), to the background bound material from MEL 
cells (de Boer et al., 2003), one can see background binding by ES cell nuclear extracts 
is more significant. Notwithstanding this high background, samples were processed by 
mass-spectrometry as immunoblotting revealed that Nanog was specifically purified in 
the BirA: BlO Nanog pull-downs (Figure 5.7a). Indeed, each of the four sets of MS data 
(MS 1-4) also confirms that Nanog is only purified from BirA: RIO Nanog nuclear 
extracts (see Table 5.3).. Methods to reduce the background include increasing the salt 
concentration or detergent concentration during the purification procedure, or 
introducing a second step in the purification procedure. For this reason, the construct 
used in this thesis has a TEV protease cleavage site cloned at the 3' end of the BIO tag. 
In the future, a second purification step could be introduced in which TEV protease can 
be used to cleave BlO Nanog and associated proteins from the beads, leaving behind the 
non-specifically bound background material. Four independent BlO Nanog purifications 
were performed on four independently prepared nuclear extracts. The conditions used 
for each experiment are overviewed in Table 5.1. If the procedure had worked 
efficiently, and the background was clear, a simple subtraction of the proteins identified 
in the BirA parental cell purification from the proteins identified in the BirA:BIO Nanog 
purification would yield a list of potential Nanog interacting proteins. Performing the 
experiment several times and analysing the overlapping proteins should focus the 
investigator on which proteins are likely to be specific Nanog partners. The mass-
spectrometry appendix shows the proteins which are identified either in all four 
purifications, three of the four purifications, and two of the four purifications but not in 
the BirA parental cell background. These tables are produced using the Genbank 
identifier (gi) numbers which are not unique, meaning a potential partner should be also 
checked manually by name in BirA background list. The tables contain only proteins 
that are either present or absent in a given purification. Firstly it can be seen that the 
only protein identified in all 4 purifications is Nanog itself, therefore the stringent 
criteria described above are not sufficient to analyse this MS data. The criteria for 
further investigation of identified proteins had to be modified; peptides identified in 
more than one purification (either absolutely or enriched compared to the background) 
were considered, particularly if their biological function was related to transcriptional 
regulation. There are two published positive controls for Nanog partner proteins i.e. 
active Smadi (Suzuki et al., 2006b) and Sa114 (Wu et al., 2006). Active Smadl was 
never identified as a Nanog partner in this study or that of Wang et a! (2006) and Sal14 
was only identified in the 4t1  purification and was enriched in the BlO Nanog pull-down 
but not absolutely absent from the BirA background (7 peptides and 3 peptides 
respectively), suggesting these complexes are either transient or unstable under the 
purification conditions used. 
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5.11.3 	Data discussion. 
5.11.3.1 	Nanog-WdrS interaction. 
Gene regulation is dependent on accessibility of the transcriptional machinery to the 
target DNA. In eukaryotic systems, this is governed not only by sequence specific 
transcription factors, but also on modificationsmade to the histone tails with the writing 
of the so called "histone code" which adds a further level of complexity to 
transcriptional regulation (Strahl and Allis, 2000). One example of a chromatin 
modification effecting gene expression is provided by the Seti family of 
methyltransferases, which are involved in catalysing di- to tn- methylation of lysine 4 
(K4) of histone H3 tails, a modification which is found at actively transcribed genes 
(Santos-Rosà et al., 2002). Set1IMLL/tnithorax complexes are capable of catalyzing di-
to tn- methylation reaction of H3K4 in a diverse range of organisms ranging from yeast 
to human (Sims, et al., 2003). The protein in the MLL complex responsible for reading 
the histone code and providing specificity for dimethylated H3K4 substrate was 
identified as the WD40 domain containing protein Wdr5 (Dou et al., 2005; Wysocka et 
al., 2005). Structural studies show that the interaction of WdrS with dimethylated H3K4 
is stabilised by a pair of hydrogen bonds that are not formed with the unmodified H3 
tail due to distance constraints (Han et al., 2006). Furthermore, when interacting with. 
WdrS, the dimethylated H3K4 is readily accessible to histone methyltransferases that 
catalyse the di- to tri-methylation reaction (Han et al., 2006). Wdr5 was identified 
specifically in two independent BIG Nanog purifications (3 peptides in MS 1 and 2 
peptides in MS4) and is unrepresented in the background binding proteins. If WdrS is a 
bona fide Nanog partner one might expect to find further MLL/tnithorax complex 
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components such as Ash2 and MLL itself co-purifying with Nanog and Wdr5. That this 
was not the case, could reflect complex instability during purification. However, 
characterised MLL complexes are reportedly stable under similar extraction conditions 
to those used here (Wysocka et aL, 2005; Dou et al., 2005). A preliminary co-
immunoprecipitation experiment shows that Wdr5 is found in Nanog 
immunoprecipitates prepared from mouse ES cells (Figure 5.1 Ob) suggesting Nanog and 
Wdr5 physically interact in ES cells. Histone tail peptide pull-down experiments using 
mouse ES cell nuclear extracts revealed that Nanog can bind to H3 tails and exhibits no 
preference for di-methylated K4 as opposed to unmodified H3 tails. MLL also shows no 
binding preference for dimethylated H3 tails although MLL does bind histone H3 
(Wysocka et al., 2005). As expected, WdrS binds H3 tails and exhibits a substrate 
preference for dimethylated K4 (Figure 5.10a). Wysocka et al (2005) suggest that the 
majority of WdrS is in free-form (non-complexed), thus allowing visualisation of the 
binding specificity difference on immunoblots. These data are encouraging as it shows 
Nanog and WdrS can bind the same histone tails in vitro. Core histones are detected as 
apparent background binding proteins in the mass-spectrometry data but as the 
chromatin is precipitated during the nuclear extraction protocol it is unlikely these 
histones represent intact nucleosomes. It is unlikely therefore that the Nanog-Wdr5 
interaction is mediated non-specifically via nucleosomes. It will however be important 
to analyse whether Nanog can bind additional core histone tails, and to repeat the co-
immunoprecipitation on lysates containing disrupted nucleosomes. In addition, further 
confirmatory co-immunoprecipitation experiments will be required to more fully 
explore the interaction between Wdr5 and Nanog. It may also be interesting to perform 
in vitro methyltransferase assays on Nanog immunoprecipitates to identify whether 
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Nanog containing complexes possess methyltransferase activity. Wdr5 was not reported 
in the screen for Nanog interactors performed by Wang et a! (2006). However, analysis 
of the supplementary MS data reveals WdrS was indeed specifically identified in one of 
the single step BlO Nanog purifications (Wang et al., 2006). A model of MLL function 
proposed by Wysocka eta! (2005) requires a sequence specific transcription factor to 
recruit the MLL complex to chromatin; it is possible that Nanog acts as a recruiter of 
the MLL complex to activate target genes or mark them as poised for activation upon 
differentiation. Indeed, in mouse ES cells, tracts of chromatin have been identified 
which are dually marked with the opposing trimethylated H3K27 and trimethylated 
H3K4 modifications which are suggested to poise genes for activation upon 
differentiation (Bernstein et al., 2006; Azuara et al., 2006). These so called "bivalent 
domains" have been identified at -50% of the genomic regions identified as Nanog 
bound regions by Loh et al (2005). This suggests Nanog could be key in establishing a 
repressive "bivalent domain" in ES cells which is released upon differentiation 
concomitant with spreading of the trimethylated H3K4 modification (Bernstein et al., 
2006). Of further interest, the H3K4 tri-methylation modification is increased sharply as 
PGC's enter the genital ridge (El 1) and persists throughout the time window (E8.5-
E12.5) during which EG cells can be derived (Seki et al., 2005; reviewed by Surani et 
al., 2007). If this modification is a critical requirement of the re-programming events 
occurring during pre-implantation development as well as during PGC maturation, and 
Nanog recruits the Wdr5-MLL complex to chromatin, then this could explain why 
mature PGC's cannot be generated by Nanog' ES cells (Chambers unpublished). 
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5.11.3.2 	Nanog-Esrrb interaction. 
Esrrb (estrogen related receptor beta, also known as Err2, Err) is an orphan nuclear 
receptor, that is to say, it is a ligand dependent transcription factor with the identity of 
the ligand remaining unknown (Robinson-Rechavi et al., 2003). Esrrb is highly 
expressed in ES and EC cells, and in vivo, post-implantation expression is restricted to 
the extra-embryonic ectoderm that forms the chorion (Pettersson et al., 1996). Esrrb 
embryos die at El0.5 as a result of early placentation defects (Luo et al., 1997). 
Examination of Esrrb expression later in development reveals Esrrb mRNA and protein 
is seen specifically in the primordial germ cells (PGCs) but not the surrounding 
mesonephros at the time PGCs arrive in the genital ridge (--Ei 1), with expression 
persisting until E16.0 (Mitsunaga et al., 2004). Functional analysis of Esrrb in the 
PGCs was carried out by aggregating diploid Esrrb embryos with tetraploid wild-type 
embryos to rescue the placental defect. This revealed that the PGC number was 
significantly reduced in rescued Esrrb embryos compared to the wild-type controls 
(Mitsunaga et al., 2004). This suggests that Esrrb has a proliferative effect on PGCs. 
Nanog is also specifically expressed in PGCs (Chambers et al., 2003; Yamaguchi et al., 
2005). Moreover, Nanog cells exhibit a more severe phenotype during PGC 
development. Nanog cells can enter the germ-cell programme and migrate to . the 
genital ridges. However, the expression of mvh, a germ cell marker activated as cells 
enter the genital ridge at Eli, is reduced at E1l.5, and by E12.5 Mvh Nanog'T cells are 
no longer detectable in chimaeric genital ridges (Chambers unpublished). Esrrb 
expression is increased in Nanog over-expressing cells (Loh et al., 2006), and RNAi 
knock-down of Esrrb in ES cells leads to morphological differentiated colonies 
suggesting it may be important for the maintenance of pluripotency (Loh et al., 2006; 
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Ivanova et al., 2006). Esrrb was identified in two of the four BlO Nanog purifications 
performed in this thesis with four peptides versus zero background peptides in MS2, 
and seven peptides versus two background peptides in MS4. This interaction was also 
reported by Wang et a! (2006) by mass-spectrometry but no confirmatory biochemistry 
was performed. The transcriptional relationship between Nanog and Esrrb, taken 
together with differentiation of Esrrb knock-down ES cells and the PGC phenotypes led 
to Esrrb being investigated in preliminary experiments to validate a Nanog interaction. 
A specific band corresponding to Nanog can be seen in Esrrb immunoprecipitates from 
mouse ES cell lysates suggesting Nanog and Esrrb interact in ES cells (Figure 5.8). A 
future experiment to epitope tag Esrrb and perform the reciprocal co-
immunoprecipitation will be important to confirm the Nanog-Esrrb interaction. As well 
as further biochemical characterisation of the interaction, it will be interesting to 
examine the expression of Esrrb in pre-implantation embryos as previous studies 
focussed upon early post-implanatation expression (Luo et al., 1997). The Esrrb 
antagonist (DES) has been shown to cause self-renewing trophoblast stem (TS) cells to 
differentiate into giant cells, and furthermore the same differentiation event occurs in 
vivo with DES injection antagonising placental development (Tremblay et al., 2001). 
To assess whether Esrrb may be a key partner of Nanog it will be interesting to 
investigate whether ES cells can be derived from Esrrb blastocysts, and whether the 
Esrrb antagonist diethylstilbesterol (DES) can antagonise ES cell self-renewal. It has 
been demonstrated that Nanog over-exprçssion can over-ride the differentiation of Esrrb 
knock-down ES cells although the colonies obtained are only weakly alkaline 
phosphatase positive (Ivanova et al., 2006). To further examine whether Esrrb and 
Nanog are functionally linked, one could examine the effect of the Esrrb antagonist 
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DES on LIF independent self-renewal of Nanog Over-expressing cells. Additional 
experiments could determine if Esrrb ES cells can be derived from blastocysts and 
whether Nanog over-expression can still guide LIF independent self-renewal of Esrrb 
ES cells. As Nanog and Oct4 are suggested to share a common subset of partner 
proteins, it may also be interesting to examine a possible Oct4-Esrrb interaction using 
the (Flag) 30ct4 expressing cells. 
5.11.3.3 	Nanog-HDAC2 interaction 
Histone deacetylase 2 (HDAC2) catalyses removal of acetyl group modifications from 
histone tails (Taunton et al., 1996). Acetylation of histone tails is generally associated 
with gene activation, therefore removing the acetyl group acts to repress genes. HDAC2 
was identified as a Nanog co-purifying protein in two of the BlO purifications 
(M52+MS4) in this thesis and also in the Wang et al (2006) study although they did not 
confirm this by co-immunoprecipitation. Later BlO Nanog purification (MS3+MS4) 
revealed HDAC2 was also found in the background fraction. As the function of 
transcription factors are often intimately linked to chromatin modifications, the putative 
Nanog-HDAC2 complex was probed further. A preliminary co-immunoprecipitation 
experiment revealed the presence of HDAC2 protein in Nanog containing complexes 
that had been immunoprecipitated from mouse ES cell lysates (Figure 5.9). It will be 
important in the future to further confirm this interaction and assay deacetylase activity 
of Nanog immunoprecipitates. Wang et al (2006) suggest Nanog interacts with the 
NuRD complex via Naci and Sa114, and although this may be the case, one should not 
rule out that it may act in other HDAC2 containing complexes such as the Sin3alMad-
Max complex which also act to repress transcription (Laherty et al., 1997). Indeed, 
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affinity purification of two NuRD complex components followed by mass-spectrometry 
does not identify Nanog as a NuRD associated protein suggesting it may be present in 
an alternative HDAC2 containing complex(es) (I.Costello, personal communication). 
To dissect which HDAC2 complex Nanog is present in, Nanog could be 
immunoprecipitated from ES cell lysates and probed with antibodies against proteins 
present in a distinct repressor complex e.g. Sin3a, or Mi2 for the NurD complex. A 
possible mechanism of Nanog-HDAC2 is that Nanog could recruit HDAC2 to generate 
repressive chromatin at lineage specific genes during the establishment of the 
pluripotent state. It may seem an apparent paradox that Nanog should interact with 
Wdr5 (associated with gene activation) and HDAC2 (associated with gene repression) 
but there are examples of transcription factors functioning in distinct complexes to 
effect both activation and repression, for example the haematopoetic transcription factor 
Gatal (Rodriguez etal., 2005). 
5.11.3.4 	Naci and Zfp281 
Naci is a BTBIPOZ transcriptional repressor previously found to be important in 
preventing neural gene expression (Mackler et al., 2000). Naci was identified in MS2 
and MS4 in this thesis, with two and three Naci co-purifying tryptic peptides being 
identified, respectively, with zero peptides detected in BirA control purifications. 
However due to time constraints, the Naci interaction was not followed up by co-
immunoprecipitation experiments. Naci was also identified in the published single step 
purifications of Nanog partner proteins and validated by co-immunoprecipitation 
experiments (Wang et al., 2006). Furthermore, Wang et a! (2006) performed ChIP 
experiments showing Nanog and Naci together with a third protein Zfp28 1, bound the 
Gata6 promoter, and that ES cells either heterozygous or knocked down for Zfp28 1 and 
Naci have increased Gata6 expression, although the extra-embryonic differentiation 
that occurs upon forced Gata6 expression (Fujikura et al., 2002) does not occur. It has 
been hypothesised that Nanog functions to repress Gata6 (Mitsui et al., 2003; Ralston 
and Rossant, 2005; Chambers, 2004). In addition, Nanog over-expressing cells cannot 
differentiate into Gata6 expressing primitive endoderm cells in embryoid bodies 
(Hamazaki et al., 2004). Wang et a! (2006) provide evidence that Nanog binds the 
Gata6 promoter and it may be that Naci and Zfp281 are critical, proteins in this 
repression. However, there still remains no evidence that Nanog is directly required for 
Gata6 repression. Indeed, in contradiction to this hypothesis, recent data shows that 
continued Nanog is not required for maintenance of pluripotency; Gata6 derepression 
and endodermal differentiation do not ensue upon acute Nanog deletion from ES cells 
(Chambers unpublished). It may be that a simultaneous reduction in the expression 
levels of Nanog plus one of either Naci or Zfp281 (or both) is required for Gata6 
derepression and endodermal differentiation. 
5.11.3.5 	Biotinylation tagging approach to Nanog partner identification. 
The BlO Nanog purifications performed in this thesis have revealed a number, of 
candidate partner proteins including Wdr5, HDAC2, Esrrb, and Naci. Preliminary co-
immunoprecipitations in this thesis have shown that WdrS, HDAC2 and Esrrb may be 
Nanog interactors, although further more rigorous confirmation is required. Furthermore, 
Sa114 was identified in MS4 as highly enriched compared to the background (14 
peptides versus 3 peptides), and this published interaction (Wu et al., 2006) is 
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confirmed in chapter 3 of this thesis. During the course of this study, Wang et a! (2006) 
performed a similar biotin tagging strategy in which they identified the molecules above 
along with an additional cohort of putative Nanog partner proteins, Oct4, Zfp28 1, Rifl 
and Daxi by mass-spectrometry followed by preliminary confirmation by co-
immunoprecipitation (Wang et al., 2006). Wang et al (2006) performed a tandem 
affinity BIO:Flag Nanog purification in addition to single step BlO Nanog purifications. 
It is interesting to note that seven out of seventeen putative partner proteins including 
Oct4 and Zfp28 1, were not detected by mass-spectrometry analysis of tandemly purified 
Nanog complexes. This may suggest that these interactions are weak or transient in 
nature. A further group of putative partner proteins were included in the Nanog "mini-
interactome" without any validation of the mass-spectrometry data. Given the 
abundance of background binding proteins, and the fact that many of the putative 
specific partners found by Wang et al (2006) were found in the background fraction of 
experiments performed in this thesis (see Table 5.3), caution should be taken when 
drawing the conclusion that these are genuine physiologically meaningful interactions. 
To further increase the likelihood of identifying Nanog partner proteins using such a 
proteomic screen, future experiments could have a second purification step introduced 
to effectively use a tandem affinity tagging approach, or to cleave the epitope tag from 
the solid phase support to release only Nanog itself, and Nanog containing complexes. 
Differences between the screen in this thesis and that of the Wang et a! (2006) study 
could also be due in part to different salt concentrations (350mM versus 100mM in this 
thesis) used for extract binding to streptavidin. It may also be useful to perform a 
parallel and complementary screen using a yeast-2-hybrid approach. Although this 
approach may suffer problems of high false positive rate and possible mis-modification 
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Table 5.3- Comparison of the proteins categorised as Nanog partner proteins by Wang 
et a! (2006) to those identified by the BlO Nanog purifications in this thesis. Numbers 
indicate the total number of peptides identified. 




BlO Nanog BirA parental BlO Nanog BirA parental 
Nanog 4+7+8 0+0+0 12+9+2+9 0+0+0+0 
Salli 3+2+ 1 0+0+0 0+0+0+0 0+0+0+4 
Sa114 4+2+ 14 0+0+0 0+0+0+7 0+0+0+3 
Rifi 12+5+5 0+0+0 0+8+0+6 0+1+0+5 
Tif1 P 11+16+13 0+0+0 23+7+1+48 22+7+1+48 
Mybbp 8+14+15 0+0+0 11+28+5+18 4+33+4+13 
Daxi 0+1+2 0+0+0 0+0+0+0 0+0+0+0 
Naci 2+0+2 0+0+0 0+2+0+2 0+0+0+0 
Zfp281 1+2+4 0+0+0 0+0+0+4 0+0+1+11 
Esrrb 7+2+ 1 0+0+0 0+4+0+7 0+0+0+2 
Elys 1+2+1 0+0+0 5+7+0+16 6+0+0+22 
Oct-4 2+0+1 0+0+0 0+0+0+4 0+0+0+1 
Z1198 0+2+5 0+0+0 0+0+0+4 3+0+0+14 
NF45 4+0+1 0+0+0 0+0+0+0 0+0+0+0 
HDAC2 2+0+ 1 0+0+0 0+1+0+5 0+0+1+7 
REST 0+0+1 0+0+0 0+0+0+0 1+0+0+0 
Spi 0+1+0 0+0+0 0+0+0+0 0+0+0-1-0 
Wapl 0+0+ 1 0+0+0 0+0+0+0 0+0+0+0 
Wdr5 1+0+0 0+0+0 3+0+0+2 0+0+0+0 
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of mouse proteins, it may identify direct protein-protein interactions, which are likely to 
be the most important and functionally relevant. In addition to the BirA:BIO Nanog ES 
cell line described here, a BirA: BlO Nanog co-expressing neural stem (NS) cell line has 
been derived (data not shown) (Conti et al., 2005). As NS cells do not express Nanog, 
this cell line will be a useful tool to identify which Nanog partners only interact with 
Nanog in an ES cell context and not in NS cells, as these are likely to be functionally 
significant. 
5.12 Summary 
This chapter has described experiments to design and generate a reagent that facilitates 
the purification of Nanog containing complexes from mouse ES cells. An inducible BlO 
Nanog construct was made, BirA:BIO Nanog expressing ES cell lines generated, and 
pilot experiments to characterise the purification efficiency were performed. Four large 
scale BlO Nanog purifications were performed and analysed via mass-spectrometry to 
identify associated proteins. The data revealed that the system could not reproducibly 
identify specific co-purifying proteins, however three proteins were further investigated 
based on their being present (either specifically or enriched) in BlO Nanog purifications, 
and there being biological rationale for these interactions. These proteins, Wdr5, Esrrb, 
and HDAC2 were preliminarily confirmed as Nanog partners by co-
immunoprecipitation experiments. In the future it will be important to perform further 





Nanog is a divergent homeodomain protein that is required to establish pluripotent cell 
types and is able to direct ES cell self-renewal in the absence of cytokine signalling. 
However, the mechanism by which Nanog acts in ES cells is incompletely understood. 
This thesis has presented experiments that begin biochemical characterisation of Nanog 
protein, in addition to experiments addressing the consequence of Nanog over-
expression on mesoderm formation in the mouse embryo. 
It has been demonstrated that Nanog can form multimers in ES cells and that the 
tryptophan repeat in the C-terminal domain of Nanog is required to mediate this 
interaction. That such multimerisation is functionally significant has been demonstrated 
by the inability of a mutant Nanog molecule lacking the tryptophan repeat to efficiently 
direct ES cell self-renewal. 
During normal mouse embryogenesis, Nanog expression in the post-implantation 
embryo is highest in the proximal posterior region of the epiblast and is rapidly down-
regulated as cells delaminate and ingress through the primitive streak. Cellular reagents 
were designed and generated to address the consequence of Nanog over-expression in 
the gastrulating mouse embryo. It was found that an elevation of Nanog protein to 2-3 
times the endogenous level does not cause an overt phenotype at this stage of mouse 
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development, and Nanog over-expressing cells can be clearly visualised in the 
mesoderm. Therefore Nanog down-regulation is not required for mesoderm 
differentiation. 
Experiments designed to investigate potential interactions between Nanog and the 
candidate molecules Oct4 and Stat3 did not establish any such physical link. Therefore 
an unbiased proteomics approach was employed to identify Nanog partner proteins in 
ES cells. A biotinylation tagging system was established, allowing biotinylated Nanog 
and associated proteins to be purified from ES cell nuclear extracts. Analysis of the 
purified material by mass-spectrometry identified putative Nanog partner proteins. 
Preliminary biochemical confirmation of three of these identified proteins, Esrrb, 
HDAC2, and Wdr5 was performed. An interaction between Nanog and the spalt family 
member Sa114 was confirmed and found to be mediated by the SLQQ motif within the 
Nanog homeodomain. Furthermore, mutation of the SLQQ motif to SAAQ was shown 
to compromise ES cell growth. The only other protein containing an SLQQ at the same 
position within the homeodomain is Oct4. Consistent with a fundamental role of this 
motif in directing efficient ES cell self-renewal, a physical interaction between Oct4 and 
Sa114 was demonstrated. 
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Oligonucleotide Appendix 
OLIGO PURPOSE SEQUENCE 5 9-3' 
NA1%'IE 
(P= 5' PHOSPHATE GROUP MODIFICATION) 
Tryptophan repeat PGATGCGTTCACCAGGCTAGCATAGCCCTG.GGG 
NheI mutagenesis AT 
Tryptophan repeat PTCCCCGAAGTFATGGCTAGCGAGCGGAGCAGC 
Nhe2 mutagenesis AT 
Amplification of TI'GGATCCGGCGGCGGCGGCGGCGCCATGGCCA 
Wdr5amp f Wdr5 cDNA CAGAGGAGAAGAA (annealing temp- 56°C) 
Amplification of TFGCGGCCGCTI1TAGCAGTCACTCTTCCACA 
Wdr5amp r WdrS cDNA 
(annealing temp- 56°C) 
Sequencing of GATATGGGACGTGAAGACAG 
Wdr5 seq f Wdr5 cDNA 
Sequencing of AGAGGCGGTGTCCCAGATC 
Wdr5 seq r Wdr5 cDNA  
1C3 Nanog sequencing 
GTACCTCAGCCTCCAGCAGAT 
1C4 
Nanog sequencing AGGCTTCCAGATGCGTFCAC 
Ml 3f 
Sequencing in GTAAAACGACGGCCAG 
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Generate by 3 fragment ligation of, 
	
GAG 	
1 lObp Not! to BaHI fragment from pTRE BlO 









BamHI BainHIJ KpnI of IPC 33 use 1.4kb fragment 
CoIE1 On 
Not!! KpnI of AGS 576 use 5.9kb fragment. 
SV40 on/pA  
-Il 	 pA 	Pac IRES 	 Diagnose via NcoI digestion; correct ligation 
BamNI 	 products have the following restriction pattern- 
Pmll 	 3.2kb, 2.8kb, 1.4kb. 
Kpnl 
1PC204 
CWMV 	 Make by 2 way ligation; 
+ 





/pm	BlO Nanog 	 Sal!! PmlI of 1PC183 use 4kb fragment. lB EcORV 
CoIE1 On 	
BlO Nan 	
products have the following restriction pattern- 
7216 bps Xmal Diagnose via EcoRV digestion; correct ligation 
1.1kb, 4.4kb, 1.7kb. 
SVori 
BSDR IRES 







floxDsRed2 IP BlO Nanog lB 





pA BSDR 	loxP Pa1 
BIO Xmal 
Xmal 
Make by 4 fragment ligation of, 
EcoRV/ XmaI of 1PC204 use 12lbp fragment. 
+ 
SfiII XmaI of IPC 204 use 2.5kb fragment. 
+ 
Digest IPC 194 with Agel and Kienow fill in the 
products. Recut with Sbfl and use 1.9kb fragment. 
+ 
SbflI Sf11 of 1PC194 use 5.1kb fragment. 
Diagnose via NcoI digestion; correct ligation 
products have the following restriction pattern-
1.6kb, 1.9kb, 2.5kb, 3.2kb, 0.5kb. 
201 
1PC332 
Oligonucleotide primers (NheI and Nhe2) were. 
.XhoI annealed to single stranded 1PC35 phagemid DNA, 
and following polymerisation and ligation, double 
stranded DNA was produced in DH5a E.coli as SP6 Promot 
7 ianog 
described in Methods 2.3.8. NheI 
NheI 
pCRII(HA)3NhelWrepeatNhel 	NotI The oligonucleotides introduced Nhel resction sites 
5013 bps 	T7 promoter flanking the W repeat. NheI digestion was performed 
to screen for mutated DNAs; these were verified by 
sequencing with oligos M13FIR, IC 3 and 1C4. 
DNA was then NheI digested, diluted to 6ng!ml and 
religated. Molecules with the W repeat deleted were 
screened for via EcoRl digest. Mutated DNA releases 
a 704bp fragment whereas non-mutated DNA releases 





Plasmid made by 2 way ligation of, 
XhoIJ NotI of 1PC332 use 900bp fragment pPAG(HA)3 deItaWt 	oI 
XhoV NotI of AGS564 use 6.4kb fragment. 
7283 bps 
+ 
CoIE1 On HA- delta W repei 
NheI













BamHI 	 pA Pac IRES 
WWWO 	 Nc 
Make via 3 fragment ligation of ,  
BamHIJ Sail of 1PC37- use 1.8kb fragment 
+ 
Sail! NotI of 1PC37- use 4.7kb fragment 
+ 
PCR amplify Wdr5 from ES cell cDNA using 
Wdr5 amp f and r primers. TOPO clone the PCR 
product and sequence verify with Wdr5seq f and r 
primers along with Ml 3 FIR primers. Then digest 
TOPOWdr5 with BamHI and NotI and use 1kb 
fragment. 
Correctly ligated plasmids can be analysed with an 
NcoI diagnostic digest yielding 1.3kb, 0.09kb, 2.8kb, 





(8554 bps) 	 Lab stock plasmid 
AGS564 
~AmpR Py GAG PromoteN\ 
a \ 
6892 bps BstXI Stuffer 
pPyCAGIP 






















pCAG-Cre IP GAG Lab Stock p1asd 
SV40 oni/pA 7450 bps 	
) 
L pA 
ac 	 re 
IRES 
204 
